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Chapter 1 
GENERAL INTRODUCTION 
The temporal relationships between certain forms of stress and the release of 
adrenaline from the adrenal medulla on the one hand and between stress and 
elevation of blood pressure on the other hand, are well known. Consequently 
adrenaline has been considered for many years as one ol the factors contributing to 
the development ol hypertension. The classical role of adrenaline is to prepare the 
body lor the demands during fear, fight or fright reaction by activating B-adrenoceptors 
in the heart and blood vessels and by inducing some "metabolic" effects such as a 
rise in blood glucose. However, adrenaline may also modulate noradrenaline release 
from sympathetic nerves and may be in that way closely related to the regulation of 
blood pressure. It is approximately 10 years ago that an hy;:Jothesis was fo'mulated 
for a mechanism by which increases in circulating adrenaline could result in more 
prolonged increases in blood pressure, which in the end coufd progress to primary 
hypertension (1-3). In this chapter, after giving a general description of some aspects 
of the sympatho-adrenal system, catecholamines, their receptors, receptor subtypes 
and function, the evidence is reviewed ior a mechanism by which adrenaline could 
modulate noradrenaline release. Special attention will be given to the possible 
involvement of adrenafine in the pathogenesis of some forms of experimentaf and 
human hypertension. Furthermore, some aspects of the metabolism of 
catecholamines and their urinary metabolites and the nature of the "metabolic" effects 
are discussed. Since an "inability" to excrete sufficient amounts of sodium seems to 
be an essential feature of all forms of hypertension, the possible role of 
catecholamines in this renal abnormality is discussed. This chapter ends with a 
formulation of the aims of our studies. 
THE SYMPATHO-ADRENAl SYSTEM 
The sympathetic nervous system and the adrenal medulla are of major importance 
in controlling the function of smooth, skeletal and cardiac muscle and concur in the 
regulation of exocrine and endocrine glands. Preganglionic sympathetic nerves 
connect the central nervous system with the ganglia of the sympathetic trunk, where 
the neurotransmitter is acetylcholine. Postganglionic sympathetic nerves connect the 
ganglia with the target organs, where the neurotransmitter is noradrenaline. Some of 
this noradrenaline spills over into the plasma. The adrenal medulla is the major source 
of the circulating N-methyl-noradrenaline (adrenaline), which is synthesized from 
noradrenaline by phenylethanolamine-N-methyltransferase (PNMT). The adrenal 
glands also release some noradrenaline. Noradrenaline and adrenaline together with 
dopamine, the precursor of noradrenaline, are the major catecholamines. Both 
noradrenaline and adrenaline elicit a variety of effects both in the central nervous 
system and peripherally, which will be discussed in detail in this thesis, whereas 
dopamine is mafnly an important neurotransmitter in the brain. 
10 
Ahlquist was the first to suggest that there are two types of catecholamine receptors: 
designated by him as a:- and B-adrenoceptors (4). He distinguished these receptors 
by physiological means. The discovery of selective agonists and antagonists for a-
and B-adrenoceptors made it possible to confirm the distinction made by Ahlquist. A 
further subclassification of these receptors in a:, a,, B, and B, has been made by 
pharmacological means as more specific and selective agents became available (5-8). 
a-Adrenoceptors 
The o:-adrenoceptors are responsive to noradrenaline and adrenaline, but little 
responsive to the nonselective B-adrenoceptor agonist isoprenaline. The "-
adrenoceptor mediated effects are antagonized by antagonists, such as phentolamine 
and phenoxybenzamine. Activation of a-adrenoceptors in smooth muscle is usually 
excitatory in nature and results, for instance, in constriction of blood vessels and 
contraction of the uterus. 
The a-adrenoceptors have been subdivided in 2 subtypes (5). The ",-adrenoceptors 
are predominantly located postsynaptically and mediate smooth muscle contraction 
or stimulation of glands. They are thought to be located close to the nerve terminals 
and to be the predominant adrenoceptors mediating vasoconstrictor responses to 
endogenously released noradrenaline. a,-Adrenoceptors can be located 
prejunctionally, where they regulate noradrenaline release in an inhibitory fashion. 
Postjunctional a:,-adrenoceptors also exist and are present in several organs, such as 
the kidney, blood vessels, uterus, platelets and certain areas of the brain. The 
proportion of postjunctional "'·-and o:,-adrenoceptors varies within the vascular bed; 
the <t,-adrenoceptor predominates in renal vessels, whereas a:,-adrenoceptor 
predominate in cerebral blood vessels. Postjunctional a:,-adrenoceptors are thought 
to be located extrasynaptically and to be activated preferentially by circulating 
catecholamines (6). 
a,-Adrenoceptor agonists increase blood pressure and peripheral resistance with 
bradycardia through an increase in vagal tone. a:,-Adrenoceptor selective agonists 
include phenylephrine and methoxamine and their antagonists prazosin and doxazosin 
(Table 1 ). Selective o:,-adrenoceptor agonists include clonidine and their antagonist 
yohimbine. Noradrenaline and adrenaline are nonselective agonists, they both 
stimulate both <t,- as well as <t,-adrenoceptors. 
B-Adrenoceptors 
Stimulation of B-adrenoceptors results in inhibition of contraction of smooth muscle, 
such as in the vascular (leading to vasodilatation) and uterine musculature, whereas 
stimulation of B-adrenoceptors mediate the excitatory effects on the heart (leading to 
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TABLE 1 o:-ADRENOCEPTOR AGONISTS AND ANTAGONISTS 
Agent Receptor influenced 
Agonists Noradrenaline a;1 +a2 +8, 
Adrenaline a:, + a:2 + B, + 62 
Phenylephrine a:, > 0:2 
Clonidlne «2 > a:, 
Guanfacine c:2 > a:, 
Antagonists Phentholamine a;, + 0:2 
Prazosln «, 
Doxazosin «, 
Labetolol a, + B, + B2 
Yohimbine «, 
ldazoxan «, 
RauwoJscine «, 
Adapted from reference 7 
tachycardia and increase in force of contraction), and lipolysis and gluconeogenesis 
in hepatic and skeletal muscle tissue. 
Lands et al (8) proposed the subdivision of B-adrenoceptors into B,- and B,-
subtypes. This concept has been confirmed later in studies with specific agonists and 
antagonists. B,-Adrenoceptors are present in cardiac, intestinal and adipose tissue, 
whereas B,-adrenoceptors predominate in bronchi, vascular beds, the uterus, skeletal 
muscle and the liver. Noradrenaline and adrenaline both stimulate B,-adrenoceptors, 
whereas the affinity of adrenaline for B,-adrenoceptors is much higher than the affinity 
of noradrenaline for these receptors. Isoprenaline is generally considered to be a pure 
nonselective B-adrenoceptor agonist. Selective B,-adrenoceptor agonists, such as 
salbutamol, relax bronchial smooth muscle. A great number of B-adrenoceptor 
blocking agents are now available, both non-selective (B, + B, such as propranolol), 
B, selective (such as atenolol and metoprolol) and B, selective (such as ICI 118551) 
(Table 2). 
Postjunctional versus prejunctional adrenoceptors 
Postjunctional adrenoceptors are located on the target organ. Their stimulation leads 
to an effect in the target organ. For instance stimulation of vascular postjunctional a,-
adrenoceptors induces vasoconstriction, it increases vascular resistance and therefore 
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TABLE 2 B-ADRENOCEPTOR AGONISTS AND ANTAGONISTS 
Agent Receptor influenced 
Agonists Noradrenaline 6, + «, + C:z 
Adrenaline B, + B2 + a., + ct2 
Dobutamine B, + a., 
Isoprenaline 13, + 62 
Fenoterol 132 ,. B, 
Saibutamol 62 ,, B, 
Terbuta!ine B2 ,. B, 
Antagonists Propranolol B, + 82 
Pindolol 13, + 82 
Tlmo[ol B, + 82 
Sotalol B, + 82 
Atenolol B,, B2 
Metopro!ol B,,. 82 
Acebutolo! B,,. 82 
ICI 118,551 132 ,, B, 
Labetolol B,+B2 +a, 
Adapted from reference 7 
blood pressure rises. 
Prejunctional adrenoceptors modulate the release of neurotransmitters in response 
to nerve stimulation. Several types of these prejunctional adrenoceptors may be 
present on the nerve ending where they reinforce or inhibit noradrenaline release. 
Prejunctional a:,-adrenoceptors exert an inhibitory action on noradrenaline release, 
when a critical concentration within the synaptic cleft is reached. The a:-agonist 
clonidine, besides its effects on the central nervous system, inhibits noradrenaline 
release through such a mechanism. Antagonists like phenoxybenzamine and 
phentholamine potentiate noradrenaline release by inhibition of the prejunctional a:,-
adrenoceptors. However, for blockade of this inhibition much higher concentrations 
are required than for the effects on postjunctional a-adrenoceptors (9). 
Prejunctional adrenoceptors capable of facilitating noradrenaline release have been 
clearly demonstrated. These adrenoceptors are suspected to play a role in the 
pathogenesis of some forms of hypertension and they are discussed in more detail 
below. 
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ADRENALINE MEDIJJ.TED MODUlATION OF NORADRENALINE RELEASE 
Prejunctional B-adrenoceptors 
The first suggestion for the presence of prejunctional B-adrenoceptors came from 
the observation of Adler-Graschinsky and Langer (10). They showed that isoprenaline 
enhanced the nerve stimulation induced release of noradrenaline from guinea-pig 
isolated atria and that this effect was blocked by propranolol. Almost at the same time 
Stjarne and Brundin (11, 12) also demonstrated the existence of an enhancing effect 
of B-adrenoceptor agonists on stimulation induced noradrenaline release. Since then 
many investigators reported similar observations with several B-adrenoceptor agonists 
in a range of isolated cardiac and vascular tissues and other sympathetically 
innervated tissues from a number of different species. On the basis of a range of 
studies with selective and non-selective agonists and antagonist the prejunctional B-
adrenoceptors appeared to be of the B,-subtype (review 13-16). 
Noradrenaline is a weak B,-adrenoceptor agonist whereas adrenaline is a potent 
agonist for this receptor. Indeed adrenaline activates B,-adrenoceptor mediated 
noradrenaline release in in vitro studies in concentrations of 100-1800 pgjml (15). 
Higher concentrations of adrenaline can inhibit noradrenaline release, through 
activating prejunctional «,-adrenoceptors {15). Under physiological conditions 
noradrenaline has no action on B,-adrencceptors. 
Adrenaline as co-transmitter. 
Adrenaline can be actively taken up into sympathetic nerve terminals, retained in the 
transmitter stores and subsequently released by nerve stimulation just like 
noradrenaline. The small amount of adrenaline normally present in the sympathetically 
innervated tissues is probably derived largely from that released from the adrenals, 
since adrenal medullectomy results in a decrease in adrenaline levels in the tissues. 
The amount of adrenaline taken up by the neurons is increased when plasma 
adrenaline is elevated (17). Once accumulated in the nerves, adrenaline can be co-
released along with noradrenaline upon nerve stimulation. The adrenaline released as 
co-transmitter can mediate a positive feedback autofacilitating loop resulting in 
increased noradrenaline release. This effect is observed in in vitro experiments in rat 
atria (18). Also in vivo in the rabbit, adrenaline given intravenously (17) or 
endogenously released by splanchnic nerve stimulation (19) resulted in an increase 
of noradrenaline release into the plasma, even well after the adrenaline has been 
cleared from the plasma but when levels in sympathetically innervated tissues were 
still raised (17,19). Pretreatment with the neuronal uptake blocker desipramine, 
abolished the effect of adrenaline injection and adrenaline released by splanchnic 
nerve stimulation in producing a subsequent increase in the rate of noradrenaline 
release. These observations are entirely consistent with the view that adrenaline 
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produced its effects as a cotransmitter and that its incorporation into the 
transmitterstores was prevented by neuronal uptake blockade by desipramine. 
Intravenously administered 'H-adrenaline in rats has a short half life (approximately 1 
minute), whereas once adrenaline is accumulated in the tissues, the half live of its 
disappearance is several hours (18). So in this way occasional bursts of adrenaline 
secretion by the adrenal medulla can have a more prolonged effect on sympathetic 
neurotransmission. 
Also in humans there is evidence lor the facilitating effect of adrenaline on 
noradrenaline release from sympathetic nerves. In isolated tissues including omental 
blood vessels (1 1, 12) and digital arteries (20) adrenaline and other B-adrenoceptor 
agonists have been found to enhance noradrenaline release. Our group observed 
dose-dependent increments rn plasma noradrenaline during graded infusions of 
isoprenaline in normotensives and borderline hypertensive subjects. The rise was 
completely abolished by concomitant infusion of propranolol. During atenolol the dose 
response curve for plasma noradrenaline was shifted to slightly higher infusion rates 
of isoprenaline (21). These results are completely compatible with the above 
described mechanism of prejunctional B,-adrenoceptor mediated enhancement of 
noradrenaline release. Similar results were later reported by several other investigators 
(22,23). 
ADRENALINE AND HYPERTENSION 
Adrenaline and exoerimental hypertension. 
The effect of chronic administration of adrenaline in producing increases in blood 
pressure that outlasted the period of adrenaline administration has been demonstrated 
in a series of experiments. The way of administration of adrenaline was a 
subcutaneous implant {24), intermittent intravenous infusion (25) or intraperitonally 
from osmotic minipumps (26). The rise in blood pressure was prevented by 
concomitant administration of metoprolol (24,26), whereas in rats implanted with 
pumps delivering noradrenaline, blood pressure did not differ from control (26). 
Borkovski and Quinn (27) also used subcutaneous implants and produced a 
sustained increase in blood pressure in SHR rats, which had their adrenal medullas 
removed. This effect was prevented by the selective B,-adrenoceptor blocker ICI-
1 18,551. Several other groups have also provided data indicating that prolonged 
infusion of adrenaline can induce hypertension in the rat (28,29). There is a number 
of animal studies on the association between stress and hypertension and stress and 
adrenaline. Exposure to continuous stimulation with flashing lights, oscillation of the 
cage and noise for several weeks, but also sound deprivation, have been reported to 
produce hypertension in rats (30,31 ). Treatment with propranolol prevented the 
development of isolation-induced hypertension (32,33). Stress-induced increases in 
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adrenaline secretion have been reported. Forced immobilization of rats by taping the 
legs to a board, results in a marked increase in urinary excretion of catecholamines 
and a depletion of the adrenal contents (34). Plasma adrenaline is also markedly 
increased by this procedure (35). Rats subjected to the chronic stress of individual 
housing and the binding of their rear legs has produced a rise in blood pressure when 
compared to control rats. In rats, which have been adrenal medullectomized prior to 
the stressing procedure, given desipramine or propranolol, the stressing procedure 
did not elevate blood pressure (36). The amount of adrenaline accumulated in the 
heart was also measured and was found to be increased by the stress. Desipramine 
treated stressed rats did not have elevated heart adrenaline levels. In adrenal 
medullectomized rats, the heart adrenaline levels were reduced in both stress and 
control rats by more than 90% (36). Taken together, these findings suggest that 
adrenaline has a role in initiating stress-induced increases in blood pressure in the rat. 
The results of blockade experiments with desipramine and propranolol are consistent 
with the hypothesis that the neuronal accumulation of adrenaline and its subsequent 
activation of prejunctional B-adrenoceptors on sympathetic nerve endings are also 
involved. 
Adrenaline in human hypertension 
Adrenaline has also been implicated in the pathogenesis of human hypertension. 
Several investigators have reported elevated plasma levels of adrenaline in patients 
with borderline hypertension {37-40), both at rest and during activities that raise blood 
pressure. Many patients with borderline hypertension have the characteristics of 
increased B-adrenoceptor activity, such as an increase in heart rate, cardiac output 
and forearm blood flow. These changes are antagonized by B-adrenoceptor blockade 
(41 ,42). 
The concept that adrenaline, by stimulating prejunctional B-adrenoceptors, facilitates 
the release of endogenous noradrenaline from sympathetic nerves leading to an 
increase in blood pressure, is also investigated in humans. As already mentioned, our 
group and others have provided evidence that B-adrenoceptor agonists can increase 
plasma noradrenaline (20,21). In a later study our group demonstrated that infusion 
of adrenaline, which raised plasma adrenaline into the high physiological range, 
augmented the pressor response to reflex sympathetic nervous system stimulation by 
standardized cold pressor and isometric exercise test (3,43,44). This amplification was 
abolished by concomitant administration of propranolol. Plasma noradrenaline was 
higher during adrenaline infusion both before and after the tests, and this effect of 
adrenaline was antagonized by propranolol. So these results seem to support the 
view that adrenaline amplifies sympathetic pressor responses in humans by facilitation 
of the release of noradrenaline. 
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Figure 1. Pathways of synthesis and metabolic breakdown of catecho!amines. 
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Ten years ago an hypothesis has been put forward, which suggested a role for 
adrenaline in the pathogenesis of human hypertension (1-3). The mechanism involved 
was though to be as follows: increased release ol adrenaline by the adrenals, for 
instance induced by "stress", leads to enhanced noradrenaline release either directly 
through stimulation of prejunctional B,-adrenoceptors, or indirectly after adrenaline had 
been taken up in the sympathetic neurons and after it was subsequently co-released 
with noradrenaline during periods of sympathetic stimulation which further increases 
noradrenaline release. 
At the time we started our experiments described in this thesis (1986), two studies 
were available on the effect of adrenaline during, but particularly also after its 
administration. Brown and Dollery studied 6 normotensive volunteers and infused 1 DO 
ngjkg/min of adrenaline over 2 hours (45). Indirectly measured blood pressure was 
higher up to 2Y2 hours after cessation of the infusion. However, the authors reported 
an absence of statistical significance for this pressor effect. Nezu et al (23) showed 
that 30 minutes of adrenaline infusion (1.25- 1.5 fig/min) resulted in a significant rise 
in blood pressure after cessation of the infusions, which lasted at least for 90 minutes. 
Pretreatment with propranolol completely abolished this effect. 
At that time no data were available on more long term (several hours) pressor 
effects of adrenaline and no studies existed examining the question whether the effect 
observed in the two studies just mentioned (23,45), was unique for adrenaline. This 
have led us to perform the studies described in this thesis. 
CATECHOI.AMIIIIES AND THEIR URINARY METABOLITES 
Understanding the metabolism of catecholamines has proved to be important in 
gaining insight in the mechanism of their function. Since it was shown that only a 
small part of infused catecholamines was excreted unchanged in the urine, much 
work has been done to clarify the pathways of synthesis and metabolic breakdown 
(Figure 1 ). It is now clear that vanillyl mandelic acid (VMA) and 4-hydroxy-3-methoxy-
phenylglycol (MHPG) are quantitatively the most important metabolites of both 
noradrenaline and adrenaline and that only a small fraction of released adrenaline and 
noradrenaline in vivo are excreted unchanged or as metanephrine or normetanephrine 
(46). Measurements of plasma and urinary concentrations of adrenaline, noradrenaline 
and various metabolites have proved to be useful in the diagnosis and management 
of certain diseases such as pheochromocytoma, Parkinson's disease, neuroblastoma 
and several psychiatric disorders (47-51). In this study we measured the amounts of 
adrenaline, noradrenaline, metanephrine, normetanephrine, VMA and MHPG excreted 
in the urine in an attempt to find an answer to the question whether or net any of the 
catecholamines or their metabolites in urine could reflect the plasma levels of 
noradrenaline and adrenaline during the infusions. 
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OTHER EFFECTS OF ADRENALINE 
Sodium excretion 
Since Claude Bernard observed an increased urine fiow following section of the 
splanchnic nerve in the anaesthetized animal, the influence of the sympathetic nervous 
system on renal sodium and water handling has been the subject of extensive 
research (52-55). It is now clear that the renal sympathetic nervous system and 
circulating catecholamines can exert profound effects on renal haemodynamics and 
in that way on sodium and water excretion. However, it is also apparent that 
adrenaline and noradrenaline also have a direct and distinct effect on renal sodium 
handling independent of their renal haemodynamic effects. In this matter the primary 
site in the nephron influenced by catecholamines appears to be the proximal tubule. 
In this study we measured urinary sodium excretion in order to gain insight in the 
effects of alterations of plasma concentrations of adrenaline and noradrenaline within 
the physiological range. 
Metabolic effects 
It was again Claude Bernard, who was the first to describe a "metabolic" effect which 
appeared to be mediated by the sympathetic nervous system, although he did not 
recognize it as such. He observed a transitory outpouring of sugar in the urine after 
he punctured rabbits into the forth ventricle (56). It is now appreciated that besides 
haemodynamic effects, adrenaline and noradrenaline exert a variety of "metabolic" 
effects. They play a role in the regulation of carbohydrate, lipid, ketone and protein 
metabolism. They contribute to the regulation of the plasma concentrations of 
electrolytes and hormones as well as thermogenesis. In this study we evaluated 
whether circulating catecholamines exert any effect on some of the above mentioned 
metabolic pathways, when they are infused intravenously in such doses that 
increments within the physiological range are reached. 
AIM OF THE STUDIES 
The questions we hoped to answer by the studies described in this thesis, were: 
1 Does adrenaline, when infused intravenously in normotensive subjects leading 
to plasma levels in the high physiological range, cause a sustained and 
protracted rise in blood pressure, which outlasts the duration of the increments 
in circulating adrenaline? And if so, does this effect on blood pressure occurs 
at rest or during periods of activation of the sympathetic nervous system? In 
view of the data of Vincent et al (43), we hypothesized that the latter would be 
the case. 
2 If the questions under number 1 are positively answered, does intravenous 
administered noradrenaline have the same effect? When the effect of 
19 
adrenaline is indeed mediated through prejunctional B,-adrenoceptors, we 
hypothesized that this would not be the case. 
3 Do the pressor responses to standardized sympathetic nervous system 
stimulation by cold pressor and isometric exercise testing before, during and 
18 hours after cessation of infusions of adrenaline, noradrenaline or dextrose 
5% differ? Again we hypothesized that infusion of adrenaline but not 
noradrenaline would lead to an amplification of the blood pressure responses. 
4 Are the changes in plasma concentrations of adrenaline and noradrenaline 
during the infusions of adrenaline and noradrenaline also detectable in 
alterations in the amounts of catecholamines and their metabolites excreted in 
the urine? 
5 Do the infusions of catechOiamines, which lead to alterations in plasma 
concentrations within the physiological range, have any effect on urinary 
sodium excretion or on plasma levels of several hormones, potassium or 
glucose? 
6 What is the effect of non-selective and B,-selective B-blockade on the 
adrenaline mediated facilitation of noradrenaline release and the adrenaline 
induced enhancement of reflex sympathetic nervous system activity? 
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Chapter 2 
STUDY PROTOCOl, SUBJECTS AND METHODS 
In this chapter a description is given on the study protocol, the subjects and 
methods concerning the data presented in chapters 3 to 7. A separate description 
on the study protocol, subjects and methods is given for chapter 8. 
SUBJECTS 
The studies were performed in 10 male non-smoking healthy volunteers, aged 25 
years (range 21-28). All subjects were normotensive, they were taken no 
medication and showed no evidence of cardiovascular disease, diabetes mellitus or 
any other serious disease based on their medical history, physical examination and 
electrocardiogram at the time of the study. Blood urea nitrogen and electrolytes 
were within the normal range of our laboratory. Urinalysis revealed no abnormalities 
and mean serum creatinine was 93 "moljl (range 83-1 03). They used an 
unrestricted diet on the days prior to the study and during the study. The purpose 
and procedures of the study were explained to the subjects. All gave their written 
informed consent and the study was approved by the Hospital Ethical Review 
Committee. 
STUDY PROTOCOL 
The study was carried out according to a double-blind crossover design. 
Adrenaline (15 ngjkg/min), noradrenaline (30 ngjkgjmin) or 5% dextrose (5.4 
mljhr) were infused for 6 hours in random order 2 weeks apart (Figure). 
Subjects arrived in the laboratory at 8.00 h after an overnight last. After they had 
used a standardized breakfast containing approximately 25 mmol of sodium, they 
emptied their bladder. The brachial artery of the nondominant arm was cannulated 
with a catheter (Seldicath Teflon, 1.0 mm thick, 11 em long, Laboratoire 
Pharmaceutique Saint-Leu-La-Foret, France) under local anaesthesia with 2% 
lidocaine. Venous catheters (Venflon 1.2 mm thick, 45 mm long, Viggo Products, 
Helsingborg, Sweden) were introduced in deep forearm veins of both forearms for 
infusion and blood sampling. After obtaining baseline values of blood pressure and 
heart rate from 9.00 to 10.00 h, the infusions were given between 10.00 h and 
16.00 h. During the infusions the subjects rested supine and were not allowed to 
eat or drink. A 5% dextrose solution was infused at a rate of 2 mljmin. Arterial and 
venous blood samples were taken simultaneously at regular time intervals. All 
passed urine was collected. The subjects left the hospital at 17.30 h after they had 
emptied their bladder. They were requested to perform similar activities during the 
evenings of the three study days and to go to bed at approximately the same time. 
They returned the next morning at 8.30 h. Before ending the blood pressure 
registration, they rested supine for 60 minutes. Again all passed urine was 
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STUDY PROTOCOL 
3 studies of 25 hours 2 weeks apart 
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RANDOMIZED 
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collected. 
The effect of the infusions on the blood pressure and heart rate response to 
isometric exercise and cold exposure (cold pressor test) was studied three times 
during each study day: approximately 30 minutes before the start of the infusion, 
after 4 'h hours of infusion, while the infusion was still running, and the next 
morning, approximately 18 hours after cessation of the infusion. 
Blood was sampled at hourly intervals for the following assays: adrenaline and 
noradrenaline (arterial and venous), renin, aldosterone, groW1h hormone, prolactin, 
insulin and cortisol (venous), before, after 1 hour and after 6 hours of infusion for 
glucose and potassium (venous). Venous and arterial catecholamines were also 
measured at 5 minutes interval during the first 20 minutes after cessation of the 
infusions. Arterial catecholamines were measured the next morning after 60 minutes 
of bedrest before the subjects performed the cold pressor and isometric exercise 
test. 
All passed urine was collected from 8.30 to 17.30 h 0nfusion period, urine 1) and 
from 17.30 to 8.30 h the next morning (postinfusion period, urine 2). This second 
urine always included the morning voiding. 
HAEMODYNAMIC MEASUREMENTS 
24 hr blood pressure and heart rate registration 
Arterial pressure was continuously monitored in the brachial artery of the non-
dominant arm by means of the Oxford technique (1). The intra-arterial cannula was 
connected to a perfusion-transducer device (Northwick Park Hospital, London, UK) 
suspended in front of the chest. The transducer signal was recorded on magnetic 
tape by means of an analogue taperecorder (Medilog Recorder II, Oxford Medical 
Instruments, Oxford, UK). The analogue signal was digitized during replay of the 
tape at 60 times real time with a sampling frequency of 33% samplesjs. Traces 
were analyzed beat by beat and were scrutinized for beat loss, clipping of the 
amplifier, damping and of moving artefacts by means of the computer system. 
These events amounted to <2% of all data and were excluded from analysis 
(2,3,4). Hourly means of systolic and diastolic arterial pressure and heart rate were 
calculated. 
Cold pressor and isometric exercise test 
The isometric exercise test was carried out by handgrip with one hand for 60 
seconds at 50% of maximal voluntary contraction, which was estimated by the 
subjects just after arrival in the laboratory. The cold pressor test was done by 
immersion of one hand up to the wrist into ice-water for 60 seconds. During all 
tests the subjects remained in the supine position. The tests were always done in 
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the same sequence, i.e. first the isometric exercise test and 10 minutes later the 
cold pressor test. The start and the end of the tests were marked on the tape with 
an event marker. The means of blood pressure and heart rate of the five minutes 
immediately preceding the tests were taken as baseline values. The changes in 
blood pressure and heart rate from these baseline values were computed as 10 
seconds averages. The changes in blood pressure and heart rate are presented as 
1 0-seconds means during the infusions and 18 hours after the cessation of the 
infusions as compared to the data for the tests done before the start of the 
infusions. The results of the dextrose study were subtracted from the results of the 
adrenaline and noradrenaline study. So the zero mmHg respectively zero beats per 
minute are in fact the results of the dextrose study. Also the mean differences with 
standard error of the means (SEM) in response of systolic and diastolic arterial 
pressure and heart rate to isometric exercise and cold pressor test during and after 
adrenaline and noradrenaline as compared to dextrose are presented. 
ANALYTIC PROCEDURES OF PlASMA 
For measurements of plasma catecholamines 10 ml venous and arterial blood 
was collected simultaneously in chilled tubes containing 19 mg EGTA and 12 mg 
gluthathione. After centrifugation at ooc, samples were stored at -70°C until assay. 
Plasma noradrenaline and adrenaline were measured by high-performance liquid 
chromatography with electrochemical detection. Results are expressed in pgjml 
(5). 
For determination of plasma renin concentration and plasma aldosterone venous 
blood was collected in tubes containing EDTA in a final concentration of 2 mgjml of 
blood. Samples were centrifuged immediately at oo C and stored at -20° C until 
assay. Renin was measured by radioimmunoassay of angiotensin I formed at 
neutral pH in the presence of saturating concentrations of sheep renin substrate. 
Results are expressed in milli-units of a standard of purified renin from human 
kidney (Medical Research Council standard 68/356, National Institute for Biological 
Standards and Control, London, UK) per litre (6). Plasma aldosterone was 
measured by commercially available radioimmunoassay (AidoKit, Labservice 
Benelux, Apeldoorn, the Netherlands). 
Cortisol and insulin were measured by commercially available radioimmunoassay 
kits (respectively "Coat-a-count", Diagnostic Products Corporation, los Angeles, 
USA and lncstar, Stillwater, Minnesota, USA). Growth hormone and prolactin were 
measured by an immunoradiometric assay (Euro-Diagnostics BV, Apeldoorn, the 
Netherlands). Glucose was measured in whole blood using the hexosekinase 
reaction. 
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ANAlYTIC PROCEDURES OF URINE 
Urine was collected in polyethylene containers over 0.5 g of Na,EDTA and 0.5 g 
of Na,S,O, and kept at 4°C in the dark. After completion of collection, aliquots were 
stored in a freezer at -70°C until assay. The catecholamines and metabolites have 
been shown to be stable for at least one year under these conditions (7). 
Adrenaline and noradrenaline were assayed by high-performance liquid chromato-
graphy with fluorescence detection and precolumn derivatization (8). 3-Methoxy-4-
hydroxyphenylglycol (MHPG), vanillylmandelic acid (VMA) and metanephrines were 
determined by high-performance liquid chromatography with electrochemical 
detection (9,10). 
Sodium was measured by flame photography and creatinine was measured with 
an EPOS 5060 analyzer (Eppendorf method: alkaline picrate, Merck creatinine kit). 
STATISTICAl ANALYSIS 
The data are presented as means with SEM unless indicated otherwise. Because 
values of renin were not distributed normally, mean values were calculated after 
logarithmic transformation. 
Analysis of haemodynamic values 
Haemodynamic baseline values, and the post-infusion values were compared 
using a Student paired t-test. Haemodynamic baseline values were also compared 
with mean values during infusions using Student paired t-test. In other comparisons 
of haemodynamic values we used a three-way analysis of variance (ANOVA, 
SPSSfPC program, Chicago Ill, USA), unless indicated otherwise, lor testing the 
treatment factor (noradrenaline, adrenaline, dextrose) on each of the parameters. 
No (subject x time) interaction was assumed. A (treatment x time) interaction was 
taken into account by testing the treatment effect for separate periods. The 
following periods were defined: baseline (9-10 h), infusion (10-16 h), daytime 
ambulation (16-24 h), bedtime (0-7 h), daytime ambulation (7-9 h), daytime bedrest 
(9-10 h). 
Analvsis of biochemical values 
Baseline plasma biochemical values (adrenaline, noradrenaline, growth hormone, 
prolactin, cortisol, insulin, potassium, glucose) and the post-infusion values were 
compared using a Student paired t-test. In other comparisons we used a three-way 
analysis of variance (ANOVA, SPSS/PC program, Chicago Ill, USA), unless 
indicated otherwise, lor testing the treatment factor (noradrenaline, adrenaline, 
dextrose) on each of the parameters. No (subject x time) interaction was assumed. 
A (treatment x time) interaction was taken into account by testing the treatment 
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effect for separate periods. In case baseline values of the three study occasions 
were different, results of measurements during the infusions were also compared 
with corresponding baseline values. 
Analysis of haemodvnamic responses to stress tests 
For analysis of the haemodynamic responses during cold pressor test and 
isometric exercise test the six 10 seconds means of the change in blood pressure 
and heart rate as compared to the preceding baseline values of the adrenaline, 
noradrenaline and dextrose study were compared using a repeated measurements 
analysis of variance (BMTP Statistical software Inc, Los Angeles, CA 90025 USA). 
When the null-hypothesis (that no difference existed) was rejected, the means of 
the six 1 0-seconds values of the change in blood pressure and heart rate were 
compared using a Student t-test for paired observations. 
Analysis of results of urinarv excretion of electrolvtes and creatinine 
The amounts of sodium, potassium, creatinine are presented. The results were 
also corrected for creatinine excretion, because of the possible failure of complete 
collection. Differences in urinary excretion of these compounds were analyzed with 
repeated measurements analys·,s of variance (SPSS/PC program, Chicago Ill, 
USA). When the null-hypothesis (that no difference existed) was rejected, the 
means of the results of the adrenaline and the noradrenaline study were compared 
with the results of the dextrose study using a Student-t-test. 
Analysis of results of urinarv excretion of catecholamines and their metabolites 
The amounts of adrenaline, noradrenaline, metanephrine, normetanephrine, VMA 
and MHPG are presented. Differences in urinary excretion of these compounds 
were analyzed with repeated measurements analysis of variance (BMTP Statistical 
software Inc, Los Angeles, CA 90025 USA). 
Interrelationships between the plasma, the urine and the haemodynamic data. 
Interrelationships between results of plasma catecholamines, urinary 
catecholamines and metabolites and haemodynamic measurements were 
determined by computing Pearsons correlation coefficients (SPSS/PC program, 
Chicago Ill, USA). 
Jn most analyses a p value of less than 5% and in some analyses, where 
considered appropriate, of less than 1%, were considered to indicate statistical 
significance. 
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Chapter 3 
SUPPORT FOR THE ADRENALINE-HYPERTENSION HYPOTHESIS: 18 HOUR 
PRESSOR EFFECT AFTER 6 HOURS OF ADRENALINE INFUSION. 
Based on: PJ Blankestijn, AJ Man in't Veld, JHM Tulen, AH van den Meiracker, F Boomsma, 
P Moleman, HJ Ritsema van Eck, FHM Derkx, P Mulder, SWJ lamberts, MADH 
Schalekamp. Support for the adrenaline-hypertension hypothesis: 18 hour pressor 
effect after 6 hours adrenaline infusion. Lancet 1988; ii: 1386-89. 
INTRODUCTION 
Adrenaline has been implicated in the pathogenesis of 'stress-linked' hypertension 
(1-5). After its release into the circulation from the adrenal medulla adrenaline can 
activate prejunctional B-adrenoceptors at sympathetic nerve terminals to enhance 
noradrenaline release and thereby increase a:-adrenoceptor mediated 
vasoconstr!ct1cn (6-8). ~n addit~on to -chis humeral effect adrenaline may also act as 
a co-transmitter of noradrenaline. Adrenaline is taken up from plasma by the 
sympathetic nerves and the amount of adrenaline that is stored together with 
noradrenaline by the neurons is increased when plasma adrenaline is elevated (9). 
At a time when plasma adrenaline concentrations are no longer elevated co-
released adrenaline can still cause activation of prejunctional B-adrenoceptors. 
In the rat slow release implants containing adrenaline elevate blood pressure lor 
several weeks, an effect which is not seen after pretreatment with B-adrenoceptor 
antagonists (10-14). Infusion of adrenaJine amplilies the blood pressure response to 
sympathetic stimulation in humans (15-17), and this amplification can also be 
prevented by prior B-adrenoceptor blockade. However, direct evidence in man that 
adrenaline can cause a sustained anc protracted elevation of blood pressure is 
lacking. Therefore we have decided to study the effects of a 6 h catecholamine 
infusion (adrenaline: 15 ngjkgjmin or noradrenaline: 30 ngjkgjmin) as compared 
to a 5% dextrose solution (5.4 mljmin) in healthy volunteers. After the infusions had 
been stopped, the subjects were tollowed for 18 h by means of ambufatory intra-
arterial blood pressure monitoring. 
SUBJECTS AND METHODS 
See chapter 2. 
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RESULTS 
Haemodynamic effects 
Mean baseline values of arterial pressure and heart rate were not different on the 
three study days (Figure 1, t-test). During the infusion of adrenaline arterial 
pressure fell from 103/62 ;: 3/2 mm Hg to 99/57 ;: 3/2 mm Hg (p<0.01, t-test) 
after 3 h, but in the second part of the infusion period arterial pressure returned to 
baseline (Figure 2). Blood pressure during adrenaline infusion was significantly 
lower than during dextrose infusion (p<0.001, ANOVA). Heart rate rose during 
infusion of adrenaline from 61 ;:3 to 63;:3 beats/min (p<0.001). During infusion of 
noradrenaline arterial pressure rose from 104/64 ;: 3/2 mm Hg to 113/70 ;: 3/2 
mm Hg (p<0.001) after 5 h of infusion and heart rate declined from 61 ;:2 to 55:t2 
beats/min (p<0.001). Blood pressure during noradrenaline infusion was 
significantly higher than during dextrose infusion (p<0.001, ANOVA). The post-
infusion period (16.00-10.00 h) was analyzed as a whole, and also over separate 
periods, i.e. 16.00 to 24.00 h, 0.00 to 7.00 h, 7.00 to 9.00 h and 9.00 to 10.00 h. 
For all periods, except for the period between 9.00 and 10.00 h, systolic arterial 
pressure (16.00-10.00 h: 6%, 16.00-24.00 h: 6%, 0.00-7.00 h: 5%, 7.00-9.00 h: 9%) 
and mean arterial pressure (16.00-10.00 h: 7%, 16.00-24.00 h: 5%, 0.00-7.00 h: 7%, 
7.00-9.00 h: 10%) were higher after adrenaline infusion than after dextrose 
(p<0.001, ANOVA). Diastolic pressure was higher in the period from 16.00 to 10.00 
h (7%) from 16.00 to 24.00 h (5%), from 0.00-7.00 h (7%) and from 7.00-9.00 h 
(13%). Heart rate after adrenaline infusion was not different from values after 
dextrose in any period. Haemodynamic values after noradrenaline infusion were 
never different from concomitant values after dextrose. 
Effects on venous and arterial catecholamine levels 
Mean baseline concentrations of adrenaline and noradrenaline were similar on the 
three study days (Table 1, t-test). During the infusion of adrenaline both arterial and 
venous concentrations of adrenaline rose approximately 10-fold (Table 1, Figure 3). 
Mean baseline venous concentrations of adrenaline increased from 21 :t 4 pg/ml 
to a mean of 230 ;: 28 pgjml during infusion (p < 0.001, t-test), and were 
significantly higher than 30 ;: 3 pg/ml, the corresponding value during dextrose 
(ANOVA, p<0.001). During infusion of noradrenaline arterial and venous plasma 
concentrations of noradrenaline rose 3- to 5-fold. Venous noradrenaline rose from 
207 :t17 pgjml to a mean of 705 ;: 58 pgjml during infusion (t-test, p<0.001) and 
was significantly higher than 219 ;: 24 pgjml, the corresponding value during 
dextrose, (AN OVA, p < 0.001 ). Within 5 minutes after cessation of the infusions 
catecholamine concentrations had returned to baseline values. At 17.00 h and the 
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Figure 1. Mean hourly values of arterial pressure and heart rate before, during and after infusion of 
adrenaline (-). noradrenaline (-) and dextrose (••••). 
next morning after 1 h of supine rest, plasma catecholamine concentrations were 
not different in the three situations and not different from the respective baseline 
values. Neither venous nor arterial plasma concentrations of noradrenaline were 
higher during adrenaline infusion than during 5% dextrose infusion. A small, 
although significant, decrease in both arterial and venous plasma adrenaline 
occurred during noradrenaline infusion as compared to corresponding values 
during dextrose infusion; mean arterial and venous adrenaline were 40 ± 7 and 22 
± 3 pgjml respectively during noradrenaline infusion and 58 ± 5 and 30 ± 3 
pg/ml during dextrose infusion (p<0.001 for both comparisons, ANOVA). 
TABLE 1: ARTERIAL PLASMA CONCENTRATIONS (MEAN ± SEM) OF NORADRENALINE 
AND ADRENALINE BEFORE. DURING AND AFTER A 6 H INFUSION OF 5% 
DEXTROSE. NORADRENALINE AND ADRENALINE. 
TIME (h) NORADRENALINE (pgjml) ADRENALINE (pgjml) 
DEX NOR ADR DEX NOR ADR 
0 186:t24 1$3±15 198:t21 42±7 36±7 34:t6 
161±16 910±51 168±14 60::!:10 43±13 348±13 
2 175±18 999±35 161::!:11 57:t8 42:!:8 360±18 
3 169±18 1038±33 153±13 51 ±6 40±7 398±26 
4 178±21 1049±45 169±17 55±6 44±8 378±19 
5 176::!:21 1061 ±69 179±19 59±8 42±7 402±23 
6 162±15 1094±50 175±22 63:!:7 45±7 440±31 
6.05 156±15 247±23 180±24 76±11 55±9 64±5 
6.10 164±14 215±18 190±30 68:~.:8 56±10 58±6 
6.15 166±15 219±17 182±28 69±7 59±9 75±10 
6.20 162±15 214±16 182±27 70±6 55:t7 76::!:11 
7 160±20 202±16 190±22 n±19 57±6 69±5 
24 175::!:22 194±17 234±40 61 ±5 68±12 77±9 
DEX = 5% dextrose, NOR = noradrenaline, ADR = adrenaline 
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TABLE 2 PLASMA CONCENTRATIONS OF RENIN, GROWTH HORMONE, PROLACTIN AND CORTISOL BEFORE, DURING AND AFTER 
INFUSION OF ADRENALINE AND NORADRENALINE. 
RENIN (mU/L) GROWTH HORMONE (~g/L) PROLACTIN (J•g/L) CORTISOL (nmoi/L) 
time(h) dex nor adr dex nor adr dex nor adr dex nor adr 
0 13.4(12.0·14.9) 15.5(14.6-21.0) 14.4(11.4-18.1) 1.4(0.6) 0.7(0.1) 0.6(0.1) 4.6(0.2) 4.4(0.2) 4.2(0.3) 425(31) 416(31) 437(53) 
1 12.8(10.5·15.6) 15.6(12.0·20.3) 21.5(18.9-24.4) 1.1 (0.2) 2.0(0.9) 1.8(0.9) 4.3(0.2) 3.9(0.2) 4.1(0.1) 334(28) 341 (38) 311(41) 
2 10.7(8.7-13.2) 18.2(13.9-23.9) 19.9(16.6-23.9) 1.5(0.5) 1.3(0.3) 1.1 (0.3) 4.6(0.5) 3.9(0.1) 4.0(0.2) 330(46) 308(39) 317(30) 
3 11. 7(10.0-13.6) 15. 7(12.4-19.8) 20.1 (16.3-24.8) 1.0(0.2) 0.7(0.1) 0.9(0.2) 4.4(0.4) 3.8(0.1) 4.1(0.2) 318(41) 281 (28) 290(31) 
4 9.9 (8.6-11.4) 18.4{13.9-24.3) 17.1 (14. 7-20.0) 1.9(0. 7) 0.7(0.1) 0.7(0.1) 4.2(0.2) 4.0(0.2) 4.2(0.2) 326(25) 305(30) 313(33) 
5 10.5(8.4-13.0) 18. 7(14.1-24.8) 17.2(14.8-19.9) 3.1 (1.6) 0.8(0.2) 1.2(0.3) 4.6(0.1) 4.1(0.2) 4.8(0.3) 347(31) 343(33) 391 (50) 
6 11.1(8.8-14.1) 17.1 (13.2-22.2) 16.4(14.1-19.2) 3.0(0.9) 1.9(0.8) 1.9(0. 7) 4.8(0.3) 4.5(0.2) 4.8(0.3) 356(34) 287(20) 282(36) 
7 10.0(8.2-12.3) 19. 7(14.9-26.1) 15.3(12.9-18.0) 3.0(0.9) 1.5(0.4) 1.0(0.2) 5.0(0.4) 5.0(0.4) 5.4(0. 7) 260(64) 268(32) 350(30) 
----------
Data are mean (SEM), except for renin which are geometric means (range). 
Dex = dextrose Infusion, nor = noradrenaline Infusion, adr = adrenaline Infusion 
Hormonal changes 
Baseline concentrations of active plasma renin were similar on the three study 
days (Table 2, t-test). Renin rose both during infusion of adrenaline and 
noradrenaline (p<0.001, ANOVA). At 17.00 h, one hour after the infusions had 
been stopped, the differences from dextrose were no longer statistically significant. 
Plasma concentrations of cortisol, prolactin and growth hormone before, during 
and after the infusions were not different during the three studies. The normal fall of 
cortisol between 9.00 and 17.00 h (p<0,01, t-test) was seen on each of the infusion 
days . 
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DISCUSSION 
The plasma concentrations of catecholamines achieved by the infusions in this 
study are well within the physiological range. Venous concentrations of 
noradrenaline of approximately 700 pgjml can be seen during quiet standing and 
mild physical exercise (18, 19). Plasma concentrations of adrenaline of 
approximately 200 - 300 pgjml have been reported during surgery, during 
moderate to severe physical exercise and during public speaking (18, 19). 
This study clearly shows, that infusion of adrenaline for 6 hours, at a rate which 
increases plasma levels of adrenaline into the high physiological range, causes a 
sustained increase in blood pressure which lasts for at least 18 hours after the 
infusion has been stopped. Our findings are compatible with the hypothesis that 
adrenaline taken up by sympathetic nerve terminals can be co-released with 
noradrenaline during sympathetic stimulation. Infusion of noradrenaline at a rate, 
which also increases plasma concentrations of noradrenaline into the high 
physiological range, lacks such an effect. Thus, the pressor effect of adrenaline is 
mediated by a B,-adrenoceptor. Obviously, the prejunctional B,-adrenoceptor, which 
increases noradrenaline release upon stimulation, is the ideal candidate to explain 
this delayed pressor effect of adrenaline. Indeed, after the infusion of adrenaline 
had been stopped, its pressor effect was only evident during periods of increased 
sympathetic activity, i.e.: 1. during ambulation after the subjects went back home, 
2. in the second part of the night when sympathetic activity is known to be 
increased during REM sleep (20-22) and 3. the next morning when the volunteers 
came back to the hospital. The pressor effect of adrenaline could not be 
demonstrated under basal conditions, i.e. 1. in the hour following cessation of the 
infusion, 2. shortly after the subjects had gone to bed and 3. the following day 
during one hour recumbency in the laboratory (Figure 4). 
Are there alternative explanations for our findings? The renin-angiotensin system 
might be a candidate for adrenaline's pressor effect. Renin release is mediated by 
B,-adrenoceptors and both adrenaline and noradrenaline are B,-adrenoceptor 
agonists (23). However, it is adrenaline and not noradrenaline that has a prolonged 
pressor effect after its infusion had been stopped. Thus, stimulation of the renin-
angiotensin system is not a very likely explanation for this effect. Another possibility 
is that adrenaline, either directly or indirectly through its peripheral effects, 
stimulates central sympathetic outflow, thereby increasing blood pressure. Release 
of adrenocorticotropic hormone may be directly stimulated by adrenaline (24). 
Release of growth hormone and prolactin can be triggered by various forms of 
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stress (25). However, cortisol values were not different in the three study situations 
and they showed their normal decline during the day. In addition growth hormone 
and prolactin concentrations were similar during the different study conditions and 
they did not rise during the infusions. 
In contrast to previous reports (4, 26), we were not able to demonstrate an effect 
of adrenaline on heart rate in the post-infusion period. In these studies of Brown 
and co-workers adrenaline had no significant effect on blood pressure, but it 
caused a long-lasting rise in heart rate after the infusion was stopped. This 
phenomenon was taken as evidence by the authors for prejunctional B-
adrenoceptor stimulation of cardiac sympathetic nerves. An increase in metabolic 
rate by adrenaline, offsetting its pressor effect and increasing heart rate, would be 
an alternative explanation for their finding (27). In Brown's study much higher 
infusion rates were used than in our study (100 vs 15 ngjkgjmin) and indeed at 
infusion rates above 50 ngjkgjmin adrenaline increases the metabolic rate with 
secondary haemodynamic consequences (27). Also in a more recent study, in 
which adrenaline was infused at the same rate as in our study (28), an increase in 
blood pressure was seen for one hour after the infusion had been stopped, 
whereas heart rate was not increased in this period. The most likely explanation for 
the absence of an effect of adrenaline on heart rate, at the time it exerted its 
delayed pressor effect, is the interference of the arterial baroreflex which may offset 
the effect of adrenaline on neurotransmitter release in cardio-accelerator nerves. 
Some studies have shown increments in plasma noradrenaline after infusion of B-
adrenoceptor stimulants, including adrenaline (16, 29-31), whereas others did not 
(32). We also were unable to detect, either in arterial or venous blood, an increase 
in plasma noradrenaline during the adrenaline infusion. Again, it should be stressed 
here, that adrenaline only exerted its delayed pressor effect during periods of 
sympathetic stimulation. Unfortunately, we only took blood samples from our 
subjects in the supine resting situation and not during sympathetic activation. 
Three recent studies by Floras et al are of particular interest, since they provide 
further evidence for the functional significance of the mentioned concept. In the first 
study (17) they compared the effects of adrenaline and isoprenaline on forearm 
vasoconstrictor responses to a reflex stimulus lor noradrenaline release (lower body 
negative pressure [LBNP]). To localise their action adrenaline (50 ngjmin) and 
isoprenaline (10 - 25 ngjmin) were infused for 40 minutes into the brachial artery 
and caused no systemic pressor effect. The vasoconstrictor response to LBNP was 
considerably augmented during but also 30 minutes after cessation of adrenaline 
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infusion. In contrast, prior infusion of isoprenaline, which is not taken up by 
sympathetic nerves, had no such aftereffect on the vasoconstrictor response to 
LBNP. Since the plasma half live of adrenaline is not more than a few minutes, 
these data provided evidence that adrenaline is taken up by sympathetic nervous 
system and released during subsequent reflex stimulation and augments 
neurogenic vasoconstriction. In a second study a comparable protocol was studied 
in borderline hypertensives (33). Again, 30 minutes after adrenaline an enhanced 
vasoconstrictor response was found, similar to the first study. In a third experiment 
normotensive subjects were studied (34). Again the forearm vasoconstrictor 
response to LBNP was measured before and after adrenaline, this time infused 
systemically. This protocol was carried out at two occasions: after placebo and 
after pretreatment with the neuronal uptake blocker desipramine. The study showed 
that the vasoconstrictor response was augmented 30 minutes after adrenaline on 
the placebo occasion, but not on the desipramine treatment day. Blood pressure 
was higher after adrenaline during placebo than during desipramine. So these 
studies clearly showed that the aftereffects of adrenaline are mediated by 
adrenaline which has been taken up in sympathetic nerves and which is 
subsequently coreleased with noradrenaline during sympathetic nervous 
stimulation. 
In our study we used intravenously infused adrenaline. To our knowledge no data 
are available on the long term pressor effect of endogenously released adrenaline 
in humans. These results would be of great interest since they would substantiate 
the above suggested role of adrenaline in the pathogenesis of hypertension. 
Various kinds of stress can induce both a rise in adrenaline and in blood pressure 
(see extensive review 35), however, whether stress induced adrenaline release is 
able to mediate a delayed and protracted pressor effect as described in this 
chapter, is not known. Researchers who would plan to organize a study to evaluate 
this question, will encounter major methodological problems and problems with 
standardization. Another way to induce a rise in endogenously released adrenaline, 
is by inducing hypoglycaemia. A study on the long term pressor effect of 
hypoglycaemia, does not exist to our knowledge. However, important problems 
would exist when performing such a study in normal volunteers, for instance 
problems of ethical nature, but also the fact that hypoglycaemia induces a marked 
rise in several other hormones except adrenaline, such as growth hormone, 
cortisol, noradrenaline and glucagon (36). When inducing hypoglycaemia in 
diabetics a possible problem would be the frequently existing impaired hormonal 
response to low blood glucose, which is particularly true for adrenaline and 
glucagon (37). So, we think that, although such studies could potentially further 
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contribute to our understanding of the role ol adrenaline in the pathogenesis ol 
hypertension, these studies can hardly be performed. 
In conclusion, man's endogenous B,-adrenoceptor stimulant adrenaline when 
elevated into the high physiological range, as seen during several forms of stress, 
mediates a delayed and protracted pressor effect. Stress levels ol noradrenaline 
are devoid ol such activity. Central nervous system activation or stimulation of the 
renin-angiotensin system can not readily explain the different effects ol the two 
catecholamines. This suggests that activation of prejunctional B,-adrenoceptors by 
stored adrenaline is responsible lor its delayed pressor effect. When co-released 
with noradrenaline upon sympathetic stimulation, adrenaline augments 
noradrenaline release, thereby amplifying vasoconstrictor nerve activity and raising 
blood pressure. 
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Chapter 4 
"STRESS" lEVELS OF ADRENALINE MEDIATE A PROTRACTED 
AMPliFICATION OF THE BlOOD PRESSURE RESPONSE TO SYMPATHETIC 
STIMUlATION IN MAN. 
Based on: PJ Blankestijn, J Tulen, AJ Man in't Veld, AH van den Meiracker, F Boomsma, P 
Moleman, MADH Schalekamp. "Stress" levels of adrenaline for 6 hours mediate a 
protracted (18 hours) amplification of the blood pressure responses to sympathetic 
stimulation in man. J Hypertens 1991, in press 
INTRODUCTION 
In most healthy human subjects, exposure of the skin to ice-cold water, the cold 
pressor test, and performance of isometric exercise increase arterial pressure, heart 
rate and vascular resistance (1-4). This response is generally believed to be the 
result of sympathetic nervous system stimulation, which gives a rise in plasma 
noradrenaline, vasoconstriction and an increase in blood pressure. This pressor 
response is abolished by o:-adrenoceptor blockade, but not by B-adrenoceptor 
blockade (5,6). The cold pressor and isometric exercise test are used to evaluate 
sympathetic neural control of peripheral circulation. The cold pressor test has been 
reported to produce exaggerated responses in hypertension-prone persons (4) and 
it is impaired in patients with orthostatic hypotension caused by efferent 
sympathetic failure (7). 
In previous studies our group has demonstrated that infusion of adrenaline 
resulting in plasma levels in the high physiological range, is capable of augmenting 
the rise in blood pressure induced by the cold pressor and isometric exercise test 
(8-10). Beta-blockade prevented the facilitation of the pressor responses. Also 
plasma noradrenaline was higher during adrenaline infusion. It was hypothesized 
that adrenaline may amplify sympathetic pressor responses by facilitation of the 
release of noradrenaline through activation of the prejunctional 8,-adrenoceptors. 
The aim of the present study was twofold: 
1. Adrenaline is likely to be the physiologic agonist of the prejunctional B,-
adrenoceptors, as opposed to noradrenaline which is virtually devoid of 8,-
adrenoceptor agonistic properties. Therefore, we measured the responses in blood 
pressure and heart rate during cold pressor test and isometric exercise test during 
adrenaline, but also during noradrenaline and dextrose infusion in order to collect 
further evidence for the hypothesis that the amplification of the pressor response by 
adrenaline indeed occurs through stimulation of 8,-adrenoceptors. 
2. Since it was hypothesized that circulating adrenaline can be taken up in the 
sympathetic neuron and can be "co-released" along with noradrenaline during 
sympathetic stimulation and subsequently facilitate noradrenaline release, we also 
measured the responses of blood pressure and heart rate during cold pressor test 
and isometric exercise test 18 hours after cessation of the infusions, in order to 
provide evidence that this mechanism might also be operational in man. 
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SUBJECTS AND METHODS 
See chapter 2. 
RESULTS 
Plasma catecholamines and haemodynamics 
During infusion of adrenaline and noradrenaline arterial plasma concentrations of 
noradrenaline and adrenaline rose from 34±6 to 387±15 pgfml and from 183±15 
to 1025±38 pgjml respectively and returned to baseline values within 10 minu1es 
after the cessation of the infusions. Plasma noradrenaline during adrenaline infusion 
did not change as compared to baseline levels and to plasma levels during 
dextrose infusion. Results of measurements of venous plasma concentrations of 
adrenaline and noradrenaline are presented in chapter 3. 
TABLE 1 ARTERIAL PLASMA ADRENALINE (pgjml) CONCENTRATIONS 
baseline during infusion 18h after infusion 
Adrenaline infusion 34 ::!::: 6 387 ± 15 *** 77 ± 9 
Noradrenaline infusion 36 ± 7 41 ± 7 68 ± 12 
Dextrose infusion 42 ± 7 58± 5 61 ± 5 
ARTERIAL PLASMA NORADRENALINE (pgjml) CONCENTRATIONS 
Adrenaline infusion 
Noradrenaline infusion 
Dextrose infusion 
data are means ± SEM 
baseline 
199 ± 21 
183 ± 15 
186 ± 24 
during infusion 18h after infusion 
167 ± 15 230 ± 40 
1025 ± 38 *** 194 ± 17 
170 ± 17 175 ± 20 
'1<'1<* p<0.001, adrenaline infusion: plasma adrenaline during infusion of adrenaline versus dextrose 
infusion, but also versus baseline of adrenaline study 
Noradrenaline infusion: plasma noradrenaline during infusion of noradrenaline versus dextrose 
infusion, but also versus baseline of noradrenaline study 
Mean arterial plasma concentrations of adrenaline and noradrenaline before the 
isometric exercise and cold pressor test performed 18 hours after the cessation of 
the infusions were not different during the three study days (Table 1). Venous 
plasma concentrations of adrenaline and noradrenaline were not measured at that 
time. 
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Figure 1. Blood pressure and heart rate response before the start of the infusions of adrenaline 
(-), noradrenaline (-)and dextrose ( .. ••). 
Left panel: isometric exercise test, right panel: cold pressor test 
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Baseline arterial blood pressure and heart rate were not different between the 3 
studies. Mean blood pressure decreased 5± 1 % during adrenaline as compared to 
dextrose and increased with 4± 1 % during noradrenaline as compared to dextrose. 
During the post-infusion period systolic and diastolic arterial pressure were 6±2% 
and 7±2 % higher after adrenaline than after dextrose, whereas blood pressure 
after noradrenaline was not different from the dextrose study. No differences in 
heart rate occurred after adrenaline or noradrenaline as compared to dextrose (see 
for more detailed information: chapter 3). 
Stress tests 
The isometric exercise and cold pressor test performed before, during as well as 
after the infusions induced a gradual increase in systolic and diastolic arterial 
pressure. 
Changes in blood pressure and heart rate during both the isometric exercise and 
the cold pressor test performed before the start of the infusions were not different 
on the 3 study days (Figure 1 ). 
TABLE 2 DIFFERENCES IN RESPONSE OF BLOOD PRESSURE AND HEART RATE TO COLD 
EXPOSURE AND ISOMETRIC EXERCISE DURING AND 18h AFTER ADRENALINE 
AND NORADRENALINE INFUSION AS COMPARED TO DEXTROSE INFUSION. 
ISOMETRIC EXERCISE 
during ADR 
SAP (mmhg) 7±2 p<0.01 
DAP (mmHg) 3±2 ns 
HR (bpm) -1±4 ns 
COLD EXPOSURE 
during ADR 
SAP (mmHg) 4±1 p<O.OS 
DAP (mmHg) 4±2 ns 
HR (bpm) -2±2 ns 
after ADR 
7±2 p<0.01 
3±2 ns 
2±2 ns 
after ADR 
9±3 p<O.OS 
6±2 p<0.01 
-2±3 ns 
during NOR 
-5±3 ns 
4±3 ns 
0±3 ns 
during NOR 
-3±2 ns 
-3±2 ns 
-1 ::!:1 ns 
Data are means ± SEM of the 6 ten seconds means during the tests. 
SAP = systolic arterial pressure, DAP = diastolic arterial pressure, HR = heart rate 
ADR = adrenaline, NOR = noradrenaline 
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after NOR 
-2±2 ns 
-1 ±1 ns 
4±2 ns 
after NOR 
0±2 ns 
-3±2 ns 
-3±3 ns 
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Figure 2. Difference in blood pressure response during isometric exercise as compared to dextrose. 
0-G during infusion, 0-0 after infusion 
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The increments in blood pressure induced by isometric exercise test were greater 
during adrenaline infusion than during dextrose infusion (Figure 2 and Table 2). 
This difference was only statistically significant for systolic arterial pressure. The 
pressor effect of isometric exercise test 18 hours after cessation of the infusion of 
adrenaline was still increased as compared to the test done 18 hours after dextrose 
(Figure 2, Table 2). Changes in heart rate during and after adrenaline and in blood 
pressure and heart rate during and after noradrenaline infusion during the isometric 
exercise test were not different from those of the dextrose study. 
The effect of adrenaline infusion on the pressor responses to cold pressor test 
were similar to the effects observed during the isometric exercise test. During, but 
also after the adrenaline infusion the rise in systolic and diastolic arterial pressure 
was more pronounced than in the dextrose study (Figure 3, Table 2). Responses in 
heart rate during and after the adrenaline and in blood pressure and heart rate 
responses during and after the noradrenaline infusion were not significantly different 
from the effects of the tests during dextrose. 
DiSCUSSION 
As has been shown in numerous earlier studies, isometric exercise and the cold 
pressor test induce a rise in both systolic and diastolic arterial pressure and heart 
rate (1-4). Our results are in concordance with these reports. This increase in blood 
pressure is a result of an activation of the sympathetic nervous system (1-6,11). 
That these tests indeed actually increase sympathetic outflow was elegantly shown 
by the group of Allyn Mark and coworkers (12,13). They measured muscle 
sympathetic nerve activity with micro-electrodes inserted percutaneously into a 
peroneal muscle nerve fascicle in the leg before and during cold pressor test. 
Arterial pressure, plasma noradrenaline and muscle sympathetic nerve activity rose 
during immersion of the hand in ice-water. The increments in muscle sympathetic 
activity during the test were well correlated with the increases in blood pressure 
and peripheral venous noradrenaline (12). In a second series of experiments they 
demonstrated that also sustained handgrip leads to an increase in muscle 
sympathetic nerve activity (13). 
In a previous studies we have demonstrated that the pressor effect induced by 
cold pressor test and isometric exercise test was amplified during adrenaline 
infusion in comparison to placebo (8-1 0). In those studies adrenaline was infused at 
a rate of 30 ngfminjkg body weight, which produced arterial plasma levels of 
approximately 700 pgfml. The present study in which we infused adrenaline at a 
rate of 15 ngfminfkg body weight, leading to arterial plasma levels of 
approximately 380 pgfml, confirm these earlier findings. This means that also 
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Figure 3. Difference in blood pressure response during cold exposure as compared to dextrose. 
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moderately increased plasma concentrations of adrenaline, such as during mild 
stress, elicit this effect on blood pressure. As was found by Vincent et al (8), we did 
not detect any difference in responses in heart rate during adrenaline as compared 
to dextrose. 
The present study also demonstrates, that infusion of noradrenaline does not 
produce an amplification of the pressor response to isometric exercise test and 
cold pressor test as observed during adrenaline infusion. This finding can be 
interpreted as an indication through which mechanism the amplification of this 
pressor response occurs. In vitro studies have shown that the release of 
noradrenaline from sympathetic nerves is enhanced by B-adrenoceptor agonists 
(14,15). The receptor involved in this facilitating response, is most likely of the 
prejunctional B, subtype (16-18). These B,-adrenoceptors are demonstrated to be 
sensitive to the naturally occurring B-adrenoceptor agonist adrenaline (15,18-19). 
These findings have led to the hypothesis that endogenous adrenaline can 
modulate noradrenaline release through stimulation of these receptors. In that way 
adrenaline may indirectly increase sympathetic vasoconstrictor tone. Our findings in 
vivo that adrenaline but not noradrenaline can amplify the blood pressure response 
to isometric exercise and cold pressor test give support to the hypothesis that this 
effect is B,-adrenoceptor mediated and that it might also be operational in man, 
since adrenaline is mans endogenous B,-adrenoceptor stimulant. 
Another important finding of our study is the fact that the pressor effect of the 
isometric exercise and cold pressor test performed the next morning, approximately 
18 hours after cessation of the adrenaline infusion, was enhanced as compared to 
the same tests after the noradrenaline and dextrose infusions. Arterial plasma levels 
of adrenaline and noradrenaline taken shortly before the isometric exercise and 
cold pressor test were not different on the three study days (Table 2). 
These data support the results of extensive animal and in vitro research on the 
possible function of adrenaline as cotransmitter of noradrenaline. It is almost 30 
years ago that is was shown that adrenaline can be taken up into sympathetic 
nerves (20). Once incorporated into the nerve terminals, adrenaline may be 
released as cotransmittor of noradrenaline during sympathetic nerve stimulation. 
When released from sympathetic nerves, adrenaline activates prejunctional B,-
adrenoceptors to further enhance noradrenaline release. Majewski et al have 
demonstrated in the anaesthetized rabbit, that adrenaline given intravenously (21) 
or released from the adrenal medulla by splanchnic nerve stimulation (22), resulted 
in an increase in the rate of noradrenaline release into the plasma well after the 
adrenaline had been cleared from the plasma. At that time the adrenaline 
concentrations in the sympathetically innervated tissues were still raised. 
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Pretreatment of the rabbits with desipramine in order to block neuronal uptake of 
adrenaline or pretreatment with B-adrenoceptor antagonist, prevented this 
facilitating effect of adrenaline on noradrenaline release completely. In other studies 
by Majewski et al (23) it was shown that rats subjected to the chronic stress of 
individual housing and binding of their rear legs had elevated blood pressures 
when compared to control rats. In rats that had undergone adrenal medullectomy 
prior to the stressing procedure, or giving desipramine or propranolol, the stressing 
procedure did not elevate blood pressure. After 12 days of "stress" the animals 
were sacrificed and adrenaline content of the heart was measured. The adrenaline 
content was higher in stressed rats than in control rats. In desipramine treated rats 
the cardiac adrenaline content was not different from desipramine treated control 
rats. All these results taken together suggest that in these animals adrenaline had a 
primary role in the stress-induced hypertension. The experiments with the neuronal 
uptake-blocker desipramine and the B-adrenoceptor blocker propranolol are 
consistent with the hypothesis that neuronal accumulation of adrenaline and 
activation of (prejunctional) B-adrenoceptors are also involved. 
Floras et al provided evidence in three recent studies that also in man adrenaline 
can be taken up and can be "co-released" along with noradrenaline during 
sympathetic nervous stimulation. In the first study (24) they compared the effects of 
adrenaline and isoprenaline on forearm vasoconstrictor responses to a refiex 
stimulus for noradrenaline release (lower body negative pressure [LBNP]). To 
localise their action adrenaline (50 ngjmin) and isoprenaline (10- 25 ngjmin) were 
infused for 40 minutes into the brachial artery and caused no systemic pressor 
effect. The vasoconstrictor response to LBNP was considerably augmented during, 
but also 30 minutes after cessation of adrenaline infusion. In contrast, prior infusion 
of isoprenaline, which is .not taken up by sympathetic nerves, had no such 
aftereffect on the vasoconstrictor response to LBNP. Since the plasma half live of 
adrenaline is not more than a lew minutes, these data provided evidence that 
adrenaline is taken up by the sympathetic nervous system and released during 
subsequent reflex stimulation and that it augments neurogenic vasoconstriction. In 
a second study a comparable protocol was carried out in borderline hypertensives 
(25). Again, 30 minutes after adrenaline an enhanced vasoconstrictor response was 
found;similar to the first study. In a third experiment normotensive subjects were 
studied (26). Again the forearm vasoconstrictor response to LBNP was measured 
before and after adrenaline, this time infused systemically. This protocol was done 
on two occasions: after placebo and after pretreatment with the neuronal uptake 
blocker desipramine. The study showed that the vasoconstrictor response was 
augmented 30 minutes after adrenaline on the placebo occasion, but not on the 
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desipramine treatment day. Blood pressure was higher after adrenaline during 
placebo than during desipramine. So these studies clearly showed that the 
aftereffects of adrenaline are mediated by adrenaline which has been taken up in 
sympathetic nerves and was subsequently coreleased with noradrenaline during 
sympathetic nervous stimulation. 
In our study in man we found that the pressor effect induced by isometric 
exercise and the cold pressor test performed 18 hours after the cessation of the 
adrenaline infusion, was still enhanced in comparison with the results of the 
noradrenaline and dextrose study. These data are compatible with the hypothesis 
which is at the base of the animal research and the studies in humans just 
mentioned. This is to say that adrenaline can be taken up in sympathetic nerve 
endings and that it can be can be co-released with noradrenaline during 
sympathetic stimulation. Subsequently it activates prejunctional B,-adrenoceptors, it 
enhances noradrenaline release and increases vasoconstrictor tone and therefore it 
raises blood pressure. Our results support the view that this mechanism is also 
operational in man. Furthermore, our finding, that adrenaline particularly increased 
blood pressure in the periods after its infusion, in which sympathetic activity was 
supposedly increased (Chapter 3), also accords with the present findings. 
In conclusion our results provide further evidence for the hypothesis that 
adrenaline amplifies the blood pressure response to sympathetic stimulation, both 
when circulating adrenaline levels are in the high physiological range (during 
stressful conditions) as well as for a period of at least 18 hours after the raised 
plasma adrenaline concentrations. This effect is most likely due to stimulation of the 
prejunctional B,-adrenoceptors, since noradrenaline is devoid of such an effect. 
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Chapter 5 
URINARY EXCRETION OF CATECHOLAMINES AND THEIR METABOLITES 
DURING AND AFTER A 6 HOUR INFUSION OF ADRENALINE AND 
NORADRENALINE 
Parts of this chapter will be published in: P Moleman, JHM Tulen, PJ Blankestijn, AJ Man in't Veld, F 
Boomsma. Urinary excretion of catecholamines and their metabolites in relation to circulating 
catecholamines. Arch Gen Psychiatry 1991: in press 
Abbreviations used in this chapter 
COMT catechol-0-methyltranslerase 
DHMA 3,4-dihydroxymandelic acid 
DHPG 3,4-dihydroxyphenylglycol 
MAO monoamine oxidase 
MHPG 4-hydroxy-3-methoxyphenylglycol 
MN metanephrine 
NMN normetanephrine 
PNMT phenylethanolamine-N-methyltranslerase 
VMA vanillyl mandelic acid 
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INTRODUCTION 
The major catecholamines are noradrenaline, adrenaline and dopamine. 
Noradrenaline is the principal neurotransmitter of the sympathetic nervous system, 
but it is also an important transmitter in the central nervous system. Adrenaline is 
almost exclusively secreted by the adrenals and exerts its major actions as a 
circulating hormone. Dopamine is the precursor of noradrenaline and adrenaline 
and is an important central nervous system transmitter, but has also some 
peripheral effects. 
When it was shown that only a small fraction of administrated oatecholamines is 
excreted in urine (1 ,2), interest in their metabolism increased. Studies with 
radiolabelled catecholamines provided insight in the metabolic transformation and it 
became clear that deamination by MAO and 0-methylation by COMT are the two 
major routes of metabolism (3). The biosynthetic interrelationships between the 
catecholamines and their metabolttes are shown in Figure 1 of Chapter 1. 
In this chapter we describe the results of measurements of the amounts of 
catecholamines and their metabolites excreted into the urine, collected during the 
infusions and during the postinfusion periods. The questions which we hoped to 
answer by this study were, firstly: are increments in plasma oatecholamines within 
the physiological range also recognizable in alterations in the urinary excretion of 
catecholamines and their metabolites? And if the answer is yes, measurement of 
which metabolite in which urine is most suitable for answering this question? If the 
answer on the first question is affirmative, the following question is, whether the 
enhanced noradrenaline release, which is hypothesized to be responsible for the 
pressor effect observed in the postinfusion period (see Chapter 3) is also 
detectable in increased excretion of noradrenaline andjor its metabolites? Since no 
plasma noradrenaline concentrations were measured in the postinfusion period, we 
hoped to collect additional support for this concept by measuring the urinary 
catecholamines and metabolites. 
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RESULTS 
Effects on plasma adrenaline and noradrenaline 
Baseline values of arterial and venous adrenaline and noradrenaline did not differ 
between the three study days. During the infusion of adrenaline venous adrenaline 
rose from 21 ± 4 to a mean of 230 ± 28 pg/ml and arterial adrenaline rose from 
34 ± 6 to 387 ± 15 pgjml. Both venous and arterial plasma levels during infusion 
of adrenaline were higher than during dextrose infusion (ANOVA, both p<0.001). 
Plasma noradrenaline did not change during adrenaline infusion. 
During noradrenaline infusion venous noradrenaline rose from 207 ± 17 to a 
mean of 705 ± 58 pgjml and arterial noradrenaline from 183 ± 15 pgjml to 1025 
± 38 pgjml. Both venous and arterial plasma concentrations were higher than 
during dextrose infusion (ANOVA, both p<0.001). 
A small although significant decrease in both arterial and venous plasma 
adrenaline occurred during noradrenaline infusion as compared to corresponding 
values during dextrose infusion; mean arterial and venous adrenaline was 40 ± 7 
and 22 ± 3 pgjml respectively during noradrenaline infusion and 58 ± 5 and 30 ± 
3 pgjml during dextrose infusion (p<0.001 for both comparisons, ANOVA). 
Five minutes after cessation of the infusions plasma concentrations of adrenaline 
and noradrenaline after respectively adrenaline and noradrenaline infusion had 
returned to baseline values. (see lor more detailed description chapter 3). The total 
amounts of adrenaline and noradrenaline infused on the respective occasions was 
5.00 ± 0.45 !'moles of noradrenaline and 2.31 ± 0.21 1-'moles of adrenaline. 
Effects on urinary excretion of adrenaline and noradrenaline and metabolites 
Infusion of adrenaline resulted in a significant increase in excretion of adrenaline 
and M during the infusion period as compared to dextrose infusion, i.e. during 
adrenaline and dextrose respectively adrenaline excretion of 149 ± 31 vs 22 ± 7 
nmoles and M excretion 559 ± 186 and 291 ± 92 nmoles (Table 1). In the 
postinfusion period adrenaline excretion after adrenaline infusion was not different 
from values after dextrose infusion, whereas M excretion was still significantly 
increased, 556 ± 219 vs 325 ± 192 nmoles respectively (Table 1). The excretion 
rate of adrenaline and M during the total collection period was significantly higher 
during the adrenaline study than during the dextrose and noradrenaline study; 
adrenaline excretion 0.17 ± 0.04 vs 0.04 ± 0.01 l'moles during adrenaline and 
dextrose study respectively and M excretion 1.13 ± 0.39 vs 0.62 ± 0.27 l'moles 
respectively (Table 2). 
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TABLE 1. URINARY CATECHOLAMINE$ AND THEIR METABOUTES DURING AND AFTER 6 
HOURS INFUSION OF ADRENAUNE AND NORADRENAUNE. 
infusion condition Condition effect 
DEXTROSE NOR ADR p 
····-------------------------
ADR 
urine 1, (nmol) 22.0± 7.7 (10) 21.0±9.6 (10) 149 ±31 (9) <0.001 
urine 2, (nmol) 20.1 ±12.8 (10) 16.9±10.6 (10) 23.4±10.5 (10) n.s. 
M 
urine 1, (nmol) 291 ± 92 (10) 298 ± 67 (9) 559±186 ( 9) <0.001 
urine 2, (nmol) 325 ±192 (10) 374 ±209 (10) 556±219 (10) <0.001 
NOR 
urine 1, (nmol) 82.5 ±32.1 (10) 290 ± 60.3 (1 0) 91.7 ±33.6 (9) <0.001 
urine 2, (nmo!) 159 ±48.3 (10) 156 ±39.7 (10) 154 ±48.9 (10) n.s. 
NM 
urine 1, (nmol) 415 ±106 (10) 521 ± 92 ( 9) 518 ±143 ( 8) 0.054 
urine 2, (nmol) 559 ±165 (10) 737 ±229 (10) 743 ±221 (10) 0.050 
MHPG 
urine 1, (IJ.mol) 6.05 ±2.98 (10) 5.35 ± 1.59 (1 0) 4.88±1.15 (9) n.s. 
urine 2, (J.Lmol) 8.67 ±3.46 (10) 7.73±4.05 (10) 7.12±3.95 (10) n.s. 
VMA 
urine 1, (JJ.mol) 7.58 ±2.11 (9) 8.40 ±1.35 (10) 8.81 ± 1.72 (9) n.s. 
urine 2, (lkmol) 10.48±4.96 (9) 11.20±4.04 (10) 10.90±4.70 (9) n.s. 
creatinine 
urine 1, (mmol) 6.9 ±1.15 (10) 6.8 ± 1.05 (1 0) 7.1 ±1.55 (9) n.s. 
urine 2, (mmol) 8.2 ±2.49 (1 0) 8.0 ±1.79 (10) 8.5 ±2.53 (10) n.s. 
volume 
urine 1, (L) 0.97±0.36 (10) 0.95±0.44 (10) 0.77±0.24 (9) n.s. 
urine 2, (L) 0.76±0.55 (10) 0.58 ± 0.34 (1 0) 0.60±0.51 (10) n.s. 
ADR indicates adrenaline; NOR, noradrenaline; M, metanephrine; NM, normetanephrine; MHPG,3-
methoxy-4-hydroxypheny!glycol; VMA, vanillylmandelic acid. 
Urine 1 indicates urine col!ected during the infusion period (8.30-17.30 h), and urine 2 indicates urine 
collected during the postinfusion period (17.30- 8.30 h next morning). 
Alt values expressed as mean ± SD (n). 
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Infusion of adrenaline resulted in an increase in NM in the infusion and 
postinfusion period, which was marginally significantly different from values 
obtained during dextrose study (Table 1). Excretion of NM during the total 
collection period of the adrenaline study was significantly increased as compared to 
the dextrose study, 1.29 ± 0.32 vs 0.97 ± 0.22 1-1moles (Table 2). Excretion of 
noradrenaline, VMA and MHPG in the urine of the infusion and the postinfusion 
period were not different from results of the dextrose study (Tables 1 and 2). 
Infusion of noradrenaline resulted in a significant increase in excretion of 
noradrenaline and NM in the urine collected during the infusion period. 
Noradrenaline excretion during noradrenaline infusion was 290 ± 60.3 and 82.5 ± 
32.1 nmoles as compared to values obtained during dextrose infusion and NM was 
521 ± 92 and 415 ± 106 nmoles respectively. Excretion of adrenaline, M, VMA and 
MHPG in the urine of the infusion period, but also in that of the postinfusion period 
were not different from the values obtained during the dextrose study. 
Noradrenaline and NM excretion in the postinfusion period were not different from 
corresponding results obtained during the dextrose study. However noradrenaline 
and NM excretion during the total collection period of the noradrenaline study was 
higher than during the dextrose study, noradrenaline excretion 0.45 ± 0.05 vs 0.24 
± 0.07 11-moles respectively and NM excretion 1.23 ± 0.25 vs 0.97 ± 0.22 11-moles 
respectively (Table 2). 
TABLE 2. URINARY EXCRETION OF CATECHOLAMINE$ AND METABOUTES DURING THE 
TOTAL COULECTION PERIOD. 
infusion condition condition effect 
--------
DEXTROSE NOR ADR p 
·--------------------
ADR 0.04±0.01 0.04±0.01 0.17±0.04 <0.001 
M 0.62±0.27 0.67±0.14 1.13±0.39 <0.001 
NOR 0.24±0.07 0.45±0.05 0.25±0.08 <0.001 
NM 0.97±0.22 1.23±0.25 1.29±0.32 0.024 
MHPG 14.7±6.2 13.1 ±4.3 12.4±4.5 ns 
VMA 18.3±6.5 19.6±5.0 19.9±5.7 ns 
Abbreviations as in table 1 
Values are expressed as J.J.moles, mean±sd. 
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Figure 1. Urinary excretion of catecholamine metabolites derived from adrenaline (1111) and noradrenaline(/ 1 /). 
(Adapted from reference 3) 
DISCUSSION 
The kidney participates in the whole body catecholamines metabolism in two 
ways. Firstly, in keeping with the fact that many renal functions are influenced by 
the renal sympathetic neNous system, the kidneys are richly inneNated and have a 
high tissue catecholamine content. Wrth the exception of PNMT, the enzyme 
needed to convert noradrenaline into adrenaline, the enzymes required for 
synthesis of catecholamines from tyrosine are present in the kidney. The principal 
enzymes for degradation, COMT and MAO, are also present. Besides this intrarenal 
synthesis, release and degradation of catecholamines the kidneys participate in 
other ways in the "whole body" metabolism. Catecholamines are extracted from the 
plasma and released into the circulation and catecholamines and metabolites are 
excreted into the urine. 
For each catecholamine only a small fraction of the total amount produced is 
excreted unchanged in the urine. Urinary noradrenaline excretion represents 1-2",1, 
of the whole body synthesis rate (4). Urinary noradrenaline is particularly derived 
from plasma noradrenaline filtered at the glomerulus. The component of urinary 
noradrenaline derived from renal sympathetic neNous system is at most 30% and 
probably less, so urinary noradrenaline provides rather an index of "overall" 
sympathetic neNous system activity, than a measure of renal sympathetic neNous 
function (5,6). Experimental studies have, however, also provided evidence of a 
contribution of active secretion of, especially, the metabolites by the renal tubules 
(5,6). 
Adrenaline is excreted in the urine approximately in proportion to its glomerular 
filtration rate, although possibly tubular secretion contributes to some extend (4). 
The major urinary metabolites of noradrenaline and adrenaline are VMA and MHPG, 
which were firstly described approximately 30 years ago (7,8). In the tissue and 
body fluids also DHPG and DHMA, and their respective 0-methylated derivatives 
MHPG and VMA exist. The excretion rate of the final products of noradrenaline and 
adrenaline are shOwn in the Figure 1. The sum of these metabolites reflects total 
body production of noradrenaline, since only a very small portion of MHPG and 
VMA is derived of adrenaline. Clearly VMA and MHPG are the major metabolites. 
Our findings of the amounts excreted during the 24 hour collection period, are in 
complete agreement with these data of the literature (Table 2). 
When analyzing our data, the first point to be discussed is the question haw 
infused catecholamines are metabolized and what the possible differences are with 
endogenously released catecholamines. Much of the insight of the metabolic 
breakdown of catecholamines, is learned from studies, mainly done in the fifties 
and sixties, with radiolabelled catecholamines and the influence of certain drugs on 
these processes. When radiolabelled catecholamines are administrated 
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intravenously their distribution is determined largely by the distribution of blood (9). 
Adrenaline, which is almost exclusively synthesized by the adrenals, is released into 
the circulation unmetabolized. Tne metabolic tate of intravenously administrated 
adrenaline is therefore suspected to parallel that of endogenously formed and 
released adrenaline (9). Besides being excreted in the urine unmetabolized, a part 
of administrated adrenaline will be a-methylated to M, which is either excreted after 
conjugation or further metabolized (deamination through MAO) to MHPG and VMA. 
The increase in adrenaline and M excretion in the adrenaline study as compared to 
the dextrose study was 0.13 11moles (0.17- 0.04) of adrenaline and 0.51 11moles 
(1.13 - 0.62) of M, respectively 5.6% and 22% of the 2.31 llmoles of infused 
adrenaline. The relative contribution of the other metabolites cannot be computed 
from these data, probably because infusion of an amount of adrenaline as in this 
study, only produces marginal and insignificant changes in the large amounts 
excreted of VMA and MHPG. Studies in the rat using radiolabelled catecholamines 
and MAO and COMT blockade have demonstrated that 0-methylation is the major 
metabolic route of infused adrenaline. However, subsequently M is extensively 
deaminated (10). 
Metabolism of endogenous noradrenaline is more complex and differs from that of 
exogenously administrated noradrenaline. Endogenous noradrenaline is 
synthesized and stored in the sympathetic nerves throughout the body and in the 
central nervous system. It may be metabolized before reaching the circulation. 
When 'H-noradrenaline is infused, part of the radioactivity is rapidly excreted, either 
as unchanged catecholamine or as NM, which, however, can be further 
metabolized to VMA and MHPG. This indicates that 0-methylation is the major 
primary route for metabolic inactivation of circulating noradrenaline (11). Part of the 
'H-noradrenaline will be taken up into the tissues. Examination of the metabolites 
found in the urine during the interval after this rapid excretion is completed, 
provides insight into the fate of intraneuronally bound noradrenaline (11 ). The 
proportion of deaminated catecholamines excreted in this phase increases 
markedly, suggesting that deamination is the imporcant route of metabolic 
inactivation of noradrenaline, which had been retained in the nerves. Based on the 
above mentioned observations and on various pharmacological studies, which are 
reviewed elsewhere (3), it is now clear that the metabolic tate of noradrenaline 
depends upon the site of its release and uptake. When endogenous noradrenaline 
reaches the circulation it is mainly 0-methylated in extraneuronal tissues. When 
uptake in the neurons occurs, storage in the vesicles prevents metabolism by 
MAO. Uptake in extraneuronal sites results in metabolism by COMT and it COMT is 
blocked deamination by MAO. Noradrenaline leaking from the storage granules is 
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destroyed by MAO. 
Metabolism ol endogenous noradrenaline is extensive before it reaches the 
circulation. This can be illustrated by the fact that to sustain a given increment in 
blood pressure in the pitched rats, noradrenaline infused intravenously must attain 
a steady-state level of noradrenaline in plasma about 1 0-fold greater than that 
attending sympathetic stimulation, which produces a similar rise in blood pressure 
(12). This suggest that the major part of noradrenaline is removed from the 
neuroeffector junction and does not reach the circulation. To some extent this is a 
desipramine-sensitive process. Hoeldtke et al (4) found that in normal humans, the 
apparent noradrenaline secretion rate (determined by isotope dilution of tritiated 
noradrenaline) is about 22% of the noradrenaline production rate (determined from 
the total of the urinary metabolites of noradrenaline). Thus, the major fraction of 
noradrenaline must have be metabolized before reaching the circulation. 
Experiments of nature frequently provide insight in the normal processes of life. 
Observations in patients with idiopathic orthostatic hypotension and multiple system 
atrophy (syndrome of Shy and Drager) have led to a better understanding of 
noradrenaline metabolism and have allowed to collect evidence in humans for the 
above mentioned routes of noradrenaline metabolism. Idiopathic orthostatic 
hypotension is a syndrome in which patients have a loss of peripheral sympathetic 
nerves and it was firstly described in 1925 {13). These patients have defective 
vasoconstrictor responses to intra-arterially administrated tyramine, which acts 
indirectly by releasing noradrenaline from sympathetic nerves (14). Multiple system 
atrophy is a distinct syndrome of orthostatic hypotension accompanying central 
neurological deficits, which appear to be a result of degenerative changes in 
several parts of the central nervous system, but largely spares the peripheral 
sympathetic nerves, although peripheral sympathetic nerves cannot be 
appropriately stimulated (15). Basal levels of noradrenaline are low in patients with 
idiopathic orthostatic hypotension and normal in multiple system atrophy. In both 
syndromes there is orthostatic hypotension and a Jack of normal posturally induced 
increments in plasma noradrenaline (16). 
Comparing the urinary excretions of metalbolites in these patients have 
contributed to the understanding of noradrenaline metabolism (17). Excretion of 
total amounts of metabolites (MHPG, VMA and NM) were low in idiopathic 
orthostatic hypotension as compared to normals and patients with multiple system 
atrophy. In multiple system atrophy patients VMA was normal and MHPG and NM 
were slightly decreased. So this confirms the inability of idiopathic orthostatic 
hypotension patients to synthesise and release noradrenaline. Patients with multiple 
system atrophy have almost normal or slightly decreased amounts of noradrenaline 
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metabolites in urine. Since the deficit in these patients appears to be the inability to 
appropriately release noradrenaline, this results in a proportionately greater 
decrease in NM as compared to VMA and MHPG. This disproportionate decrease 
in NM in patients with multiple system atrophy support the observations done in 
experimental animals, which are briefly outlined above, showing that intraneuronally 
metabolized noradrenaline is mainly deaminated, whereas after its release from the 
nerve endings into the tissue or reaching the circulation, noradrenaline is mainly a-
methylated to form NM. 
Our data demonstrate a significant increase in excretion in noradrenaline and NM 
during the infusion period of noradrenaline and of NM in the postinfusion period. 
The increase in noradrenaline and NM excretion in the total infusion period was 
only 0.47 ~moles ([0.45-0.24] + [1.23-0.97]), which is approximately 9% of the 
noradrenaline infused. We found no differences in excretion rates of VMA and 
MHPG, but small alterations in the amounts excreted may be unnoticeable in this 
study. 
These data provide some valuable information on the supposed mechanism of 
the pressor response observed in the postinfusion period of adrenaline. Since NM 
is formed primarily from released noradrenaline, its proportion of the total amount 
of noradrenaline metabolites excreted, is sensitive to sympathetic neuronal activity 
(3). In the postinfusion urine of the adrenaline study a significant increase in NM 
excretion as compared to dextrose was found (Table 1), also NM excretion during 
the total collection period was higher (Table 2). These results might be taken as an 
indication for the existence of increased sympathetic nervous system activity in this 
postinfusion period, which is hypothesized to be the cause of the observed 
increase in blood pressure in this period. However, no relation was found between 
the mean differences in mean blood pressure during the postinfusion period of the 
adrenaline study as compared to corresponding values of the dextrose study and 
the mean of the increases in NM excretion during the adrenaline study as 
compared to the dextrose study (r=-0.06, n=10, p=0.87). 
The results of the measurements of urinary excretion rates of noradrenaline and 
adrenaline and their metabolites presented in this chapter, allow the following 
conclusions: 1. Adrenaline and noradrenaline excreted in the urine are the most 
sensitive indicators of changes in circulating adrenaline and noradrenaline during 
their respective infusions. 2. Changes in circulating plasma adrenaline and 
noradrenaline are not readily reflected in changes in urinary VMA and MHPG, 
probably because these changes are quantitatively unimportant as compared to 
other metabolic origins of VMA and MHPG. 3. Changes in NM excretion rate can 
be due not only to changes in circulating noradrenaline, but also indirectly to those 
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in circulating adrenaline. 5. The increased NM excretion after the adrenaline infusion 
might be taken as an indication that the hypothesized mechanism of the observed 
pressor effect in this period as discussed in chapter 3, is indeed true. 
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Chapter 6 
METABOliC AND HORMONAl EFFECTS OF INFUSED NORADRENAliNE AND 
ADRENAliNE IN NORMAl MAN. 
Based on: PJ Blankestijn, AJ Man in 't Veld, JHM Tulen, AH van den Meiracker, FHM Derkx, F 
Boomsma, P Moreman, SWJ lamberts, MADH Scha!ekamp. Gardiovascular. 
hormonal and metabolic effects of a 6 hours infusion of adrenaline and noradrenaline 
in normal man. In preparation. 
INTRODUCTION 
It was probably Claude Bernard who first described a metabolic effect mediated 
by catecholamine, althOugh it could not have been recognized as such at that time. 
He observed a transitory outpouring of sugar in the urine alter he punctured the 
forth ventricle of rabbits. It is now clear that "puncture hyperglycaemia" is the result 
of release of adrenaline !rom the adrenals in response to sympathetic activation (1). 
The precise roles of the catecholamines in metabolic (patho) physiologic processes 
have only begun to emerge in more recent years. It is now appreciated that 
catecholamines play an important role in the regulation of carbohydrate, lipid, 
ketone and protein metabolism, the release of several hormones and the regulation 
of the plasma concentrations of certain electrolytes as well as thermogenesis (2). It 
is also clear that their role is changed in certain disease states such as in insulin-
dependent diabetes mellitus (3). Much of the insight in the role of catecholamines 
has been gained by infusion experiments with relatively high loads of catechola-
mines. Furthermore, the effects of adrenaline has been studied in much more detail 
than those of noradrenaline. 
In this chapter we describe the results of experiments in which low doses of 
adrenaline and noradrenaline were infused for 6 hours in normal volunteers. The 
effects on carbohydrate metabolism, growth hormone, prolactin, cortisol, renin, 
aldosterone and potassium are reported. 
SUBJECTS AND METHODS 
See chapter 2. 
VIA RATIO FOR 
NORADRENALINE 
Figure 1. Venous-arterial ratio of plasma 
noradrenaline during adrenaline{-), 
noradrenaline (-) and dextrose 
(•••••} infusion. 
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RESUlTS 
Effects on adrenaline and noradrenaline 
Baseline values of arterial and venous adrenaline and noradrenaline did not differ 
between the three study days. During the infusion of adrenaline venous adrenaline 
rose from 21 ± 4 to a mean of 230 ± 28 pgjml and arterial adrenaline rose from 
34 ± 6 to a mean of 387 ± 15 pgjml (both p < 0.001). Both venous and arterial 
plasma levels during infusion of adrenaline were higher than during dextrose 
infusion (ANOVA, both p<0.001). Neither venous nor arterial plasma noradrenaline 
changed during adrenaline infusion. 
During noradrenaline infusion venous noradrenaline rose from 207 ± 17 to a 
mean of 705 ± 58 pgjml and arterial noradrenaline from 183 ± 15 pgfml to a 
mean of 1025 ± 38 pgfml. Both venous and arterial plasma concentrations were 
higher than during dextrose infusion (ANOVA, both p<0.001). Venous and arterial 
plasma adrenaline were little, although significantly, lower during noradrenaline 
infusion as compared to corresponding values during dextrose infusion (both 
p<0.001, ANOVA). 
The mean (SEM) ratios of venous/arterial noradrenaline before administration of 
the infusions were not different on the three study occasions; before dextrose 1.17 
(0.08), before noradrenaline 1.14 (0.05) and before adrenaline 1.06 (0.09). The 
mean ratio during adrenaline and dextrose infusion were not different, respectively 
1.22 (0.08) and 1.29 (0.05). The mean ratio during noradrenaline was 0.69 (0.04) 
and was significantly lower than during dextrose (see Figure 1). This decrease was 
caused by the fact that arterial noradrenaline was more markedly increased (mean 
560%) than venous noradrenaline (mean 341%). 
Effects on glucose and insulin 
Baseline glucose levels were not different between the three study occasions 
(Table 1, Figure 2). During adrenaline infusion glucose rose from 4.5 ± 0.2 mmol/1 
to 5.5 ± 0.2 mmol/1 after one hour and was still increased with 5.5 ± 0.1 mmoljl 
after 6 hours (p < 0.001 as compared to corresponding values during dextrose 
infusion). Glucose remained unchanged during dextrose infusion; baseline 4.3 ± 
0.1 mmolfl to 4.5 ± 0.1 after one hour and 4.4 ± 0.1 after 6 hours of infusion. 
During noradrenaline infusion glucose rose from 4.5 ± 0.2 mmol/1 to 4.9 ± 0.2 
mmoljl after one hour and 5.0 ± 0.1 mmoljl after 6 hours (p < 0.002 as compared 
to the dextrose study). 
Basal insulin levels were identical during the three study days. During all 3 
infusions insulin decreased during the day. Insulin levels during adrenaline infusion 
were higher than in the control study (ANOVA, p < 0.02). Insulin during 
noradrenaline tended to be higher, but this difference was not significant from the 
dextrose study. 
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Figure 2. Plasma glucose and insulin during infusion of adrenaline (-). noradrenaline (-) and 
dextrose ( ..... ). 
* p < 0.05, ** p < 0.01, *** p < 0.001 as compared to dextrose infusion 
80 
TABLE 1 CONCENTRATIONS OF PLASMA INSULIN AND BLOOD GLUCOSE BEFORE AND 
DURING INFUSIONS OF NORADRENALINE AND ADRENALINE 
INSULIN (mU/L) GLUCOSE (mmoi/L) 
time (h) dex nor adr dex nor adr 
0 1 0.5(1.3) 12.1(1.7) 13.4(1.5) 4.3(0.1) 4.5(0.2) 4.5(0.1) 
9.4 (1.3) 12.6(1.9) 15.4(2.6) 4.5(0.2) 4.9(0.2) 5.5(0.2) 
2 8.1 (1.0) 9.4 (1.5) 13.0(2.0) 
3 7.8 (1.1) 8.7 (1.1) 11.5(1.4) 
4 6.9 (0.9) 8.4 (1.0) 10.6(1.7) 
5 7.1 (0.6) 8.2 (0.1) 10.4(1.5) 
6 7.1 (0.6) 7.9 (0.8) 9.3 (1.5) 4.4(0.1) 4.9(0.2) 5.5(0.1) 
Data are mean (SEM) 
dex = dextrose infusion, nor = noradrenaHne infusion, adr = adrenaline infusion 
TABLE 2 PLASMA CONCENTRATIONS OF GROWTH HORMONE, PROLACTIN AND 
CORTISOL BEFORE, DURING AND AFTER INFUSIONS. 
GROWTH HORMONE (~g/L) PROLACTIN (~gjL) CORTISOL (nmoi/L) 
time (h) dex nor adr dex nor adr dex nor adr 
0 1.4(0.6) 0.7(0.1) 0.6(0.1) 4.6(0.2) 4.4(0.2) 4.2(0.3) 425(31) 416(31) 437(53) 
1 1.1 (0.2) 2.0(0.9) 1.8(0.9) 4.3(0.2) 3.9(0.2) 4.1(0.1) 334(28) 341 (38) 311(41) 
2 1.5(0.5) 1.3(0.3) 1.1 (0.3) 4.6(0.5) 3.9(0.1) 4.0(0.2) 330(46) 308(39) 317(30) 
3 1.0(0.2) 0.7(0.1) 0.9(0.2) 4.4(0.4) 3.8(0.1) 4.1(0.2) 318(41) 281 (28) 290(31) 
4 1.9(0.7) 0.7(0.1) 0.7(0.1) 4.2(0.2) 4.0(0.2) 4.2(0.2) 326(25) 305(30) 313(33) 
5 3.1(1.6) 0.8(0.2) 1.2(0.3) 4.6(0.1) 4.1(0.2) 4.8(0.3) 347(31) 343(33) 391 (50) 
6 3.0(0.9) 1.9(0.8) 1.9(0.7) 4.8(0.3) 4.5(0.2) 4.8(0.3) 356(34) 287(20) 282(36) 
7 3.0(0.9) 1.5(0.4) 1.0(0.2) 5.0(0.4) 5.0(0.4) 5.4(0.7) 260(64) 268(32) 350(30) 
Data are mean (SEM). 
Dex = dextrose infusion, nor = noradrenaline infuslon, adr = adrenaline infusion 
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Figure 3. Effects of adrenaline (-), noradrenaline (--) and dextrose (•••••) on p!asma 
concentrations of growth hormone, prolactin and cortisol. 
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Effects on cortisol. growth hormone and prolactin 
Basal plasma concentrations of cortisol, growth hormone and prolactin during the 
three study occasions did not differ. The normal fall in cortisol between 9.00 h and 
17.00 h (p < 0.01, t-test) was seen on each of the infusion days. There were no 
differences in plasma cortisol, growth hormone or prolactin during the three 
infusion experiments (Table 2, Figure 3). 
Effect on potassium 
Baseline serum potassium levels were not different on the study days of 
adrenaline and dextrose infusion (Table 3). During the adrenaline infusion a small 
but significant decrease in potassium concentration as compared to corresponding 
values during dextrose infusion was detected alter 6 hours of infusion; alter one 
hour of adrenaline respectively dextrose infusion potassium concentrations were 
3.95 ± 0.06 and 4.01 ± 0.07 mmol/1 respectively (not different), and alter 6 hours 
3.80 ± 0.04 respectively 3.97 ± 0.07 mmolfl (p=0.016) (Table 3, Figure 4). 
Baseline values on the noradrenaline study occasion were significantly lower 
(p=0.034, t-test) than corresponding values of the dextrose study. During 
noradrenaline infusion plasma concentrations were not different from those in the 
dextrose study; after one hour 3.97 ± 0.07 and after 6 hours 3.91 ± 0.05 mmol/1. 
Also no significant differences existed between values alter one hour of infusion as 
compared to baseline and after 6 hours of infusion as compared to baseline. 
TABLE 3 PLASMA CONCENTRATIONS OF POTASSIUM 
BEFORE AND DURING INFUSIONS OF NORADRENALINE 
AND ADRENALINE 
POTASSIUM (mmoi/L) 
time(h) dex nor adr 
0 3.97(0.09) 3.83(0.05) 3.94(0.06) 
4.01 (0.07) 3.97(0.07) 3.95(0.06) 
6 3.97(0.07) 3.91(0.05) 3.80(0.04) 
Data are means (SEM) 
dex = dextrose, nor = noradrenaline, adr = adrenaHne 
Urinary excretion of potassium was measured during the infusions and in the 
postinfusion period. No differences in urinary potassium excretion between 
adrenaline or noradrenaline versus dextrose were detected (Table 4) 
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Table 4 URINARY POTASSIUM EXCRETION DURING AND AFTER INFUSION OF 
ADRENALINE, NORADRENALINE OR DEXTROSE 
ADRENALINE NORADRENALINE 
infusion period 
mmol 37 (6) 34 (3) 
mmo!jh 4.1 (0.6) 3.8 (0.4) 
mmoljmmol creatinine 5.4 (0.7) 4.9 (0.5) 
post-infusion period 
mmol 37 (5) 34 (5) 
mmolfh 2.2 (0.3) 2.0 (0.3) 
mmo!jmmol creatinine 5.6 (1.5) 3.7 (0.5) 
total period 
mmol 74 (9) 68 (7) 
mmoljh 3.0 (0.4) 2.7 (0.3) 
mmoljmmol creatinine 5.2 (0.7) 4.2 (0.3) 
data are means (SEM) 
infusion period "" 8.30 - 17.30 h, postinfusion period = 17.30 - 8.30 h next morning, 
total period = infusion period + postinfusion period 
DEXTROSE 
36 (4) 
4.0 (0.5) 
5.4 (0.7) 
33 (4) 
1.9 (0.3) 
4.6 (0.6) 
69 (8) 
2.8 (0.3) 
4.7 (0.5) 
Differences between the adrenaline and noradrenaline condition versus dextrose were not significant. 
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Effects on renin and aldosterone 
Baseline concentrations of renin were similar on the three study days. Renin 
values rose during the adrenaline and noradrenaline infusions and they were 
slightly, although significantly higher as compared to dextrose study; mean (range) 
renin concentrations during adrenaline and noradrenaline were 17.9 (14.1-24.8) and 
17.3 (12.0-24.8) mU/L respectively, both significantly different (ANOVA, p<0.001) 
as compared to dextrose, 11.6 (8.4-15.6) mU /L. 
Baseline plasma aldosterone levels were not different on the three study days; 
before adrenaline, noradrenaline and dextrose 80 ± 6, 72 ± 4 and 72 ± 5 ngjL 
respectively. During adrenaline infusion mean plasma aldosterone was slightly 
although significantly higher than during dextrose (70 ± 4 vs 52 ± 4 ngjl, ANOVA 
p<0.01). No difference existed between the mean values during noradrenaline and 
dextrose (61 ± 6 vs 52 ± 4 ngjl). 
TABLE 5 PlASMA CONCENTRATIONS OF RENIN AND ALDOSTERONE BEFORE, DURING 
AND AFTER INFUSIONS. 
RENIN (mU/L) ALDOSTERONE (ng(L) 
time(h) dex nor adr dex nor adr 
0 13.4(12.0-14.9) 15.5(14.6-21.0) 14.4(11.4-18.1) 72(5) 72(4) 80(6) 
12.8(1 0.5-15.6) 15.6(12.0-20.3) 21.5(18.9-24.4) 62(5) 62(6) 88(6) 
2 10.7(8.7-13.2) 18.2(13.9-23.9) 19.9(16.6-23.9) 62(5) 69(8) 71 (5) 
3 11.7(1 0.0-13.6) 15.7(12.4-19.8) 20.1 (16.3-24.8) 54(6) 63(8) 69(7) 
4 9.9 (8.6-11.4) 18.4(13.9-24.3) 17.1 (14.7-20.0) 51(5) 58(7) 60(4) 
5 10.5(8.4-13.0) 18.7(14.1-24.8) 17.2(14.8-19.9) 50(5) 56(4) 62(6) 
6 11.1(8.8-14.1) 17.1 (13.2-22.2) 16.4(14. 1-19.2) 46(5) 58(6) 70(8) 
7 10.0(8.2-12.3) 19.7(14.9-26.1) 15.3(12.9-18.0) 51 (6) 62(9) 75(8) 
Data of aldosterone are mean (SEM) and of renin are geometric means (range). 
Dex = dextrose infusion, nor = noradrenaline infusion, adr = adrenaline infusion 
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DISCUSSION 
In this study we have demonstrated that moderately increased plasma 
catecholamines concentrations after infusion of adrenaline or noradrenaline elicit 
some metabolic effects besides the haemodynamic effects as described in chapter 
3. The plasma concentrations of catecholamines achieved by the infusions in this 
study are well within the physiological range. Venous concentrations of 
noradrenaline of approximately 700 pgjml can be seen during quiet standing and 
mild physical exercise (4). Plasma concentrations of adrenaline of approximately 
200 - 300 pgjml have been reported during surgery, during moderate to severe 
physical exercise and during public speaking (4,5). Plasma concentrations achieved 
during the infusions in this study were comparable with those in studies in which 
approximately the same amounts were infused (6,7,8). The ratio venous/arterial 
noradrenaline, as a crude measure for net local noradrenaline production was not 
different during adrenaline and dextrose infusion, whereas it was suppressed during 
noradrenaline infusion. This seemed to be a result of a more marked increase in 
arterial noradrenaline than in venous noradrenaline during noradrenaline infusion. 
Venous noradrenaline is mainly derived from local production (9). Whether the 
relatively less increased venous plasma concentration of noradrenaline as 
compared to the arterial plasma concentration is the result of activation of 
prejunctional e<,-adrenoceptors can not be determined from this study. Stimulation 
of these adrenoceptors leads to inhibition of noradrenaline release (10). 
Effects on glucose and insulin 
The primary controllers of glucose metabolism are insulin and glucagon released 
by the endocrine pancreas in response to neural, humoral and local factors. 
However, it has became apparent that the catecholamines and in particular 
adrenaline, have clear effect.s on glucose metabolism, i.e. they increase blood 
glucose levels. The mechanism of this hyperglycaemic effect is complex. 
Catechclamines alter glucose metabolism directly, by affecting liver and skeletal 
muscle metabolism and indirectly by an effect on the function of the endocrine 
pancreas. In this hyperglycaemic process both e<- and B-adrenoceptor mediated 
actions play a role. This study provides a further contribution to the understanding 
of the different parts of each of these processes in the hyperglycaemic effect of 
catecholamines. 
!n the early phase of the rise of blood glucose during adrenaline infusion an 
indirect effect on the endocrine pancreas seems to be important, because this rise 
is associated with an decrease in insulin concentrations. This effect is observed by 
some (7), but not by other investigators (11). However, within 30-40 minutes of the 
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adrenaline induced hyperglycaemia, a rise in plasma insulin levels occurs. The initial 
limitation of insulin secretion seems to be mediated by a,-adrenoceptors in the 
mouse and the rat and probably sJso in man. It is an important indirect 
hyperglycaemic mechanism (7,12,13). This is evidenced for instance by the sharp 
increase in plasma insulin levels in response to elevated glucose concentrations, 
that follows discontinuation of adrenaline infusion (7). Another indication of the 
importance of this insulin suppressor mechanism is apparent when one considers 
that isoprenaline, a non-selective B-adrenoceptor agonist devoid of a-adrenergic 
agonistic properties, produces minimal increments in plasma glucose, despite its 
prominent direct (B-adrenergic) glycaemic actions (11, 14). Despite this inhibitory 
effect of adrenaline on insulin release, we found slightly higher insulin levels during 
adrenaline infusion than during the control study. This finding is in accordance with 
several other studies (7, 15, 16) and is probably a response to the increase in blood 
glucose concentration. This small increase in insulin is a critical regulatory event to 
limit the glycaemic response to adrenaline, since this glycaemic response is 
increased substantially when insulin levels are kept "constant" experimentally with 
somatostatin, or when insulin secretion can not vary as in insulin dependent 
diabetes mellitus (16). The difference in insulin levels during adrenaline and 
noradrenaline infusion in our study can be explained by the difference in the 
magnitude of the rise in blood glucose. So the a-adrenoceptor mediated inhibition 
of insulin release is counterbalanced by the stimulation of insulin secretion by the 
rise in blood glucose. 
In this study we did not measure glucagon, the other important pancreatic blood 
glucose regulating hormone. Increments in plasma glucagon during adrenaline 
infusion have been observed in some studies in normal humans but not in others 
(12, 15, 17). Of course it can be argued that since an increase in plasma glucose 
would be expected to suppress glucagon secretion, the absence of this decrease 
during adrenaline induced increments in blood glucose in fact implies stimulation of 
glucagon secretion (2). However, adrenaline induced increments in blood glucose 
clearly occur in the absence of glucagon release (17-19). Furthermore, the finding 
that the glycaemic response to adrenaline is increased substantially despite 
prevention of any increase in glucagon, when an increase in insulin secretion is 
prevented in normal humans (16), all suggest that glucagon is not a major factor in 
the hyperglycaemic response to adrenaline. 
What remains to be discussed is the quantitatively different glycaemic responses 
to infused noradrenaline and adrenaline. The direct hyperglycaemic action of 
catecholamines include stimulation of hepatic glucose production and limitation of 
glucose utilization. The enhanced glucose production by the liver is a result of a 
transient rise in glycogenolysis and gluconeogenesis. Several studies have 
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indicated that hepatic glucose production have returned to basal levels after 60 to 
120 minutes of adrenaline infusion (11,12). However, the maintenance of basal 
rates of glucose production during prolonged infusion of adrenaline in the presence 
of a degree of hyperglycaemia, that had completely suppressed glucose production 
when produced by an exogenous glucose infusion, indicates that prolonged 
infusion of adrenaline continues to have a stimulating effect on the hepatic glucose 
output. This stimulating effect is predominantly mediated through a B,-adrenergic 
mechanism (18). Several studies (13,18) demonstrated that the effects of adrenaline 
on glucose production were not completely blocked by propranolol, which could be 
an indication for a small, although deftnrte «-adrenoceptor mediated contribution in 
the adrenaline stimulated glucose production. Indeed it has been shown that the 
human livercell contains both B,- and «-adrenergic receptors (20). 
The limitation of glucose utilization is a sustained effect of adrenaline infusion (21 ). 
This effect is B-adrenoceptor mediated. Indirect evidence suggests that the subtype 
of B,-adrenoceptors is involved (22). So, the sustained rise of blood glucose during 
a 6 hours infusion of adrenaline as demonstrated in this study is an effect of 
decreased glucose utilization and to some extent to the absence of suppression of 
hepatic glucose production. 
Another interesting finding of this study was the fact that blood glucose after 6 
hours of noradrenaline infusion was still higher than during control study. As stated 
before it has been suggested that the sustained rise in glucose after prolonged 
adrenaline infusion is mainly the result of the limitation of glucose utilization, which 
is probably B,-adrenoceptor mediated. Also the effect of adrenaline on hepatic 
glucose production appears to be predominantly B,-adrenoceptor mediated. 
However, noradrenaline infusion for 2 hours also gives a transient rise in liver 
glucose production, which is much less than the one induced by adrenaline and 
which returns to basal levels after approximately 60 minutes of infusion (11). Our 
finding of the maintained increase in blood glucose after 6 hours of noradrenaline 
infusion supports 2 conclusions: 1, Since noradrenaline has no effect on glucose 
utilization (11), the fact that glucose production during sustained infusion of 
noradrenaline returns to basal and not below that level indicates that also 
noradrenaline has a prolonged effect on hepatic glucose output. g, Besides B,-
adrenoceptor mediated mechanisms of stimulation of liver glucose output, also an 
«-adrenoceptor mediated effect is operational. 
In conclusion, the integrated mechanisms of the hyperglycaemic effect of 
catecholamines, which are outlined in Table 6, differ considerably. This is a 
consequence of the different affinities of the catecholamines to the adrenergic 
receptor subtypes, which are involved in regulating the glucose homeostasis. The 
results confirm the fact that adrenaline in contrast to noradrenaline is man's 
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TABLE 6 EFFECTS OF DIFFERENT CATECHOLAMINE$ ON GLUCOSE METABOLISM 
GLUCOSE INSULIN 
production utilization concentration concentration 
Adrenaline (a:, 82 > B,) n r r 0- I iii I 
Noradrenaline (a., B, >13.J It 0 It 0 
isoprenaline (81 + BJ It =0 ttl 
endogenous B,-adrenoceptor stimulant. Whether or not the current topic of insuline-
resistence in essential hypertension (23) can be (partly) explained by the 
adrenaline-hypertension hypothesis, leading to intermittently elevated insulin levels, 
merits further investigation 
Effect on arowth hormone. prolactin and cortisol 
The anterior pituitary lacks direct neuronar innervation, however, its hormonal 
secretions are controlled precisely by the overlying brain. Regulation of the anterior 
pituitary hormone secretion is achieved with specific hypothalamic releasing 
hormones and for some pituitary hormones by feedback mechanisms. These 
releasing hormones are, among others, somatostatin, growth hormone releasing 
hormone and corticotropin releasing factor. The control of pituitary function by the 
central nervous system is provided by neuronal alferents, which synapse on 
hypothalamic releasing factor cells. The releasing factor cells have been termed 
"neuro-endocrine transmitters", since they translate a neuronal (neurotransmitter) 
input into a hormonal output. Neurons may either stimulate or inhibit these cells 
through interactions in the median eminence or at other brain sites. Severa! 
neurotransmitter substances such as noradrenaline, adrenaline, dopamine and 5-
hydroxytryptamine have been investigated lor their role in the regulation of the 
anterior pituitary. Circulating adrenaline and noradrenaline are hydrophylic 
substances and therefor they do not cross the blood-brain barrier (24,25), but they 
do reach the pituitary gland and to a certain extend the median eminence. 
Growth hormone 
The release of growth hormone from the pituitary is regulated by inhibitory 
(somatostatin) and excitatory (such as growth hOrmone releasing hormone) 
hypothalamic hormones. Extensive animal research (for review see reference 26) 
has provided evidence that the release of catecholamines from nerve terminals in 
the hypothalamus modifies growth hormone release. It is likely, that c:-
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adrenoceptors mediate the stimulating effect on growth hormone secretion induced 
by noradrenaline. Noradrenaline injected into the hypothalamus of conscious 
baboons stimulates growth hormone secretion and phentolamine, an c:-
adrenoceptor antagonist, reduces it. The B-adrenoceptor involved in the regulation 
of growth hormone release is probably of the B,-subtype. Salbutamol, a selective B,-
adrenergic receptor agonist, lowers growth hormone levels. Conversely B-
adrenergic receptor antagonism by propranolol or the selective B,-adrenoceptor 
blocker ICI-118551, markedly elevated plasma growth hormone levels. Practolol, a 
B,-selective adrenoceptor antagonist, does not alter basal growth hormone levels 
(27). Elevation of growth hormone by B-adrenoceptor antagonist may be due to 
inhibition of somatostatin release, since isoprenaline applied to rat brain slices 
stimulated the release of somatostatin. 
Also in man adrenergic receptors mediates modulation of growth hormone 
secretion. L-dopa, the precursor of dopamine and noradrenaline, stimulates growth 
hormone release in man, an effect, which is blocked by phentholamine (28). 
Systemic administration of c:-adrenoceptor antagonists inhibits growth hormone 
secretion (29), whereas the c:-adrenoceptor agonist clonidine stimulates growth 
hormone release (30). Since clonidine is a relative selective c:,-adrenoceptor 
agonist, this modulation of growth hormone secretion seems to be o:,-adrenoceptor 
mediated. Supporting this view is the finding that yohimbine, a selective "'-
adrenoceptor blocker, blunted the rise of growth hormone induced by insulin-
induced hypoglycaemia (31). In vitro experiments have disclosed that clonidine is 
able to release growth hormone releasing hormone from the perifused 
hypothalamus (32). Therefore the growth hormone releasing effect of clonidine 
probably acts via increased endogenous growth hormone releasing hormone 
release. Recently it was suggested that clonidine acts by inhibiting somatostatin 
release (33). The ability of c:,-adrenoceptor agonists to trigger growth hormone 
synthesis may have clinical impact in certain growth disorders (defective release but 
intact synthesis of growth hormone releasing hormone). Indeed, it has been shown 
that clonidine is able to accelerate growth velocity in some children with 
constitutional growth delay (34). 
Activation of B-adrenergic receptors exerts an inhibitory action on growth 
hormone release. An increase in circulating growth hormone levels was present 
during combined administration of propranolol and adrenaline (35), whereas 
inhibition occurred by concomitant infusion of phentholamine (36). An explanation 
which has been suggested for these findings with adrenaline in the presence of 
propranolol was that these were the results of an unopposed a:-effect. Also a 
marked enhancing effect of propranolol on the growth hormone releasing hormone 
induced growth hormone rise was demonstrated in children {37), whereas it is 
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ineffective in altering basal levels per se. 
The above mentioned results indicate that both tt- and 6-adrenoceptor mediated 
mechanisms are involved in the regulation of growth hormone release. The effect 
on the growth hormone release seems to be a result of alteration of the release of 
somatostatin and/or growth hormone releasing hormone from the hypothalamus to 
the hypophysis. 
In this study, in which adrenaline and noradrenaline were infused intravenously 
leading to high physiological plasma concentrations no effect on growth hormone 
levels were detected. This is in accordance with other studies in which adrenaline 
(7) or noradrenaline (6,38) were infused intravenously, generally however in much 
higher doses. In none of these studies an effect on growth hormone levels was 
reported. These results, however, do not rule out that circulating catecholamines 
even in concentrations achieved in this study can have an inhibitory or stimulating 
effect on growth hormone secretion. Further research, for instance measurements 
of growth hormone response to stimuli during catecholamine infusion leading to 
physiological plasma concentrations is needed to clarify in more detail the role of 
catecholamines on growth hormone secretion. 
Cortisol 
Studies of the effects of adrenaline and noradrenaline on ACTH and cortisol 
release in vitro and in vivo have produced conflicting results in animals (35,38). 
Some studies describe the absence of effects of adrenaline and noradrenaline, 
whereas others show a direct stimulating effect on ACTH secretion. Probably the 
discrepancies are explicable on the basis of interspecies and methodological 
differences (39,40). 
In man, intravenous infusion of the lipid soluble tt,-adrenoceptor agonist 
methoxamine, which passes the blood-brain barrier, stimulates ACTH secretion and 
this effect is abolished by concomitant administration of the a,-adrenoceptor 
antagonist thymoxamine. Hydrophylic noradrenaline in equipotent doses with 
respect to cardiovascular responses, did not produce this effect (41). Further 
studies with a,- and 6-adrenoceptor agonists and antagonists demonstrated that 
the additional Q.e. a:,- and B-agonistic) properties of noradrenaline do not account 
for this different response to methoxamine. 
In man, intravenous infusion of adrenaline which elevates plasma adrenaline 
concentrations to 600-700 pgjml (41) or to about 350 pgjml (42) had no effect on 
basal levels of cortisol or on the stimulating effect of corticotrophin releasing factor. 
Also, several studies in man indicate that circulating noradrenaline and adrenaline, 
administrated exogenously leading to high physiological plasma concentrations, do 
not alter plasma ACTH and cortisol (6, 7,44,45). Clutter et al (7) infused adrenaline 
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in normal man resulting in plasma levels of around 1000 pgjml and Silverberg et al 
(6) infused noradrenaline (plasma concentrations approximately 2100 pgjml). In 
both studies no changes in plasma cortisol were detected. The results of the last 
mentioned study in which systolic arterial pressure increased from 107 to 130 
mmHg, seems to be in contrast with 2 other studies, in which very high doses of 
noradrenaline were infused in order to increase systolic arterial pressure by 24% 
(41) and 30% (45). In the latter two studies cortisol (41,45) and ACTH (45) 
decreased. It was argued that high doses of noradrenaline might be able to inhibit 
vasopressin release and vasopressin may act as or augment the actions of 
corticotrophin releasing factor (45). 
Our data show that infusions of neither noradrenaline nor adrenaline leading to 
plasma concentrations in physiological range, exert an effect on plasma cortisol. 
These results are in accordance with the above mentioned results in the literature. 
Prolactin 
Prolactin is unique in that its secretion is tonically inhibited by the hypothalamus, 
while other adrenohypophysial hormones are mainly regulated by releasing 
hormones. This inhibitory action is mediated by prolactin inhibiting factors, of which 
dopamine seems to be the most important one (46). Experimental data also 
suggest the existence of prolactin releasing factors. Serotonin (47), TRH (48,49) 
and several other peptides have been proposed as prolactin releasing factors. The 
stimulation of prolactin release by various forms of stress (hypoglycaemia, exercise, 
surgery) is considered to arise from stimulation of prolactin releasing factors rather 
than removal of dopaminergic inhibition (48,49). Psychological stress is not 
accompanied by increases in prolactin, except for "stresses" directly connected with 
reproduction (50). 
In animal studies it remains controversial whether there is a role for circulating 
noradrenaline and adrenaline in the control of prolactin release, with reports of a 
stimulating or an inhibitory effect or no effect at all on prolactin secretion (46). This, 
again, might be caused by interspecies differences. 
In man, it seems unlikely that circulating adrenaline and noradrenaline are 
important in stimulating prolactin release. Woolf et al (51) studied the prolactin 
response to insulin induced hypoglycaemia in patients with absent adrenaline 
(bilateral adrenalectomy) or impaired sympathetic nervous function (complete C5-6 
cervical cord transection). The adrenalectomized patients had normal prolactin 
responses while the patients with spinal cord transection had exaggerated 
responses. It was concluded that neither adrenaline nor noradrenaline were 
important in stimulating prolactin release, although an inhibitory action of 
noradrenaline cannot be ruled out. 
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Our data demonstrate that circulating adrenaline and noradrenaline in 
physiological concentrations do not affect plasma prolactin levels. So, whereas it is 
established that central catecholaminergic (mainly dopaminergic) systems 
participate in the regulation of prolactin release, there is not much evidence to 
suggest that circulating adrenaline and noradrenaline have any contribution in this 
process. 
Effect on potassium 
More than 50 years ago D'Silva (52) showed that adrenaline might play a role in 
potassium homeostasis. He found that an intravenous infusion of adrenaline into 
anaethetised cats resulted in an initial transient rise in plasma potassium followed 
by a prolonged decline. Only the last decade, the clinical significance of the 
regulatory function of catecholamines, in particular adrenaline, in the potassium 
homeostasis has been recognized (53-55). 
It is now appreciated that renal excretion is the dominant factor in determining the 
potassium balance (for review reference 53), however, cellular uptake of potassium 
is of great importance in the maintenance of the plasma potassium within narrow 
limits. There is now much evidence that catecholamines have considerable 
influence on extrarenal potassium regulation (54,55). 
Intravenous administration of adrenaline leads to an initial increase followed by a 
decrease in potassium. The initial rise is the result of potassium released by the 
liver (56,57) and the subsequent decrease in potassium reflects an accelerated 
uptake in potassium, primarily in the skeletal muscles, but probably also in the 
heart and liver (54,58) The hyperkalaemic response is inhibited by a:-adrenoceptor 
blockade (59). The decline in potassium has been found to be independent of 
insulin, aldosterone and renal excretion of potassium (54). In previous studies from 
our group the effects on plasma potassium of graded infusions of B-adrenoceptor 
agonists isoprenaline (non-selective), prenalterol (B,-adrenoceptor selective) and 
salbutamol (B,-adrenoceptor selective) were studied (60). All agonists induced a 
decrease in potassium but the magnitude of the hypokalaemia-inducing effect was 
in the order: salbutamol > isoprenaline > prenalterol. These results confirmed 
other reports indicating that this effect is mediated by B,- rather than B, 
adrenoceptors (61 ). This conclusion was further substantiated by the observation 
that propranolol, but not atenolol, was able to antagonize the hypokalaemic effect 
of isoprenaline, when the latter was given in doses high enough to overcome the 
blockade of the heart rate response. In the study of Brown et al (61) it was 
demonstrated that an adrenaline infusion that produced plasma levels of 
approximately 1700 pg/ml resulted in a significant decrease in potassium, an effect 
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that could be prevented by prior administration of the B,-adrenoceptcr antagonist 
ICI-118551. So the hypokalaemic effect appeared indeed to be B,-adrenoceptor 
med"1ated. 
In the current study we found that only moderately increased plasma adrenaline 
concentrations already induce a small although significant decrease in plasma 
potassium. These alterations occurred without changes in the urinary excretion rate 
of potassium. These observations are cf clinical importance since adrenaline levels 
which have been observed in patients during various forms of stress, such as 
myocardial infarction, appear to be able to reduce plasma potassium. In patients 
with myocardial infarction this hypokalaemic effect can predispose these patients to 
cardiac arrhythmias, particularly when they are more susceptible because of 
concomitant therapy with digitalis or because of diuretic induced potassium 
depletion (62). Hypokalaemia is clearly associated with an increased incidence and 
severity of arrhythmias. 
Another area where this B,-adrenoceptor mediated effect is suspected to be of 
clinical relevance is in patients who used B,-agonists because of asthma. Workers 
from Utrecht showed that inhalation of fenoterol, a B,-agonist, in doses frequently 
used by asthma patients, was able to induce marked a decrease in plasma 
potassium (63). In asthma patients this effect might even be more pronounced 
when the phosphodiesterase inhibitor theofylline is used concomitantly. The 
combination of aminophylline and the B,-adrenoceptor agonist hexopreline, both 
given intravenously, has been shown to have a greater effect on plasma potassium 
than either drug given alone (64). So it was suggested (63) that the hypokalaemia 
induced by inhalation therapy increases the risk of cardiac dysrhythmias, which 
might account lor a proportion of the sudden deaths seen in asthma patients. 
While B,-adrenergic stimulation enhances extrarenal potassium uptake, there are 
indications that "-adrenoceptor stimulation has the opposite effect. In man, Williams 
et al (65) showed that the rise in potassium after a potassium load was augmented 
by phenylephrine. This effect could be blocked by phentholamine. Urinary 
potassium excretion did not change during these studies. In an other set of 
experiments (66) the same group studied the effects of a- and B-adrenoceptor 
blockade on exercise induced hyperkalaemia. Plasma noradrenaline and adrenaline 
increased to around 1600 and 340 pgjml respectively during exercise. They 
showed that propranolol increased the exercise-induced rise in potassium, whereas 
phentholamine inhibited the response. The effect appeared to be independent of 
venous pH, bicarbonate, glucose and insulin concentrations, whereas also 
potassium excretion was not altered. So, this a-adrenoceptor mediated mechanism 
is likely to inhibit cellular uptake of potassium. Although, in our study the plasma 
potassium during noradrenaline tended to be higher than during control, the 
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differences were not stetistically significant. 
All these results indicate that catecholamines exert an effect on potassium 
homeostasis, which can be of great clinical relevance. Our study shows that only 
mildly increased plasma adrenaline already has a lowering effect on plasma 
potassium. 
Effects on renin and aldosterone 
The kidney is by far most, if not the only, source of renin in plasma, since in 
bilateral nephrectomized patients plasma renin is very low or below the detection 
limit (67,68). Extensive research has demonstrated that adrenergic receptor-
mediated processes are important in controlling renin release (69). The release of 
renin is governed by both intra- and extrarenal mechanisms. lntrarenal 
baroreceptors are influenced by "stretch" changes in the afferent arteriole: 
increased perfusion pressure increases stretch which somehOw reduces renin 
secretion. Reduced "stretch" increases renin release. The second intrarenal 
mechanism is the "macula densa" chemoreceptor mechanism. The macula densa is 
stimulated by a decrease in NaCI delivery in the distal tubule, which then leads to 
an increase in renin release. The extrarenal mechanisms comprise the feedback by 
plasma angiotensin II and the renal nerves and plasma catecholamines. 
B,-Adrenoceptor agonists have been shewn to induce renin release from the 
juxtaglomerular cells, in which granulae renin is produced, stored and excreted 
{69). Also renal nerve stimulation was demonstrated to increase renin secretion 
(70). In these earlier studies there were gross (renal) haemodynamic changes, 
which might have accounted for a stimulation of renin release. However, later 
Osborn et al (7i) showed that low frequency renal nerve stimulation, which did not 
affect renal haemodynamics or sodium excretion, still induced a considerable 
increase in renin secretion. 
Also in man plasma renin is increased during infusion of B,-adrenoceptor 
agonists. There are, however, also reports which suggest a B,-adrenoceptor 
mediated enhancement of renin release. This is probably an indirect effect. Kopp 
and DiBona infused a low dose of adrenaline bilaterally in dogs in an innervated 
and a denervated kidney and measured renin secretion rate (72). They showed that 
the enhancement of the renin secretion produced by adrenaline was much more 
pronounced on the innervated site. Both metoprolol (B,-adrenoceptor selective 
antagonist) and ICI-i 18551 (B,-adrenoceptor selective antagonist) abolished the 
increased renin secretion induced by adrenaline. These results support the 
hypothesis that adrenaline enhances renin secretion indirectly through activation of 
prejunctional B,-adrenoceptors, which results in enhancement of noradrenaline 
96 
release which on its turn stimulates postjunctional B,-adrenoceptors on the 
juxtaglomerular cells (72). In vitro experiments indeed have indicated that activation 
of prejunctional B,-adrenoceptors in the kidney facilitate noradrenaline release (69) 
and it was also demonstrated that renal nerve stimulation results in an increase of 
noradrenaline outlaw from the kidney (74). 
Our group has provided data indicating that this process of renin secretion 
enhancement is also operational in humans (75). It was shown that prenalterol (B,-
adrenoceptor selective agonist), salbutamol (B,-adrenoceptor selective agonist) and 
isoprenaline (non-selective agonist) all induced a rise in plasma renin. The B,-
adrenoceptor-agonist induced rise in renin was correlated with the rise in plasma 
noradrenaline. During treatment with atenolol (B,-selective blockade), ICI-118551 
(B,-adrenoceptor selective blockade) and propranolol (non-selective) baseline 
plasma renin was decreased in all three cases. The antagonistic effect of atenolol 
and propranolol on the isoprenaline induced rise of renin were comparable, 
whereas ICI-118551 had only a minor inhibiting effect. These results are compatible 
with the hypothesis that the B,-adrenoceptor agonist induced rise of plasma renin is 
a result of activation of prejunctional B,-adrenoceptors, subsequent noradrenaline 
release, which then stimulates postjunctional B,-adrenoceptor mediated renin 
release. 
There are also indications that a-adrenoceptor mediated mechanisms are involved 
in the regulation of renin release (76,77). De Leeuw et al have studied the 
contribution of renal o:-adrenoceptors (78-80). In a series of experiments they 
showed in untreated hypertensives that intrarenal administration of doxazosin ( o:,-
adrenoceptor antagonist) slightly, but phentholamine (non-selective a-adrenoceptor 
antagonist) markedly enhanced renin secretion during isometric exercise (78). In a 
second study they showed that intrarenal infusion of yohimbine ( o:, antagonist) was 
more effective in raising renin secretion than doxazosin (79). In a third set of 
experiments the same group evaluated whether o:,-adrenoceptors are able to 
modify the renin release on its own or whether it required the presence of 
functioning B,-adrenoceptors (80). One could argue that the a,-adrenoceptor 
mediated effect shown in the previous studies is a consequence of modulation of 
prejunctional c:,-adrenoceptors. Stimulation of these adrenoceptors leads to a 
reduction of noradrenaline release and subsequent decreases in activity of 
postjunctional B,-adrenoceptors. lntrarenal infusion of yohimbine markedly 
increased renin release, however in the presence of atenolol this response was 
blunted. So experimental work (76, 77) and studies in humans indicate that o:,-
rather than o:,-adrenoceptors might be involved in inhibition of renin secretion and 
that, at least in part, these adrenoceptors are located prejunctionally. 
In this study we have demonstrated that both adrenaline and noradrenaline had a 
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very small but significant effect on plasma renin concentration. Despite the fact that 
we did not find an increase in plasma noradrenaline during adrenaline infusion, 
(which then would have been an indication lor the above mentioned "indirect" B,-
adrenoceptor mediated effect) renin was higher during adrenaline than during 
dextrose. However, blood pressure was lower during adrenaline than during 
dextrose and this might also have been responsible for the stimulation of renin 
secretion. 
As a consequence of the activation of renin release also plasma aldosterone 
concentrations were little, but significantly, increased during adrenaline as 
compared to dextrose. Also during noradrenaline aldosterone tended to be higher, 
but this was not significant. The question, whether also a direct stimulating effect on 
aldosterone secretion through B-adrenoceptors, as was demonstrated in vitro (81), 
is also present in vivo, can not be answered by our data. 
So extensive research has established that the renal autonomic nervous system 
and circulating adrenaline and noradrenaline can have considerable effect on renin 
release. Our results support this conclusion for the effects of these plasma 
catecholamines in the high physiological range. 
Conclusion 
In the century after Claude Bernard it has been established that the circulating 
hormone adrenaline but also the neurotransmitter noradrenaline have considerable 
impact on various parts of metabolism in man. Our results confirm and extend this 
knowledge and they clearly demonstrate that adrenaline and noradrenaline in 
physiological plasma concentrations can elicit multiple metabolic effects. 
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Chapter 7 
EFFECTS OF "STRESS" LEVELS OF NORADRENALINE AND ADRENALINE ON 
URINARY SODIUM OUTPUT IN NORMAL SODIUM REPLETE MAN. 
Based on: PJ Blankestijn, AJ Man in 't Vek:l, JH Tulen, F Boomsma, FHM Derkx, P Mo!eman, 
MADH Schalekamp. Effects of "stress" levels of noradrenaline and adrenaline on urinary 
sodium output in normal sodium replete man. Submitted. 
INTRODUCTION 
Evidence suggesting that the renal sympathetic nervous system may influence 
urinary sodium and water excretion was first presented by Claude Bernard more than 
100 years ago (1). He observed an increase in urine flow following section of the 
splanchnic nerve in the anaesthetized animal. Since then a great number of studies 
have established that this system can contribute to the regulation of sodium excretion 
(for reviews 2-5). Renal denervation has provided an approach to examen the role of 
renal nerves. Studies in animals with pharmacologically and anatomically denervated 
kidneys and pharmacological interventions in man, have addressed this issue. Another 
approach to examine the role of renal nerves in sodium homeostasis, has been the 
use of renal nerve stimulation. More than 30 years ago is was noted that direct renal 
nerve stimulation results in an ipsilateral decrease in urinary sodium excretion (6). In 
those studies marked decreases in renal blood fiow and glomerular filtration rate 
accompanied this anti natriuresis. More recent studies have demonstrated that low level 
electrical stimulation reduces sodium excretion without afiecting glomerular Mration 
rate or renal blood flow (7). The primary site in the nephron influenced by 
catecholamines appears to be the proximal tubule. 
Studies on the effects of circulating catecholamines in man have produced conflicting 
results, probably due to methodological differences such as variation in the doses 
used and the duration of the experiments. In this study we examined the effects of a 
6 hours lasting intravenous infusions of noradrenaline and adrenaline resulting in 
plasma concentrations in the high physiological range, on renal sodium excretion for 
24 hours. 
SUBJECTS AND METHODS 
See chapter 2. 
RESULTS 
Hormones 
The mean baseline concentrations of plasma adrenaline and noradrenaline were 
similar under the three different conditions. During the infusion of adrenaline venous 
adrenaline rose from 21 :o: 4 to a mean of 230 :': 28 pgjml and during noradrenaline 
infusion venous noradrenaline rose from 207 :': 17 to a mean of 705 :': 58 pgjml 
(Table 1). Plasma adrenaline during adrenaline and plasma noradrenaline during 
noradrenaline infusion were significantly higher than corresponding values during 
dextrose (ANOVA, both p<0.001). Less than 5 minutes after the infusions were 
stopped catecholamines concentrations had returned to baseline values (for a more 
detailed description see Chapter 3). 
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TABLE 1 MEAN VENOUS CONCENTRATIONS OF ADRENALINE, NORADRENALINE, RENIN AND 
ALDOSTERONE BEFORE AND DURING A 6 HOUR INFUSION OF ADRENALINE AND 
NORADRENALINE 
INFUSION CONDITION 
dextrose noradrenaline adrenaline 
adrenaline (pg(ml) 
-baseline 31 (6) 22(4) 21(4) 
- infusion period 30(3) 22(3) 230(28)*** 
noradrenaline (pgjml) 
-baseline 204(20) 207(17) 203(21) 
- infusion period 219(24) 705(58)*"'* 197(17) 
renin (mU/L) 
- baseHne 13.4(12.0-14.9) 15.5(14.6-21.0) 14.4(11.4-18.1) 
- infusion period 11.6(9.6 -13.9) 17.3(13.8-21.5)*** 17.9(15.5-20.8)*** 
aldosterone (pg(ml) 
- baseHne 72(5) 72(4) 80(6) 
- infusion period 52(4) 61 (6) 70(4) .. 
Data are mean (SEM), mean values of renin (range) were calculated after logarithmic transformation. 
Baseline period == 9.00 - 10.00 h, infusion period == 10.00 - 16.00 h. 
** p < 0.01. *** p < 0.001 adrenaline or noradrenaline versus dextrose 
Baseline concentrations of active renin and aldosterone were not different. During 
both the infusions of adrenaline and noradrenaline active renin increased and was 
significantly higher than during dextrose. There were no significant differences between 
the plasma renin values during adrenaline and noradrenaline. Also one hour after 
cessation of the infusions there was no significant dtfference. Aldosterone during 
adrenaline was slightly although significantly higher than during dextrose (for a more 
detailed description see Chapter 6). 
Haemodynamics 
The mean (SEM) baseline blood pressure values were not dtfferent (adrenaline study 
103(3)/62(2), noradrenaline study 104(3)/64(2), dextrose study 106(3)/63(2) mmhg) 
(Table 1). Arterial pressure during adrenaline infusion was lower and during 
noradrenaline infusion higher than during dextrose (resp. 102(2)/57(3) and 
109(2)/66(2) versus 106(2)/63(2) mmHg, both p<0.001 ANOVA). In the post-infusion 
period arterial pressure after adrenaline was higher than after dextrose (107(2)/66(2) 
vs 103(2)/64(1) mmHg, p<0.001 ANOVA). Blood pressure after noradrenaline was not 
different from the dextrose study (for more detailed description of haemodynamic 
results see Chapter 3). 
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TABLE 2 MEAN BLOOD PRESSURE BEFORE DURING AND AFTER A 6 HOUR INFUSION OF 
ADRENALINE AND NORADRENALINE 
BLOOD PRESSURE (mmHg) 
dextrose noradrenaline adrenaline 
baseline 106(3)/63(2) 104(3)/64(2) 103(3)/62(2) 
infusion period 1 06(2) /63(2) 109(2)/66(2)*** 102(2)/57(3)*** 
postinfusion period 103(2)/64(1) 104(3)/63(3) 107(2)/66(2)*** 
Data are mean (SEM) 
Baseline period = 9.00~10.00 h, infusion period = 10.00-16.00 h, postinfusion period = 16.00-9.30 h. 
*** p < 0.001 adrenaline or noradrenaline versus dextrose 
Sodium excretion 
During the infusion periods and during the postinfusion periods no differences in 
sodium excretion were detected (Table 3). 
TABLE 3 URINARY SODIUM AND CREATININE EXCRETION DURING AND AFTER INFUSION OF 
ADRENALINE, NORADRENALINE OR DEXTROSE 
ADRENALINE NORADRENALINE 
SODIUM 
infusion period 
mmol 119 (14) 122 (13) 
mmo!jh 13 (1) 13 (1) 
mmoljmmo! creatinine 18 (1) 18 (2) 
post-infusion period 
mmol 85 (12) 107 (22) 
mmoljh 5 (1) 7 (1) 
mmoljmmol creatinine 12 (3) 12 (2) 
total period 
mmol 204 (21) 230 (27) 
mmoljh 8 (1) 9 (1) 
mmoljmmol creatinine 14 (2) 15 (2) 
data are means (SEM) 
infusion period = 8.30- 17.30 h, postinfusion period = 17.30-9.30 h next morning, 
total period = infusion period + postinfusion period 
Differences between adrenaline and noradrenallne versus dextrose were not significant. 
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DEXTROSE 
123 (14) 
13 (2) 
19 (3) 
102 (19) 
6 (1) 
13 (2) 
224 (26) 
9 (1) 
15 (1) 
DISCUSSION 
The mechanism by which catecholamines enhance the renal sodium reabsorption 
may be multifactorial. Firstly, catecholamines have the ability to infiuence renal blood 
flow and glomerular filtration rate and can thereby alter physical factors of the proximal 
tubular environment. In addition it has been shown that renal nerve activity can activate 
the renin-angiotensin system, which can influence sodium excretion. Thirdly, there are 
indications of a direct action of catecholamines on proximal tubular cells (3-5). 
The evaluation of the individual contributions of the above mentioned mechanisms 
by which adrenergic mechanisms could modify renal sodium excretion, is not without 
difficulties. This appears to be due to the counteracting renal and extrarenal actions 
of the sympathetic nervous system. Activation of the autonomic nervous system may 
enhance sodium reabsorption (direct renal effect) whereas the systemic 
haemodynamic effect (increase in blood pressure) tend to reduce sodium 
reabsorption. This problem is illustrated in studies with the sympatholytic agent 
guanethidine. When given in doses not affecting the systemic pressure, the adrenergic 
effect on the kidney was blocked, resulting in an increase in sodium excretion (8). 
However, when the drug is used in higher doses which reduce blood pressure, the 
hypotensive effect predominates and sodium retention occurs. 
There is abundant evidence that renal nerves and catecholamines are able to exert 
a sodium retaining action. Bello-Reuss (9) showed that renal nerve stimulation can 
increase sodium reabsorption without affecting glomerular filtration rate. She further 
demonstrated that the increased sodium reabsorption occurs at the proximal tubular 
site, but also in the ascending loop of Henle. Indeed sympathetic nervous system 
fibres were found to innervate, besides the juxtaglomerular apparatus and renal 
vessels, also the proximal tubule segments (1 0). In studies in rats, dogs and rabbits 
the sodium retaining effect seems to be o:-adrenoceptor mediated, most likely through 
the postjunctional a,-adrenoceptor subtype (5, 11, 12). Osborn et al demonstrated in a 
study in dogs using low-frequency renal nerve stimulation (so that renal blood flow and 
glomerular filtration rate remained unchanged), that intrarenal infusion of 
phentholamine (non-selective o:-adrenoceptor blockade) and prazosin (selective "'·-
adrenoceptor blockade), but not yohimbine (selective "',-adrenoceptor blockade), 
propranolol or atenolol, were all able to inhibit the renal nerve stimulation induced 
antinatriuresis (11). So apparently o:,-adrenoceptors, but not o:,-, B,- and B,- play a role 
here. 
Another system which has been utilized to assess the role of catecholamines on 
renal sodium excretion has been the isolated perfused kidney. This system allows for 
the evaluation of direct effects of various agents on renal function, since the kidney is 
denervated and perfused outside of the body with artificial medium devoid of renin 
substrate or other vasopressor substances. The concentrations of catecholamines can 
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be altered and renal perfusion pressure and renal flow can be controlled. Besarab et 
al (13) showed that both adrenaline and noradrenaline have a direct effect on sodium 
handling in the isolated perfused rat kidney. When perfusion pressure was kept 
constant, sodium excretion decreased markedly after addition of either of the agents. 
This effect was blocked by propranolol. Thus at least in isolated rat kidney studies, 
there seems to be a direct role for B-adrenoceptor stimulation in the control of sodium 
excretion. Propranolol enhances renal excretion of sodium in the rat by a tubular 
mechanism. Since metoprolol causes a similar effect it is likely that the receptor 
involved is of the B,-subtype (14,15). In summary, the receptor involved in the tubular 
transport effect of low level renal nerve stimulation is an a,-adrenoceptor. However, 
with other -primarily pharmacological- forms of stimulation a, and B-adrenoceptors may 
also influence tubular transport function. 
As stated before, interactions of the direct tubular effect with other mechanisms might 
be important. Sympathetic nervous system activation also leads to augmented renin 
release, especially during reduction of renal perfusion pressure or volume depletion. 
The precise role of angiotensin II in the antinatriuretic effect of renal nerve stimulation 
is not completely elucidated. Handa & Johns have used converting enzyme inhibition 
and angiotensin II antagonism in rats to demonstrate an angiotensin II requirementfor 
renal nerve stimulation to increase renal sodium reabsorption (16). However, 
Zembraski and DiBona showed that angiotensin II antagonism did not modify the renal 
sodium conserving action of renal nerve input (17). 
Renal sympathetic nerve activity is also a stimulus for prostaglandin production (18). 
Prostaglandins are known to inhibit sodium reabsorption in the thick ascending limb 
and collecting duct. Sodium reabsorption induced by renal nerve stimulation in the dog 
was not affected by prostaglandin synthesis inhibition (19), whereas it impairs acute 
denervation natriuresis in the rat (20). 
So it has become clear from animal studies, that renal nerves and catecholamines 
are able to contribute to the regulation of renal sodium excretion. 
In this study in sodium replete normal humans we found no differences in urinary 
sodium excretion during a 6 hours infusion of noradrenaline or adrenaline as 
compared to control. The infusions resulted in plasma concentrations in the high 
physiological range. These findings argue against a major role of circulating 
noradrenaline or adrenaline in renal salt handling. There are, however, indications that 
the adrenergically mediated sodium conserving effects are operational in man. Gill and 
Bartter (21) demonstrated in normal human subjects that when autonomic insufficiency 
is produced by guanethidine, urinary sodium excretion could not be sufficiently 
reduced to avoid negative sodium balance in response to reduction in dietary sodium 
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intake, despite decreases in glomerular filtration rate and marked increases in urinary 
aldosterone excretion. Also patients with idiopathic autonomic insufficiency could not 
lower their urinary sodium excretion below 50-60 mmoljday while consuming a diet 
with sodium intake of 17 mmoljday. Even mineralocorticoid drug substitution failed to 
correct the negative sodium balance (22). These clinical studies support the view that 
renal innervation appears to be essential for the kidney to express its full ability to 
maximally reabsorb sodium in response to reduction of dietary sodium intake. 
Several studies have addressed the question of the possible effects of circulating 
adrenaline and noradrenaline on sodium excretion in humans. Older studies in which 
noradrenaline and adrenaline were infused in much higher doses than we did, inducing 
substantial rises in blood pressure and decreases in renal blood flow, generally show 
a marked sodium retention (23-25). Also in a recent study in normal man 
noradrenaline was infused leading to approximately the same plasma levels as in our 
study (26). A marked decrease (20%) in sodium excretion was found. Since creatinine 
clearance was not effected, but a decline in lithium clearance was found, the results 
were taken to indicate an increase in tubular sodium reabsorption. The investigators 
did not detect major blood pressure changes, although blood pressure was monitored 
indirectly, and small haemodynamic changes might have gone unnoticed. 
In our study no effect of adrenaline or noradrenaline on natriuresis was noted during 
the infusions as compared to the control experiment, while blood pressure was higher 
during noradrenaline and lower during adrenaline as compared to control. It was in 
1925, when Starling and Verney studied isolated perfused kidneys and reported that 
alterations in renal perfusion pressure were accompanied by parallel changes in 
urinary sodium excretion (27). It is now understood from both isolated kidney studies 
and in vivo experiments that a small elevation of blood pressure results in an increase 
in urinary sodium excretion (28,29). The mechanism by which increases in renal 
perfusion pressure cause natriuresis appears to involve small increases in glomerular 
filtration rate and filtered sodium load as well as reduction in tubular reabsorption (29). 
In the "autoregulatory" range, which is in the dog a renal perfusion pressure between 
80-180 mmHg, the increase in urinary sodium excretion is largely a consequence of 
altered tubular behaviour, whereas glomerular filtration rate remains remarkably 
constant (30). In our study, however, there was no enhanced sodium excretion during 
the noradrenaline infusion, despite the fact that blood pressure during noradrenaline 
was higher than during dextrose and adrenaline infusion. Either the haemodynamic 
effects of noradrenaline were insufficient to cause natriuresis, or it might be possible 
that the pressor natriuresis was counteracted by the stimulating effect of noradrenaline 
on the proximal tubular reabsorption, which led to the zero net result in sodium 
excretion. In the post-infusion period after adrenaline infusion, in which blood pressure 
was higher than after noradrenaline and control infusion, we also did not detect an 
111 
enhanced sodium excretion. Since one might have expected increased noradrenaline 
levels in this period (see Chapter 3), these could have led to enhanced sodium 
reabsorption leading to the net result of a sodium output in balance. Thus, one could 
argue that adrenaline like noradrenaline is an antinatriuretic factor. 
In our study blood pressure decreased during adrenaline infusion. A decrease in 
sodium excretion could have been expected. However, sodium loss during adrenaline 
was not significantly different from control infusion. Johnson et Barger found during 
intravenous administration of adrenaline (5, 25 and 125 ngjkgjmin) in dogs a 
decrease in urinary sodium loss without affecting glomerular filtration rate and renal 
blood fiow (31). lntrarenal infusion did not have the same effect. The authors 
concluded that the effect of adrenaline was a result of an extrarenal mechanism. The 
sustained reduction in blood pressure during the 25 ngjkg/min infusion and the 
transitory fall in blood pressure during 125 ngjkg/min might have been of importance. 
The increased renin secretion and/or an enhanced renal sympathetic nerve activity 
were hypothesized to be the cause of the antinatriuretic effect. In another study in 
dogs isoprenaline was infused in low dose without infiuencing blood pressure and 
increased sodium excretion was noted, which was suspected to be the result of the 
vasodilator response to isoprenaline (32). However, intravenous infusion of 
isoprenaline leading to substantial blood pressure reduction resulted in an overall 
decrease of sodium excretion, although the direct effect (increased sodium excretion) 
was still detectable during concomitant intrarenal administration of isoprenaline. Thus 
the systemic effect (blood pressure reduction - decrease in sodium excretion) 
antagonized the renal effect (enhanced sodium excretion). It was suggested that this 
antagonism was caused by an increased sympathetic nervous system stimulation to 
the kidneys during the blood pressure fall (32). In a more recent study in dogs Kopp 
and DiBona showed that renal intra-arterial infusion of adrenaline, not affecting 
systemic blood pressure, had no effect on urinary sodium loss (33). Finally the 
anti natriuretic response to low frequency electrical stimulation in dogs (without affecting 
renal blood flow) was not influenced by atenolol or propranolol {11 ). So, in dogs 
adrenaline in subpressor doses does not appear to have an effect on sodium 
excretion, whereas an enhancing effect of B-adrenoceptor stimulation was documented 
in the rat (14, 15). In our study in humans no significant effect on sodium excretion was 
found. Since blood pressure decreased, the B,-adrenoceptor mediated vasodilatory 
action of adrenaline must have predominated. The possible sodium excretion 
enhancing effect of this (renal) vasodilation as was observed in the dog (32) must have 
been counteracted by the systemic effect (lowering blood pressure - inhibiting sodium 
excretion). Since we have no data on renal haemodynamics, the exact mechanism of 
our findings is not elucidated by our study. Adrenaline infused in higher doses 
resulting in a rise in blood pressure, so when a-adrenoceptor mediated actions 
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predominate, results in a marked decrease in sodium excretion, by enhancing tubular 
reabsorption (23). 
The abundant amount of data in the literature, which are briefly outlined in this paper, 
have clearly demonstrated that the adrenergic control of renal tubular sodium excretion 
is recognized as an important physiological mechanism in the overall regulation of 
sodium and water homeostasis in mammalian organisms. The antinatriuresis is 
mediated by renal ct,-adrenoceptors. Research in animals on the exact role of B-
adrenoceptors produced conflicting results, which might be caused by interspecies 
differences. 
Our data show that circulating adrenaline and noradrenaline in physiological 
concentrations in plasma do not affect renal sodium excretion in normal sodium 
replete men. These results are in keeping with the assumption of DiBona (5) that the 
renal adrenergic system is not required for the renal regulation of sodium balance 
during normal or even moderate reduction in dietary sodium intake. This conclusion 
is also supported by the above mentioned observations in humans with autonomic 
failure, in whom only very severe reduction in dietary sodium intake leads to negative 
sodium balance. Also patients with a kidney transplant appeared to be able to maintain 
sodium balance (34). In a study in 5 patients who had had their own kidneys removed 
previously and had received a kidney transplant 46 to 922 days earlier, it was 
demonstrated that the ability of the patients to conserve sodium on a dietary intake of 
10 mmoljday appeared to be normal. The authors assumed that renal nerve 
regeneration did not occur. In rats, however, there is evidence for beginning functional 
renal nerve regeneration about 1 month after bilateral denervation (35,36). 
Our results could be interpreted also in another way. The increased blood pressure 
during noradrenaline infusion did not result in an enhancement in natriuresis, which 
can be taken as an indication of increased sodium reabsorption. In the post-infusion 
period after adrenaline infusion, the observed rise in blood pressure was not 
accompanied by an increase in urinary sodium loss. Again, this might be a 
consequence of higher plasma noradrenaline which are suspected to occur in this 
period (Chapter 3). In both situations a higher blood pressure was needed to maintain 
natriuresis. It was Borst (37) and later Guyton (38) who suggested that "deficient" 
sodium excretion is the essential feature in essential hypertension. According to their 
theory the renal abnormality involves a change in the normal relationship between 
arterial pressure and sodium excretion, in such a way that a higher than normal 
pressure is required for sodium excretion to match sodium intake. It is now clear that 
this abnormality exists in many if not all types of experimental and clinical hypertension 
(39-41). The mechanism responsible for this resetting and the question whether it is 
a cause or consequence of hypertension is, however, still a matter of debate. Our 
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results would fit in an involvement of the catecholaminergic system. Indeed there is 
evidence from animal studies for the existence of an increased renal nerve activity in 
certain forms of experimental hypertension (lor review 42). Workers from Maastricht 
also provided evidence for a causal relationship between efferent renal nerve activity 
and hypertension (43,44). lntrarenal infusion of noradrenaline in doses that were 
ineffective or much less effective when given intravenously, induced a sustained 
increase in blood pressure. The intrarenal mechanism which is triggered by the 
increased nerve activity and leads to an increase in blood pressure, might be the 
enhanced sodium resorption as was observed in dogs (45,46). These observations 
were, however, not confirmed in the rat (47). 
Insulin, like aldosterone, can be regarded as a sodium-retaining hormone (48). The 
higher circulating insulin and aldosterone concentrations during the adrenaline infusion 
as compared to the other conditions, could also have contributed to the "inability" of 
the kidneys to excrete a sufficient amount of sodium. 
Although drfficult to obtain there is also evidence that efferent renal sympathetic nerve 
activity is increased in human essential hypertension. Hollenberg et al demonstrated 
that the increase in renal blood flow in response to the intra-renal administration of the 
a-antagonist phentholamine, was greater in humans with essential hypertension than 
in normotensive controls, suggesting an increased vasoconstrictor influence on renal 
vasculature (49). Esler et al have demonstrated that noradrenaline spillover to plasma, 
an index of total sympathetic nervous system activity, is increased in essential 
hypertension and that this derives in large part from the increase in renal noradrenaline 
spillover (50). 
In conclusion, our results combined with the data in the literature, which are briefly 
summarized above, suggest an involvement of the renal adrenoceptor system in the 
pathogenesis of human hypertension and that the mechanism of this involvement 
might be its interaction with renal salt handling. At any rate, the potential role of 
adrenaline in the pathogenesis of hypertension might have two faces: the release of 
noradrenaline which causes vasoconstriction along with the prevention of pressure-
natriuresis through an antinatriuretic action. 
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Chapters 
ADRENAliNE-INDUCED ENHANCEMENT OF SYMPATHETIC ACTIVITY IN 
MAN; INHIBITION BY NON-sElECTIVE AS WEll AS 61-SElECTIVE 
13-ADRENOCEPTOR BlOCKADE. 
Reprinted from: AH van den Meiracker, AJ Man in 't Veld, F Boomsma, PJ Blankestijn, MADH 
Schalekamp. Epinephrine-induced enhancement of sympathetic activity in 
humans: inhibition by non-selective as well as 51-selective 6-adrenoceptor 
blockade. J Cardiovasc Pharmaco11990; 15: 610-617 
INTRODUCTION 
In numerous in-vitro studies using animal as well human tissues it has been well 
established that stimulation of prejunctional B-adrenoceptors facilitates the neuronal 
release of noradrenaline (1-4). Adrenaline is likely to be the physiological agonist of 
the prejunctional B-receptor (5-9). This has stimulated interest for a possible role of 
adrenaline in the pathogenesis of certain forms of hypertension (1 0-12). 
Studies in man have shown that sympathetic activity, as assessed by plasma 
noradrenaline concentrations and as assessed by neurogenic vasoconstriction, is 
increased by low-dose infusions of adrenaline (13-19). Other studies, however, 
failed to demonstrate such an effect (20-23). In some instances these discrepant 
results could be related to the doses of adrenaline that have been used. Too high 
levels of adrenaline may not only activate the stimulatory B-type prejunctional 
B-adrenoceptors, but also the inhibitory a-type, thereby masking a facilitating effect 
of adrenaline on noradrenaline release (22). Furthermore, since noradrenaline is 
extensively metabolized in tissues, the site of noradrenaline sampling may also be 
important for the demonstration of adrenaline-induced increments in noradrenaline 
plasma levels. In fact, in one study arterial plasma levels of noradrenaline rose 
during intravenous infusion of adrenaline, whereas venous levels did not (24). 
The present study was conducted in order to collect more information on the 
facilitating effect of adrenaline on noradrenaline release in man. Our aim was 
twofold. First, to confirm and extend earlier observations that adrenaline, in 
concentrations within the physiological range, enhances resting and activated 
sympathetic activity. Second, to study the effects of non-selective and B,-selective 
B-adrenoceptor blockade on this adrenaline-induced enhancement in sympathetic 
activity. Arterial plasma levels of noradrenaline were used as an index of overall 
sympathetic activity, whereas the production of noradrenaline in the forearm, with 
exclusion of the hand, was used as an index of local muscle sympathetic activity. 
SUBJECTS AND METHODS 
Sixteen subjects with a mean age of 41 years, range 24 to 52 years, participated 
in the study after they had given informed consent. All subjects had mild 
hypertension. Their sitting diastolic blood pressure varied between 95 and 105 mm 
Hg, when untreated. A secondary cause of hypertension was excluded by routine 
clinical and laboratory evaluation. None of the subjects had a history or clinical 
signs of ischaemic heart disease, cardiac failure, cerebrovascular disease, chronic 
obstructive lung disease, diabetes mellitus or any other serious illness. 
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Study Protocol. 
A washout phase of at least 2 weeks was followed by a single blind placebo 
period of 2 weeks. After this period 10 subjects were randomly allocated to either 
atenolol or bopindolol in a double-blind cross-over comparison. Atenolol and 
bopindolol were given for one week. To avoid a carry-over effect this active 
treatment period was interrupted by a second placebo period of two weeks. 
Studies were performed at the end of the first placebo period and at the end of 
both active treatment periods. Placebo capsules during the active treatment and 
placebo periods were matched. One capsule had to be taken every morning. 
Adherence to the medication was checked by pill counting. Atenolol was given in a 
once daily dose of 50 mg. Bopindolol, which is a long-acting non-selective 
B-adrenoceptor antagonist with some degree of partial agonist activity (25), was 
given in a once daily dose of 1 mg. 
Procedures and Tests. 
Patients arrived at 8 A.M. in the laboratory after a light breakfast at home. While 
resting supine on a tilt-table the brachial artery of the non-dominant arm was 
cannulated with a 1.0 mm thick, 5 em long, Teflon catheter after local anaesthesia 
with a 2% lidocaine solution. A deep antecubital vein was cannulated in the same 
arm for venous blood sampling. An indwelling catheter in a vein of the contralateral 
forearm was used for intravenous infusions. The flow in the non-dominant arm was 
measured semicontinuously by an ECG triggered venous occlusion 
plethysmograph (Janssen Scientific Instruments, Beerse, Belgium). A 
mercury-in-Silastic strain gauge was placed around the mid-forearm. The venous 
occlusion pressure of 50 mm Hg was intermittently applied for a period of three 
heart beats, with a recovery period of two heart beats. During flow measurements 
the arm was slightly elevated above heart level and handflow was excluded from 
the circulation by a small wrist cuff inflated 30 mm Hg above the systolic arterial 
pressure. Heart rate was derived from a continuously recorded ECG. 
After completion of instrumentation an intravenous saline infusion (5.4 ml per 
hour) was started. Thirty minutes after start of this infusion baseline arterial and 
venous plasma catecholamines, active plasma renin and haemodynamics were 
measured. Ten minutes afterwards an isometric exercise test, cold pressor test, 
orthostatic stress test and a mental stress test (colour word stress test) were 
subsequently performed, with a period of 15 minutes supine rest between each 
test. After completion of the colour word test the saline-infusion was switched to an 
intravenous adrenaline infusion with an infusion rate of 20 ngjkg/min. The timing 
and sequence of measurements and tests during the adrenaline-infusion were the 
same as during infusion of saline. For evaluating possible sequence effects, 6 
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additional subjects only receiving placebo capsules (control group), were studied. 
In the control group, a second saline-infusion was given instead of the 
adrenaline-infusion. 
Isometric exercise test was performed by lifting a weight of approximately 9% of 
body weight over a pulley by 90° flexion of the elbow of the dominant arm, while 
resting supine. This test lasted three minutes. For the cold pressor test the hand up 
to the wrist of the dominant arm was immersed in ice-cold water for one minute. 
Orthostatic stress test was performed by 60° head-up tilting for ten minutes by 
means of a tilt-table. For mental stress an audio-visual version of Stroop's colour 
word conflict test was used. This test consists of four different colour-words written 
in incongruent colours. The words are randomly shown on a television monitor with 
a frequency of 140 words per five minutes. The task of the subject is to ignore the 
written word and to mark the colour on an answer-sheet on which successive rows 
of randomly ordered abbreviations of the four colours are printed. The test lasts for 
5 minutes. 
Just before and immediately at the end of each test arterial and venous blood 
was simultaneously sampled for measurement of catecholamines. Forearm fiow 
was measured during isometric exercise test, cold pressor test and colour word 
test, but for technical reasons, it was not measured during orthostatic stress test. 
Analytical Procedures and Calculations. 
For determination of catecholamines 10 ml of arterial and venous blood was 
collected in chilled tubes containing 12 mg gluthatione and 5 IE sodium heparin. 
After centrifugation at oo C, plasma was removed and stored at -70° until assay. 
Plasma catecholamine concentrations were determined by high performance liquid 
chromatography (HPLC) with electrochemical detection (26). 
The fractional extraction (%) of adrenaline in the forearm was calculated as 
(arterial adrenaline - venous adrenaline)/ arterial adrenaline x 100. The production 
of noradrenaline in the forearm was calculated as the product of forearm fiow and 
the venous-arterial difference of noradrenaline plus the extraction of noradrenaline 
in the forearm. Noradrenaline extraction was calculated as arterial noradrenaline x 
fractional extraction adrenaline, assuming that the fractional extractions of 
noradrenaline and adrenaline in the forearm are similar (27). 
Active plasma renin concentration was measured by RIA, as described previously 
(28). 
122 
Statistical Analysis. 
Data are presented as mean values ± SEM. For active renin the mean was 
calculated after logarithmic transformation of the values, since values were not 
distributed normally. For statistical analysis Student's t-test for paired observations 
was used. p-Values < 0.05 were considered to indicate a statistically significant 
difference. 
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Figure 1. Arterial (B) and venous (/ () plasma tevels of adrenaline during placebo, ateno!ol and 
bopindoloL Upper pane!: infusion of saline, lower panel: infusion of adrenaline (20 ngjkg min). 
* p < 0.05, ** p < 0.01 atenolo! or bopindolol versus placebo 
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RESULTS 
Resting Conditions. 
Values of arterial and venous plasma levels of adrenaline 30 min after starting the 
infusions of saline and adrenaline are shown in Figure 1. During saline arterial 
adrenaline was lower with bopindolol (p < 0.05) than with placebo. During infusion 
of adrenaline arterial adrenaline and venous adrenaline increased five- to tenfold. 
Compared to placebo the adrenaline-infusion induced increments in arterial and 
venous adrenaline were higher with the two B-adrenoceptor antagonists (Figure 1 ). 
The frac<Jonal extraction of adrenaline in the forearm during saline-infusion on 
placebo was 40±5%. Comparable values were seen with atenolol (37±6%) and 
with copindolol (34±6"/o). Infusion of adrenaline caused an increase in the fractional 
extraction of adrenaline in the forearm to respectively 49±5% (p<0.01) during 
p·zcebo, to 44±2% during atenolol (n.s.) and to 50±8% (p<0.05) during 
bopindolol. In the control group resting values of arterial and venous adrenaline 
and the fractional extraction of adrenaline in the forearm 30 min after the first and 
second saline-infusion were not different. The duplicate values were 78±14 and 
52±7 pg/ml lor arterial adrenaline, 35±5 and 30±4 pgjml for venous adrenaline 
and 46±6"/o and 40±9% lor the fractional extraction of adrenaline. 
Active renin decreased to a similar degree after atenolol and bopindolol. Values 
were 23.1±1.3 mU/l during placebo, 11.3±1.2 mU/l (p<0.01) during atenolol, 
and 10.9±1.2 mU/l (p<0.01) during bopindolol. Active renin did not ohange by 
infusion of adrenaline during any of the three treatments: the values during 
placebo, atenolol and bopindolol were 24.5±1.2, 12.9±1.2 mU/L and 8.3±1.2 
m U jl respectively. 
As compared to placebo resting blood pressure and heart rate were reduced by 
the B-adrenoceptor antagonists (Table 1). Forearm flow was not affected by the 
two B-adrenoceptor antagonists. Infusion of adrenaline caused a decrease in 
diastolic arterial pressure both during placebo and during 8,-selective B-blockade 
with atenolol. In contrast, with bopindolol adrenaline-infusion Jed to a small increase 
in diastolic pressure (Table 1). Neither during placebo nor during the two 
B-adrenoceptor antagonists did infusion of adrenaline cause any change in systolic 
arterial pressure. Forearm flow did not change significantly by adrenaline during 
any of the three treatments. Systolic and diastolic arterial pressure, heart rate and 
forearm flow in the control group 30 min after the first and second saline-infusion 
were not different (Table 1). 
Resting values of arterial noradrenaline and the production of noradrenaline in the 
forearm 30 min after start of saline or adrenaline-infusion are shown in Figure 2. 
Although the values of these two parameters during placebo, atenolol or 
bopindolol, at the time of saline-infusion, did not differ, arterial noradrenaline tended 
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Figure 2. Effects of adrenaline on resting concentrations of noradrenaline and forearm noradrenaline 
production during placebo, atenolol and bopindolo! (D saline, I J j adrenaline infusion) 
* p < 0.05, ** p < 0.01 adrenaline versus saline or sa[ine versus saline control group. 
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TABLE 1. EFFECTS OF ADRENALINE ON RESTING VALUES OF SYSTOLIC AND DIASTOLIC ARTERIAL 
PRESSURE. HEART RATE AND FOREARM FLOW DURING PLACEBO. ATENOLOL AND 
BOPINDOLOL 
PLACEBO ATENOLOL BOPINDOLOL CONTROL# 
SAL ADR SAL ADR SAL ADR SAL SAL 
SAP mmHg 154±5 151 ±6 130±5 128±5 140±5 143±5 147±4 145±4 
DAP mmHg 89±2 78±3** 72±2 67±3* 79±2 82±3 86±3 84±4 
HR bpm 71 ±3 78±2** 59±3 58±2 63±3 61 ±3 68±1 65±3 
FAF 3.0±0.3 3.5=0.5 3.4±0.7 2.6±0.3 3.2±0.3 2.9±0.4 4.7±1.3 3.9±0.7 
mljminj100ml 
# Control group saline infusion only. 
SAL = saline and ADR = adrenaline infusion. SAP and DAP systolic and diastolic arterial pressure respectively; 
HR = heart rate; FAF = forearm flow. 
"'p<O.OS; ** p<0.01 adrenaline versus saline. 
to be lower with bopindolol. Infusion of adrenaline during placebo caused an 
increase in arterial noradrenaline (p<0.01) and noradrenaline forearm production 
(p < 0.05). No adrenaline-induced change in these parameters occurred with 
atenolol, whereas with bopindolol adrenaline-infusion led to a decrease in arterial 
noradrenaline (p<0.05), but not to a decrease in noradrenaline forearm production 
(Figure 2). In the control group arterial noradrenaline during the second 
saline-infusion was lower (p < 0.05) than during the first infusion, but no difference in 
noradrenaline forearm production was seen during the first and second 
saline-infusion (Figure 2). 
Stress Tests 
The responses of systolic arterial pressure and diastolic arterial pressure to the 
four stress tests during placebo, atenolol and bopindolol were the same (Table 2). 
The increments in heart rate in response to the isometric exercise test, the colour 
word conflict test and orthostatic stress test during placebo were attenuated or 
abolished by the two B-adrenoceptor antagonists. As compared with placebo, the 
two B-adrenoceptor antagonists had no effect on the responses of forearm flow or 
forearm vascular resistance to the isometric exercise test or the cold pressor test. 
However, the increase in forearm flow during the colour word conflict test was 
diminished by atenolol. During placebo, but not during atenolol and bopindolol, the 
increase in systolic arterial pressure in response to isometric exercise test and the 
increase in diastolic arterial pressure in response to orthostatic stress were 
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TABLE 2. Effects of adrenaline on responses of SAP, DAP, HR, FAF and FVR to the four stress tests during placebo, 
atenolol and bopindolol. 
PLACEBO ATENOLOL BOPINDOLOL CONTROL~ 
SAL ADR·SAL SAL ADR·SAL SAL ADR·SAL SAL SAL·SAL 
tET 
SAP (mmHg) 29±5 4±2* 26±3 3±3 24±2 -1 ±3 27±8 -3±3 
DAP (mmHg) 18±3 1±2 19±2 1±3 16±2 0±1 18±4 1±1 
HR (bpm) 10±1 -4±1** 5±1# 1 ± 1 6±1# 0±1 13±4 -4±4 
FAF (ml/100ml/mln) 0.9±0.4 -0.5±0.3* 1.1 ±0.5 0.2±0.5 0.5±0.4 0.6±0.3 1.4±0.5 -0.1 ±0.5 
FVR (U) 0±4 19± 13* 1±4 2±4 3±10 -2±8 -3±3 2±2 
CPT 
SAP (mrnHg) 12±3 3±2 11 ±3 3±2 15±3 1 ±3 13±2 0±2 
DAP (mmHg) 9±3 0±2 9±2 0±1 11 ±2 -2±2 10±2 1±2 
HR (bpm) 2±2 -1 ±2 0±2 1±2 1±3 1±4 5±2 1±2 
FAF (mi/100ml/mln) -0.2±0.2 -0.5±0.3 0.2±0.3 -0.2±0.3 -0.2±0.2 0.0±0.4 -0.2±0.4 0.3±0.3 
FVR (U) 6±3 4±3 13±8 -3±9 13±6 3±11 2±4 5±6 
CWT 
SAP (mmHg) 24±3 7±4 21 ±5 -1 ±3 22±5 -1 ±3 21±4 -2±1 
DAP (mmHg) 16±2 0±3 13±3 0±3 16±3 -2±2 14±4 -2±1 
HR (bpm) 18±4 -2±3 7±1## 1±1 7±1## 2±12 13±2 3±2 
FAF (mi/100ml/mln) 2.6±0.6 -0.8±0.7 1.0±0.2# 0.0±0.6 1.0±0.5 -Q.2±0.3 2.7±0.4 0.2±0.2 
FVR (U) -12±5 10±7 -10±6 13±8 10±7 ·11 ±9 -13±5 1.0± 1 
OST 
SAP (mmHg) -3±1 2±1 -3±1 2±2 -4±2 -3± 1 -2±3 ·2±3 
DAP (mmHg) 2±2 5±2"" -2±1 2±1 4±1 ·4±2 4±2 0±1 
HR (bpm) 11 ±2 -1 ±2 0±1### 0±3 5±1## 3±1 9±3 2±4 
lET, isometric exercise test; CPT, cold pressor test; CWT, colour word test (mental stress); OST, orthostatic stress test; ADR-SAL, difference In response 
between ADR and SAL; SAL-SAL, difference in response betvleen the second and the first SAL Infusion; FVR, forearm vascular resistance; other 
abbreviations as In Table 1 
~ control group, SAL infusion only 
" p < 0.05, "" p < 0.01 ADR versus SAL 
# p < 0.05, ## p < O.o1, ### p < 0.001, atenolol or boplndolol versus placebo 
TABLE 3. Effects of adrenaline on arterial levels of noradrenaline (pgjml) before and after isometric exercise, cold 
provocation, orthostatic stress and mental stress during placebo, atenolol and bopindolol. 
PLACEBO ATENOLOL BOPINDOLOL CONTROL~ 
SAL ADR SAL ADR SAL ADR SAL SAL 
lET B 202±20 234±24 223± 16 202±24 185±24 118±16 203±34 186±27 
A 256±22 314±27 326± 19 305±26 269±28 200±26 273±20 261 ±34 
CPT B 208±23 231 ±21 229± 18 196±24 189±23 121±18 207±37 212±39 
A 235±30 278±26 263± 19 232±27 228±27 154±26 240±41 255±43 
OST B 194±22 237±22 221 ± 17 189±21 192±22 119± 18 199±36 214±37 
A 350±35 405±38 380±27 361 ±38 375±33 285±50 353±41 384±45 
cwr B 238±22 270± 22 274±2 231±24 236± 19 162±21 233±45 254±49 
A 299±43 366±38 329±29 296±32 261 ±21 209±34 291 ±51 286±40 
'II Control group saline infusion only. 
lET: isometric exercise test; CPT: cold pressor test; OST: orthostatic stress test; cwr: colour word test. 
TABLE 4 Effects of adrenaline on forearm noradrenaline production (pg ml"' min"') before (B) and after (A) isometric 
exercise, cold provocation, orthostatic stress and mental stress during placebo, atenolol and bopindolol. 
PLACEBO ATENOLOL BOPINDOLOL CONTROL# 
SAL ADR SAL ADR SAL ADR SAL SAL 
lET B 263±55 661±117 308±82 310±67 273±92 233±54 468±127 362±95 
A 526±79 938±219 747±168 785± 131 416±226 505±92 919±279 672±343 
!J. 263±81 277± 155 439± 122 474±132 143±69 272±63 451±157 309±272 
CPT B 267±66 558± 110 267±43 312±73 253±69 251 ±43 470± 166 285±80 
A 352±57 590± 135 463±89 499± 109 334±78 363±73 795± 180 556± 136 
l'o. 85±60 32±55 196±79 187±80 80±57 112 ±57 325± 154 271±97 
CWT B 401±67 787± 157 295±62 395±73 320±76 279±80 396± 109 441±181 
A 733± 170 1014±296 524± 113 502±96 554±114 517±114 619±111 701 ± 131 
l'o. 332± 147 227±239 229±64 106±63 223±72 237±73 223± 167 259±110 
# Control group saline infusion only. 
lET: isometric exercise test; CPT: cold pressor test; CWT: colour word test. 
augmented by adrenaline infusion. In the control group, the haemodynamic 
responses to the first and second series of tests were not different. 
All lour tests caused an increase in arterial noradrenaline (Table 3). This 
increment was highest during orthostatic stress test and lowest during cold 
provocation (Figure 3). As compared to placebo the response of arterial 
noradrenaline to isometric exercise test, but not to the other three tests was higher 
with atenolol (p < 0.05) and with bopindolol (p < 0.05). During placebo, infusion of 
adrenaline enhanced the responses di arterial noradrenaline to isometric exercise 
test (p<0.05), cold pressor test (p<0.05) and colour word test (p<0.01), but not to 
orthostatic stress test (Figure 3). This enhancement was abolished by bopindolol 
as well as by atenolol. In the control group there was no difference in the 
responses of arterial noradrenaline to the respective tests during the first and 
second saline-infusion (Figure 3). The responses of noradrenaline forearm 
production to isometric exercise test, cold pressor test and orthostatic stress test 
are summarized in Table 4. With the three different treatments (placebo, atenolol 
and bopindolol) the responses of noradrenaline forearm production to the stress 
tests showed a considerable variation, but differences were never significant. Unlike 
to what was observed for the responses of arterial noradrenaline, the noradrenaline 
forearm production in response to the stress tests was not enhanced by 
adrenaline-infusion during placebo. Adrenaline had also no effect on the responses 
of noradrenaline forearm production during administration of atenolol or bopindolol. 
In the control group changes in noradrenaline forearm production in response to 
the first and second series of tests did not differ (Table 4). 
DISCUSSION 
Effects of B-Adrenoceptor blockade on plasma adrenaline. 
With the infusion rate of adrenaline currently used venous levels of adrenaline 
increased to approximately 200 pgjml during placebo. These levels are within the 
high physiological range (29). It is well known that adrenaline is cleared by 
B-adrenergic mechanisms and that B-adrenoceptor antagonists diminish the 
clearance of adrenaline (30). This explains why both arterial and venous levels of 
adrenaline were higher during administration of the two B-adrenoceptor 
antagonists. During infusion of adrenaline arterial adrenaline rose relatively more 
than venous adrenaline. The fractional extraction of adrenaline in the forearm was 
therefore increased. An adrenaline-induced increase in the fractional extraction of 
adrenaline was also observed during administration of atenolol and bopindolol, 
which is at variance with a report of Best and Halter {24). In their study an acute 
intravenous dose of propranolol during adrenaline-infusion undid the adrenaline-
induced increase in forearm fractional extraction of adrenaline. Differences in the 
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Figure 3. Effect of adrenaline on delta responses of arterial plasma levels of ·noradrenaline to 
isometric exercise (lET), cold provocation (CPT), orthostatic stress (OST) and mental stress (CWT) 
during placebo, atenolol and bopindolol. 0 saline, 1 f J adrenaline infusion. 
"' p < 0.05, ** p < 0.01 adrenaline versus saline. 
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haemodynamic effects of B-adrenoceptor antagonists, when administrated acutely 
or for a more prolonged period, might account for the difference between Best and 
Halter's findings and our study. 
Effects of adrenaline on plasma noradrenaline. 
An increase in plasma noradrenaline during relatively low-dose intravenous 
infusions of adrenaline has been demonstrated (13-18). In the present study these 
observations could be confirmed. In addition, the responses of arterial plasma 
noradrenaline to three of the four stress-tests were also augmented by adrenaline. 
That these increments in plasma noradrenaline were indeed an effect of 
adrenalineis stressed by the absence of such an effect in the control group to 
which only repeated saline infusions were given. 
Effect of adrenaline on local noradrenaline oroduction. 
In an attempt to collect also information on local sympathetic activity, 
predominantly in the muscles, the production of noradrenaline in the forearm 
(excluding the hand) was calculated. The production at rest was markedly 
increased by adrenaline but, unlike the responses of arterial plasma noradrenaline, 
the responses of noradrenaline forearm production to the stress tests were not 
increased by adrenaline. For these differential effects of adrenaline on arterial 
plasma noradrenaline and on noradrenaline forearm production during stress we 
have no easy explanation. One possibility is that changes in local muscle 
sympathetic activity do not run in parallel with changes in overall sympathetic 
activity, a phenomenon that might be related to regional differences in sympathetic 
activation during different forms of stresses (31). Another possibility to consider is 
that during stress the changes in the fractional extraction of adrenaline are not 
representative for the changes in the fractional extraction of noradrenaline, so that 
under these circumstances the formula by which we calculated noradrenaline 
production was not valid. 
Effects of adrenaline on baroreflex activitv_ 
The haemodynamic effects of adrenaline might have influenced sympathetic 
discharge by changing afferent arterial barorellex activity. In this regard, the 
influence of changes in pulse pressure appear to outweigh the influence of 
changes in mean arterial pressure (32). It would therefore be expected that the 
haemodynamic effects of adrenaline will stimulate rather than suppress 
baroreceptors, and as a consequence, will diminish sympathetic activity. This is 
supported by a recent study of Arnold et al (33), showing that a constant infusion 
of the non-selective B-adrenoceptor agonist isoprenaline, with haemodynamic 
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effects comparable to that of adrenaline, caused a reflex-increase rather than a 
reflex-withdrawal of vagal cardiac tone. Furthermore, in the present study, although 
adrenaline-induced changes in arterial pressure during placebo and atenolol were 
comparable, noradrenaline increased only during placebo, suggesting that other 
than haemodynamic changes underlie the alterations in noradrenaline. 
Effect of adrenaline on noradrenaline clearance. 
For interpretation of plasma concentrations of noradrenaline not only changes in 
its release into plasma, but also changes in its clearance rate from the plasma have 
to be considered. The clearance of noradrenaline appears not to be influenced by 
relatively low concentrations of adrenaline (16). On the other hand B-adrenoceptor 
antagonists tend to diminish the clearance of noradrenaline (34). In light of this 
knowledge it is unlikely that alterations in the clearance of noradrenaline are 
responsible for the observed adrenaline-induced changes in plasma noradrenaline 
either during placebo or during administration of the two B-adrenoceptor 
antagonists. 
Role of prejunctional B-adrenoceptors. 
The demonstration that the adrenaline-induced elevations in plasma noradrenaline 
and noradrenaline forearm production is abolished by bopindolol as well as by 
atenolol, indicates the involvement of B-adrenoceptors. Similar observations were 
reported previously (13,14,17,18). The present study adds to this that in this regard 
B,-selective blockade with atenolol is equally effective. This finding seems to 
contradict some pharmacological studies that suggest that prejunctional 
B-adrenoceptors are of a B, subtype (3,4). However, in other experiments it has 
been shown that facilitation of noradrenaline outflow by stimulation of prejunctional 
B-adrenoceptors can indeed be abolished by the B,-selective B-adrenoceptor 
antagonist metoprolol (5,7,35). Therefore, some caution is necessary, when the in 
vitro classification of the prejunctional B-adrenoceptor is extrapolated to the in vivo 
situation. 
The sympathetic nervous system and the renin angiotensin system are closely 
interrelated. Angiotensin II enhances sympathetic activity in several ways (36). 
However, active renin was not increased by infusion of adrenaline, which makes it 
unlikely that the adrenaline-induced elevations in noradrenaline were mediated by 
the renin-angiotensin system. 
In conclusion, the present results provide evidence for the hypothesis that 
elevated levels of adrenaline are capable of enhancing sympathetic activity in man. 
This enhancement is mediated by B-adrenoceptors and can be antagonized not 
only by non-selective, but apparently also by B,-selective B-adrenoceptor blocking 
agents. 
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Chapter 9 
SUMMARY AND CONCLUSIONS 
That stress can be detrimental for man's health, is widely accepted. However, the 
mechanisms through which stress could have such a deleterious effect has long 
been a matter of debate. In this thesis we describe studies exploring the possibility 
of adrenaline playing a role in the pathogenesis of a rise in blood pressure that 
could lead to the development of primary hypertension. 
The relationships between stress and the release of adrenaline and between 
stress and the elevation of blood pressure are well recognized. However, since 
infused adrenaline leading to plasma concentrations in the high physiological range, 
rather decrease than increase blood pressure, the mechanism through which 
adrenaline would be able to lead to an increase in blood pressure therefore 
remained to be elucidated. It was some 10 years ago that an hypothesis was put 
forward indicating a possible way through which adrenaline-mediated increases in 
blood pressure could occur (1-3). At that time it was clear from experimental 
studies that adrenaline could enhance noradrenaline release through stimulation of 
prejunctional B-adrenoceptors, thereby increasing vasoconstrictor tone (4). This 
effect was thought to be mediated by circulating adrenaline. Experimental studies 
also indicated that adrenaline could be taken up in sympathetic neurons and be 
"co-released" along with noradrenaline during sympathetic stimulation and then 
exerts its noradrenaline release enhancing effect (4). In that way adrenaline could 
mediate its blood pressure increasing effect also after plasma adrenaline 
concentrations had returned to normal again. It was hypothesized that these 
adrenaline mediated effects on blood pressure would also be operational in man 
and thereby suggesting that adrenaline could play a role in the pathogenesis of 
hypertension (1 -3). Indeed our group demonstrated that infusion of B-adrenoceptor 
agonists resulted in an increase in plasma noradrenaline (5). Furthermore it was 
shown that infusion of adrenaline leading to plasma concentrations into the high 
physiological range, augmented the pressor responses to refiex sympathetic 
nervous system stimulation by standardized cold pressor and isometric exercise 
testing (3,6,7). 
At the time we started our experiments (1986), two studies were available on the 
haemodynamic effects of adrenaline during, but also after its administration. Brown 
and Dollery studied 6 normotensive volunteers and infused adrenaline over 2 hours 
(8). Indirectly measured blood pressure was higher upto 2'h hours after cessation 
of the infusion, however, the authors reported an absence of statistical significance. 
Nezu et al (9) showed that 30 minutes of adrenaline infusion resulted in a significant 
rise in blood pressure after cessation of the infusions, which lasted at least for 90 
minutes. Pretreatment with propranolol completely abolished this effect. No data 
were available on more long term (several hours) pressor effects of adrenaline and 
no studies existed examining the question whether the effect observed in the two 
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studies just mentioned (8,9), was unique for adrenaline. So we formulated 
questions addressing these issues and we hoped they could be answered by the 
studies presented in this thesis. 
The questions, which are described in Chapter 1, were: 
1 Does adrenaline, when infused intravenously in normotensive subjects 
leading to plasma levels in the high physiological range, cause a sustained 
and protracted rise in blood pressure, which outlasts the duration of the 
increments in circulating adrenaline? And if so, does this effect on blood 
pressure occur at rest or during periods of activation of the sympathetic 
nervous system? 
2 If the questions under number 1 are positively answered, does intravenously 
administered noradrenaline have the same effect? When the effect of 
adrenaline is indeed mediated through prejunctional B,-adrenoceptors, we 
hypothesized that this would not be the case. 
3 Do the pressor responses to standardized sympathetic nervous system 
stimulation by cold pressor and isometric exercise testing before, during and 
18 hours after cessation of infusions of adrenaline, noradrenaline or dextrose 
5% differ? Again we hypothesized that infusion of adrenaline but not 
noradrenaline would lead to an amplification of the blood pressure 
responses. 
4 Are the changes in plasma concentrations of adrenaline and noradrenaline 
during the infusions of adrenaline and noradrenaline also detectable in 
alterations in the amounts of catecholamines and their metabolites excreted 
in the urine? 
5 Do the infusions of catecholamines, which lead to alterations in plasma 
concentrations within the physiological range, have any effect on urinary 
sodium excretion or on plasma levels of several hormones, potassium or 
glucose? 
6 What is the effect of non-selective and B,-selective B-blockade on the 
adrenaline mediated facilitation of noradrenaline release and the adrenaline 
induced enhancement of refiex sympathetic nervous system activity? 
In Chapter 2 an outline is given of the study protocol, the subjects, the methods 
and the statistical tests that were used. 
In Chapter 3 we addressed question 1 and 2, as mentioned above. We studied the 
effects of intravenously administered adrenaline in normotensive subjects. Since it 
was hypothesized, that the blood pressure increasing effect of adrenaline would be 
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mediated through B,-adrenoceptors, we compared the results not only with those of 
placebo infusion {dextrose 5%), but also with those of noradrenaline infusion. It was 
found that, as could be expected from the literature, during the infusions, while the 
subjects rested supine in a quiet and half-dark room (in order to achieve a 
condition of low-grade sympathetic nervous system activity), blood pressure 
decreased during adrenaline and increased during noradrenaline, whereas heart 
rate increased during adrenal"lne and decreased during noradrenaline. However, 
during the 18 hours postinfusion period a significantly higher blood pressure was 
found during the adrenaline study as compared to the dextrose study, whereas 
noradrenaline did not exert a similar pressor effect. The effects on blood pressure 
were especially seen in periods of (assumed) increased sympathetic nervous 
system activity, that is during ambulation and in the second part of the night Qn 
which more frequent periods of REM sleep, which are accompanied by increased 
activity of the sympathetic nervous system, are known to occur). The blood 
pressure effects were less clear during the first part of the night and the next 
morning, while the subjects were lying in supine position for 1 hour, both periods in 
which sympathetic nervous system activity is low. 
Question 3 was addressed in Chapter 4. The blood pressure response during cold 
exposure and isometric exercise testing is a result of sympathetic nervous system 
activation. The blood pressure responses during the tests performed before starting 
the infusions, were similar. The blood pressure values obtained during the tests 
during the infusions, showed an enhanced response during adrenaline, whereas 
results during noradrenaline and dextrose infusion were not different. The tests 
done approximately 18 hours after cessation of the infusions showed similar results, 
that is an enhanced response during the adrenaline study as compared to the 
noradrenaline and dextrose study and no differences between the noradrenaline 
and dextrose studies. 
In Chapter 5 question 4 was addressed. It is clear from the results presented in this 
chapter, that the major urinary metabolites of adrenaline and noradrenaline are 
vanillyl mandelic acid (VMA) and 3-methOxy-4-hydroxyphenylglycol (MHPG). 
Relatively small amounts of unmetabolized adrenaline and noradrenaline and 
metanephrine and normetanephrine are excreted. The amounts of adrenaline 
infused during our studies induced a detectable increase in the amounts of 
adrenaline and metanephrine excreted. However, only about 28% of the infused 
adrenaline could be "traced" back by increased excretions of these metabolites. In 
the amounts of VMA and MHPG excreted no changes were detected. Significantly 
enhanced excretion of noradrenaline and normetanephrine was observed during 
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the noradrenaline study, however, only approximately 9% of the amount of 
noradrenaline infused could be "traced" in this way. Again no changes in the 
amounts of VMA and MHPG excreted were found. During the postinfusion period of 
the adrenaline study, we also found an increased excretion of normetanephrine. 
Since normetanephrine is primarily formed from released noradrenaline, these 
results might be taken as an indication of increased noradrenaline release in this 
period, which is hypothesized to be the explanation of the observed pressor effect 
(see discussion of Chapter 3). 
Ouesf1on 5 was explored in Chapter 6. Small although significant changes in blood 
glucose and plasma concentrations of potassium and some hormones like renin, 
aldosterone and insulin were found, both during adrenaline and noradrenaline 
infusion. These results extend the knowledge on the so-called "metabolic" effects of 
circulating catecholamines and they clearly show that adrenaline and noradrenaline 
have besides haemodynamic effects, definitely also "metabolic" effects, which could 
be of clinical relevance. 
In Chapter 7 the results of measurements of sodium excretion are presented 
(question 5). Although there are several possible mechanisms through which 
catecholamines can influence renal sodium excretion, we did not find any difference 
between the three infusion conditions during, but also not in the 18 hour period 
after the three infusions, despite the fact that the infusions had marked 
haemodynamic effects. The possible explanations for these findings are discussed 
in Chapter 7. At any rate the results are compatible with the suggestion of Borst 
and others (1 0), that "deficient" sodium excretion is an essential feature in the 
development and maintenance of hypertension. They further suggest a role for 
catecholamines mediated mechanisms in establishing this "deficient" sodium 
excretion. 
Question 6 was addressed in Chapter 8. As was shown in previous studies of our 
group, low dose intravenous infusion of adrenaline increased arterial levels of 
noradrenaline as an index of overall sympathetic activity. Infusion of adrenaline also 
increased the production of noradrenaline in the forearm as an index of local 
muscle sympathetic activity. This facilitating effect of adrenaline was abolished by 
both B,-selective and non-selective B-adrenoceptor antagonists. 
Final conclusions 
Considering the above mentioned findings, it can be concluded that the 
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"adrenaline-hypertension" hypothesis might indeed be true in man. The studies 
clearly show that the adrenaline mediated effect can occur while plasma 
concentrations are increased (during infusion), since we observed an amplification 
of the blood pressure response during cold exposure and isometric exercise 
testing. But adrenaline can also exert a pressor effect after plasma concentrations 
had been returned to normal. We observed an increased blood pressure during the 
18 hour postinfusion period and also an amplification of the blood pressure 
response to cold exposure and isometric exercise testing done 18 hours after 
cessation of the adrenaline infusion. Since plasma half-live of adrenaline is only a 
few minutes, this effect is probably a result of adrenaline being taken up in 
sympathetic neurons and being co-released along with noradrenaline during 
sympathetic stimulation. Subsequently adrenaline can facilitate noradrenaline 
release and in that way increase vasoconstrictor tone. Since noradrenaline is 
devoid of this facilitating effect, the adrenoceptors involved are hypothesized to be 
of B,-subtype. The finding that the adrenaline mediated enhancement of 
noradrenaline release and its pressor effects can be antagonized by B-
adrenoceptor blockade, further support the view that B-adrenoceptors are involved 
in this mechanism. 
The results described in this thesis also present an explanation lor the observed 
"vasodilatory" action of B-adrenoceptor antagonists, in that they interfere with the 
adrenaline-induced amplification of sympathetic activity (11, 12). Indeed, it has been 
shown that a B,-selective adrenoceptor antagonist lowers blood pressure (13). We 
have, however, to conclude that the results of these pharmacological studies 
indicate, that in vivo the prejunctional B-adrenoceptors involved are not of an 
absolute B,-selective subtype, since atenolol (B,-adrenoceptor selective) besides 
bopindolol (non-selective) antagonized the effects of adrenaline. Another possibility 
might be that atenolol in the dosage used in this study was able to antagonize the 
prejunctional B,-adrenoceptor, despite its proven selectivity lor postjunctional B,-
adrenoceptors at the dose used. 
That the observed sustained and protracted pressor effect of adrenaline in the 
period after the infusion had been stopped, is indeed a result of enhanced 
noradrenaline release, is supported by the finding of increased urinary 
normetanephrine excretion in that period. Because normetanephrine is formed 
primarily from released noradrenaline, it can be taken as a measure lor increased 
sympathetic neuronal activity. 
A potential additional role of adrenaline in the pathogenesis of hypertension is its 
interaction with renal sodium excretion in such a way, that it counteracts pressure 
natriuresis. We observed no increased sodium excretion despite of the fact that 
blood pressure was higher in the postinfusion period of adrenaline. 
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Finally, we have demonstrated that both adrenaline and noradrenaline, besides 
having haemodynamic effects, also induce some "metabolic" changes and can 
influence the plasma concentrations of some hormones at plasma concentrations 
of these catecholamines well wrthin the physiological range. 
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Chapter 10 
SAMENVATT!NG EN CONCLUS!ES 
De stelling, dat stress slecht is voor de gezondheid, is algemeen aanvaard. Echter 
hoe stress zijn nadelige invloed kan uitoefenen is niet geheel opgehelderd. In dit 
proefschrift worden studies beschreven naar de mogelijke rol van het 
bijniermerghormoon adrenaline bij het ontstaan van hypertensie. 
Dat stress leidt tot een toename van de adrenaline secretie door de bijnier is al 
lang bekend. Echter hoe adrenaline een bloeddrukverhogend effect zou moeten 
hebben was minder duidelijk. Wanneer men een zodanige hoeveelheid adrenaline 
per infuus toedient, dat de plasmaspiegel van adrenaline hoog fysiologische 
concentraties bereikt, zoals die in het dagelijks Ieven ook voorkomen, blijft de 
bloeddruk gelijk of neemt zelfs iets af. Circa 10 jaar geleden werd een hypothese 
geformuleerd omtrent het mechanisme van het bloeddrukverhogende effect van 
adrenaline (1-3). Deze hypothese was gebaseerd op uitgebreid in vitro en 
dierexperimenteel onderzoek (4). Volgens deze hypothese zou adrenaline, wanneer 
het in verhoogde plasmaconcentraties voorkomt, de vrijmaking van noradrenaline 
kunnen Iaten toenemen door stimulatie van prejunctionele B-adrenoceptoren. 
Noradrenaline is een sterk vaatvernauwende stof en leidt op die wijze tot 
bloeddrukverhoging. Ook zou het mogelijk zijn dat adrenaline wordt opgenomen in 
het sympatisch neuron. Adrenaline zou dan kunnen worden vrijgemaakt tezamen 
met noradrenaline tijdens activatie van het sympatische zenuwstelsel en vervolgens 
de vrijmaking van noradrenaline verder kunnen stimuleren via activatie van de 
prejunctionele B-adrenoceptoren. Op deze wijze zouden ook tijdelijke verhogingen 
van de plasmaconcentratie van adrenaline kunnen leiden tot dit bloeddruk 
verhogende effect. Resultaten van experimenteel onderzoek bevestigden het 
bestaan van dit mechanisme. Bij de mens was dit nog niet bewezen. Wei had onze 
groep reeds aangetoond dat B-adrenoceptor agonisten de plasma noradrenaline 
concentratie konden doen toenemen (5). Voorts was inmiddels aangetoond dat de 
bloeddrukrespons op reflex sympatische stimulatie (onderdompeling van een hand 
in ijswater en isometrische inspanning) tijdens de infusie van adrenaline was 
toegenomen (3,6,7). 
Rond de tijd dat wij onze onderzoekingen begonnen (1986) waren slechts 2 
studies gepubliceerd die de hemodynamische veranderingen beschreven tijdens 
doch vooral ook na adrenaline infusie. Brown en Dollery infundeerden adrenaline bij 
6 vrijwilligers gedurende 2 uur en registreerden de bloeddruk gedurende 2:6 uur 
(8). Zij vonden ten opzichte van een controle experiment een verhoogde bloeddruk 
na beeindiging van het adrenaline infuus, doch de verschillen waren niet significant. 
Nezu en medewerkers (9) vonden een significant verhoogde bloeddruk na 
adrenaline infusie ten opzichte van een placebo studie gedurende 1:6 uur na 
beeindiging van het adrenaline infuus. Dit effect werd tenietgedaan door 
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propranolol. 
Het doel van de onderzoekingen, die zijn besc~rt!ven in dit proefschrift, was dus: 
het nagaan of het bestaan van bovengeschets bloeddrukverhogend mechanisme 
oak bij de mens waarsch~nlijk kon worden gemaakt De vragen die wij ons daartoe 
hebben gesteld, staan geformuleerd in Hoofdstuk 1. 
De vragen waren: 
1 Geeft adrenaline, wanneer het intraveneus ge'infundeerd wordt in zodanige 
hoeveelheden dat plasmaconcentraties worden bereikt binnen het 
fysiologisch bereik, een verhoging van de bloeddruk welke Ianger duurt dan 
de duur van het infuus? Wanneer dit inderdaad het geval is, treedt dit effect 
dan op in rust of tijdens sympatische activatie? 
2 lndien de eerste vraag onder 1 bevestigend was beantwoord, heeft dan 
intraveneuse toediening van noradrenaline hetzelfde effect op de bloeddruk? 
3 Zijn de veranderingen in de bloeddruk, welke optreden tijdens op 
gestandaardiseerde wijze uitgevoerde stimulatietesten van het sympatisch 
zenuwstelsel (onderdompeling van een hand in ijswater en isometrische 
inspanning), voor, tijdens en 18 uur na beeindiging van infusies van 
adrenaline, noradrenaline en placebo (glucose 5%) verschillend? 
4 Zijn de veranderingen in de plasmaconcentraties van adrenaline en 
noradrenaline tijdens en na de infusen van adrenaline en noradrenaline oak 
te herkennen in veranderingen in de hoeveelheden van deze catecholamines 
en van de catecholamine metabolieten, die in de urine worden 
uitgescheiden? 
5 leiden de infusen van adrenaline en noradrenaline tot veranderingen in de 
plasmaconcentraties van hormonen als renine, aldosteron, groeihormoon, 
prolactine en cortisol, kalium en glucose en wat is het effect op de 
natriumuitscheiding in de urine? 
6 Wat is het effect van non-selectieve en B,-selectieve adrenoceptor blokkade 
op de door adrenaline gemedieerde stimulatie van noradrenaline vrijmaking 
en de door adrenaline gemedieerde versterking van de sympaticus activiteit? 
In Hoofdstuk 2 worden het studieprotokol, de proefpersonen, de methoden van 
onderzoek en de procedures voor statistische bewerking beschreven. 
In Hoofdstuk 3 beschrijven wij de effecten op de bloeddruk en hartfrequentie van 
de infusies van adrenaline, noradrenaline en placebo. Tijdens de infusen van 
adrenaline neemt de bloeddruk af en tijdens die van noradrenaline toe, terwijl de 
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hartfrequentie toeneemt tijdens adrenaline en afneemt tijdens noradrenaline. In de 
ongeveer 18 uur durende periode, dat de bloeddruk nag geregistreerd werd na 
beeindiging van de inlusen, vonden wij dat de bloeddruk na adrenaline hager was 
dan na noradrenaline of placebo. Dit effect van adrenaline op de bloeddruk in deze 
postinlusie periode was het meest uitgesproken in perioden van (veronderstelde) 
toegenomen sympatische activiteit d.w.z. tijdens mobilisatie en tijdens het tweede 
deel van de nacht (wanneer REM slaap vaker voorkomt en de sympatische activiteit 
hager is) en het minst duidelijk in perioden van lage sympatische activiteit, d.w.z. in 
het eerste deel van de nacht en gedurende de 1 uur durende periode van bedrust 
de volgende ochtend voor het beeindigen van de bloeddrukregistratie. De 
bloeddruk na noradrenaline inlusie was niet verschillend van die na placebo 
toediening. Verschillen in hartfrequentie werden niet gevonden in de postinfusie 
period en. 
In Hooldstuk 4 beschrijven wij de effecten op de bloeddruk en hartfrequentie tijdens 
de koude expositie en isometrische inspanning. De veranderingen in de bloeddruk 
tijdens de testen gedaan voorafgaand aan de 3 infuus condities, vertoonden geen 
significante verschillen. De bloeddruk tijdens de testen, welke werden uitgevoerd 
tijdens de inlusies en 18 uur na beeindiging hiervan, vertoonde een sterkere stijging 
bij de adrenaline studie dan bij de placebo studie. Bij de noradrenaline studie werd 
dit versterkende effect niet waargenomen. Veranderingen in de hartfrequentie zowel 
voor, tijdens als na de infusen vertoonden geen significante verschillen tussen de 3 
infuus condities. 
In Hooldstuk 5 worden de meetresultaten van de urine-uitscheiding van de 
hoeveelheden adrenaline, noradrenaline en metabclieten beschreven. 
Vanillylamandelzuur (VMA) en 3-hydroxy-4-hydroxyfenylglycol (MHPG) blijken 
kwantitatief de belangrijkste metabolieten van adrenaline en noradrenaline te zijn, 
terwijl een geringe hoeveelheid van de twee catecholamines ongemetabolizeerd of 
als normetanefrine of metanefrine in de urine verschijnt. lnfusie van adrenaline leidt 
tot een toename van de urine-uitscheiding van adrenaline en metanefrine, terwijl 
infusie van noradrenaline leidt tot een toename van noradrenaline en 
normetanefrine uitscheiding. Aangezien de totaal ge'infundeerde hoeveelheden 
adrenaline en noradrenaline slechts gering waren, konden geen veranderingen in 
de uitscheiding van VMA en MHPG worden vastgesteld. Opvallend en mogelijk van 
groat belang was de bevinding dat tijdens de periode na de adrenaline infusie een 
verhoogde uitscheiding van normetanefrine werd gevonden. Daar verondersteld 
wordt dat dit metaboliet met name afkomstig is van neuronaal vrijgemaakt 
noradrenaline kan deze bevinding worden beschouwd als een aanwijzing dat in 
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deze periode inderdaad een toegenomen hoeveelheid noradrenaline is vrijgemaakt. 
Zoals gesteld is Hooldstuk 3, veronderstellen wij dat het bloeddrukeffect van de 
adrenaline inlusie tijdens deze postinlusie periode te verklaren is door een 
toegenomen noradrenaline vrijmaking. 
In Hooldstuk 6 wordt beschreven, dat adrenaline en noradrenaline, behalve 
hemodynamische effecten ook invloed hebben op de plasmaspiegel van kalium en 
de bloedspiegel van glucose. Tevens bleken de plasmaconcentraties van renine, 
aldosteron en insuline te veranderen onder invloed van infusies van zowel 
adrenaline als noradrenaline. 
In Hoofdstuk 7 worden de meetresultaten van de natriumuitscheiding in de urine 
beschreven. Zowel tijdens de infusen als gedurende de 18 uur durende postinlusie 
periode, werden geen verschillen in natriumuitscheiding gevonden. Dit ondanks het 
feit dat tach duidelijk waarneembare hemodynamische veranderingen optraden. De 
mogelijke mechanismen van de catecholamine gemedieerde effecten op de 
natriumuitscheiding worden besproken. In ieder geval moet worden vastgesteld dat 
deze waarneming past in de door Borst (1 0) in de begin zestiger jaren 
geformuleerde hypothese. Hij veronderstelde dat een "ontoereikende" 
natriumuitscheiding een centrale "afwijking" was bij hypertensie, in die zin dat bij 
hypertensie een hogere bloeddruk noodzakelijk is om de natriumuitscheiding op 
peil te houden. Onze resultaten suggereren een rol voor een catecholamine 
gemedieerd mechanisms in deze "afwijkende" natriumuitscheiding, zowel voor 
adrenaline als noradrenaline. 
In Hoofdstuk 8 bevestigen wij eerdere bevindingen van onze groep dat lage 
doseringen adrenaline intraveneus toegediend leiden tot een toename van de 
plasmaconcentratie van noradrenaline. Adrenaline induceert oak een toename van 
de noradrenaline productie in de arm. Dit faciliterende effect van adrenaline kan 
worden tegengegaan door B-adrenoceptor blokkade. 
Eindconclusies 
Bovengenoemde resultaten steunen de "adrenaline-hypertensie" hypothese. De 
studies tonen aan dat inlusie van adrenaline, waardoor plasmaconcentraties 
worden bereikt welke in het hoog fysiologische bereik liggen, leidt tot amplificatie 
van de bloeddrukresponse tijdens koude expositie en isometrische inspanning. 
Beide testen veroorzaken een stimulatie van het sympatisch zenuwstelsel en inlusie 
van adrenaline leidt tot versterking daarvan. 
Adrenaline blijkt echter oak een effect te hebben nadat het infuus was beeindigd 
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en de plasmaconcentraties van adrenaline weer op uitgangsniveau waren 
teruggekeerd. Wij vonden namelijk een hogere bloeddruk in de 18 uur durende 
postinfusie periode van adrenaline in vergelijking met de bloeddruk in die periode 
na placebo infusie. Tevens is de bloeddruk response tijdens koude expositie en 
tijdens isometrische inspanning 18 uur na beeindiging van het adrenaline infuus 
groter dan de responsen tijdens de testen na noradrenaline en placebo infusie. 
Aangezien de halfwaarde tijd van plasma adrenaline niet meer is dan enkele 
minuten, zijn deze resultaten het best als volgt te verklaren. Circulerend adrenaline 
kan worden opgenomen in sympatische neuronen en kan worden vrijgemaakt 
tezamen met noradrenaline tijdens sympatische activatie. Vervolgens kan 
adrenaline de prejunctionele B-adrenoceptoren stimuleren, wat leidt tot verdere 
toename van de noradrenaline vrijmaking, hetgeen vasoconstrictie veroorzaakt en 
stijging van de bloeddruk tot gevolg heeft. Aangezien noradrenaline de 
bovengeschetste effecten niet heeft, wordt verondersteld dat de verantwoordelijke 
adrenoceptor van het B,-subtype is. De bevinding dat de adrenaline gemedieerde 
toename van noradrenaline vrijmaking en de toegenomen bloeddrukstijging tijdens 
de testen die leiden tot toegenomen sympatische activatie, kunnen worden 
tegengegaan door B-adrenoceptor blokkade, is een extra aanwijzing dat inderdaad 
B-adrenoceptoren een rol spelen in dit proces. Het te-niet-doen van de adrenaline 
geinduceerde toename van sympatische activiteit door B-adrenoceptor blokkers 
kan ook worden beschouwd als een mogelijke verklaring veer de beschreven 
vaatverwijdende werking van deze medicamenten (11,12). Onze groep toonde aan 
in een voorgaande studie, dat een B,-selectieve adrenoceptor blokker een 
bloeddrukverlagend effect bleek te hebben (13). Oat de adrenaline gemedieerde 
potentiering van de sympatische activiteit kan worden tegengegaan door zowel een 
B,-selectieve (atenolol) als een niet-selectieve B-blokker (bopindolol), suggereert dat 
in vivo de prejunctionele adrenoceptoren niet strikt B,-selectief zijn. Een andere 
verklaring zou kunnen zijn dat atenolol in de dosering zeals die in deze studie werd 
gebruikt, ook in staat is prejunctionele B,-adrenoceptoren te blokkeren, ondanks de 
gebleken selectiviteit van atenolol veer postjunctionele B,-adrenoceptors in de 
gebruikte dosering. 
In de postinfuus periode van de adrenaline studie vonden wij een verhoogde 
uitscheiding in de urine van normetanefrine. Aangezien van normetanefrine wordt 
verondersteld dat deze metaboliet met name wordt gevormd uit neuronaal 
vrijgemaakt noradrenaline kan deze bevinding worden gezien als een aanwijzing dat 
er in deze periode inderdaad sprake was van een toegenomen noradrenaline 
produktie. Zeals beschreven in Hoofdstuk 3 vermoeden wij dat deze toegenomen 
noradrenaline vrijmaking de verklaring is van het gevonden effect op de bloeddruk 
in de postinfusie periode van adrenaline. 
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Een andere mogelijke bijdrage van adrenaline in de pathogenese van hypertensie 
is het effect op de natriumuitscheiding in de urine. Het bleek namelijk dat "druk-
natriurese" werd voorkomen, daar wij geen toegenomen natriumuitscheiding 
vonden in de periode na het adrenaline inluus, terwijl in deze periode de bloeddnuk 
verhoogd was. 
Tenslotte bleek dat zowel adrenaline als noradrenaline toegediend in een 
zodanige dosering dat plasmaconcentraties worden bereikt in het hoog 
fysiologische bereik, neg andere dan hemodynamische effecten hadden. 
Veranderingen werden geconstateerd in plasma kalium en bleed glucose terwijl ook 
de plasmaconcentraties van renine, aldosteron en insuline werden be"invloed. 
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